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Abstract
The genomic revolution has brought about large advances in the identification of disease-associated
variants. However, despite the recent explosion of genetic data, the problem of missing heritability
persists. Variants with low penetrance remain difficult to identify, as do variants which are rare or
unique to a single individual. To fully understand disease mechanisms and design targeted therapies,
the molecular mechanisms underlying the pathogenic effects of such variants must be clarified.
A prime example of missense variants which are difficult to classify is provided by those which
localise the Titin gene, a number of which are associated with titinopathies. Due to titin’s large
size, even the majority of healthy individuals possess one or more rare titin missense variants. This
results in the paradox that rare titin variants are commonly found; therefore, pathogenicity cannot
be inferred from frequency alone. To address this issue we have created a web application, TITINdb
(http://fraternalilab.kcl.ac.uk/TITINdb/), which integrates structural, variant, sequence and isoform
information along with precomputed in-silico analyses, in order to facilitate the prioritisation of
variants for further wet-lab investigation.
Recently available databases allow access to missense variant data on an unprecedented scale.
We sought to harness this information to better understand the characteristics of variants associated
with health and disease, through a large scale-analysis of population variants from the gnomAD
database, as well as disease-associated variants (ClinVar) and somatic cancer-associated variants
(COSMIC). Here we established that variants from each data set target distinct functional pathways
and proteomics features. In order to accomplish this analysis, we created a database, web interface
and REST API, ZoomVar (http://fraternalilab.kcl.ac.uk/ZoomVar/), to allow for the mapping of
variants to a 3D integrated protein-protein interaction network and calculation of the regional
enrichment of missense variants.
Despite the multitude of features which are able to segregate deleterious from neutral missense
variants, a number of problem cases remain. This motivated us to investigate whether features
extracted frommolecular dynamics simulations could improve predictions of variant deleteriousness.
To accomplish this we constructed a dataset of rare population and deleterious titin variants, and
created machine-learning (random forest) based models of variant impact. We show that dynamics-
based features are able to segregate the majority of disease-associated titin variants from population
variants. Ultimately, we believe a collaborative framework for the sharing of mutant and wild-
type trajectories must be set up; both to enable investigation into the possible benefits of using
dynamics-based features, and to harness their power.
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Chapter 1
Introduction and background to the
work
The basis of life is code. In this manner, all living beings are not so dissimilar to computer programs.
However, unlike such programs, at least those which are reasonably well documented, living beings
do not come with an instruction manual. Rather than binary code, as in computing, four different
base pairs are possible. Errors in this code give rise to phenotypic variety. This is a double-edged
sword, as such variety can result in both selective advantages and lend a species the flexibility to
adapt to environmental changes, however it can also lead to detrimental variants. A number of
different types of variants can occur, parts of the code can be deleted or extra pieces of code can
be inserted, or reading of the code can be brought prematurely to a halt. These types of variants
are called indels (insertions and deletions) and truncating variants. Here we focus instead on
single nucleotide variants; those variants where one nucleotide is swapped for another one. More
specifically we focus on non-synonymous single nucleotide variants (nsSNVs). These are variants
which occur in protein coding regions of the genome and result in a change in the amino acid
sequence of a protein. Such variants can also be termed single amino acid variants (SAVs), and are
commonly notated as a string in which the letter representing the wild-type amino acid is followed
by the position within the protein or domain and finally the mutant amino acid (e.g. T560M).
As no instruction manual exists we must endeavour to decipher the code, and, importantly, to
understand which variants lead to disease and why. Huge progress has been made since the first
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human genome sequence was solved in 2004 (International Human Genome Sequencing Consortium,
2004), an endeavour which took 10 years to complete. Of particular importance was the development
of next-generation sequencing (NGS) technology. This has massively decreased the cost and time
for sequencing. Now genetic data exists for a huge number of individuals - over 100,000 in the
gnomAD database (Lek et al., 2016), and the bottleneck has shifted to analysis and interpretation of
this data. Initially, research focussed on so-called low hanging fruits and identified variants with
easily detectable disease associations. However, for a large number of diseases and phenotypes
thought to be heritable, the genetic component remains unidentified, resulting in the so-termed
problem of "missing heritability" (Manolio et al., 2009). With the enormous amount of data which is
now available, it becomes imperative to go beyond identifying the most obvious disease-associated
variants. In this light, it is essential to understand how disease-associated missense variants differ
from neutral variants in their localisation to protein structure and impact on protein function.
Moreover, this knowledge can be used to inform prediction.
This work endeavours to reach an improved understanding of the properties of human missense
variants in health and disease, and to contribute to the development of computational variant impact
predictors. Although at times we take a proteome-wide approach, the majority of this work is
focussed on the protein titin, so named for its titanic size (the longest isoform is 35,991 amino acids in
length). Variants which localise to this protein are particularly difficult to classify, although several
disease-associations have already been uncovered. As a large number of titin variants of unknown
significance are found, improved impact prediction is particularly essential for their assessment.
Moreover, we believe that the methods used here offer scope for further development and can be
applied to other proteins with problem-case variants, and ultimately contribute to the elucidation of
missing heritability.
1.1 Detecting phenotype-associated nsSNVs
Understanding the impact of nsSNVs on phenotype is a complex task. The first hurdle is simply
identifying which variants contribute to a phenotype. Variants on the same chromosome in close
proximity tend to be co-inherited, as they are only segregated in the event of recombination during
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crossover. Due to such co-inherited genetic "blocks", termed haplotypes, it must be deciphered
whether a variant which is associated with disease actually plays a causative role or is simply
co-inherited with an actual causal variant (Sazonovs and Barrett, 2018). Such co-inherited single
nucleotide variants are termed marker variants (Gabriel et al., 2002). Although these variants cannot
be used to understand the molecular mechanisms underlying a disease phenotype, they can play a
useful diagnostic and/or prognostic role. Notably, haplotypes are population specific and have been
catalogued by the HAPMAP project (Gabriel et al., 2002; Goldstein and Cavalleri, 2005).
Two major approaches exist to identifying variants with disease associations; both with dif-
ferent strengths and weaknesses. These are linkage or cosegregation studies (Ott et al., 2015), and
association studies. Historically, the first genotype-disease associations were discovered through
linkage studies (Bodmer and Bonilla, 2008), with causal links established between human leukocyte
antigen (HLA) alleles and a number of diseases, including Hodgkin’s disease, ankylosing spondylitis,
and hemochromatosis (Bodmer, 1973; Feder et al., 1996). Here, variants which cosegregate with a
disease phenotype are identified as likely causal variants. Since the first discoveries, this method has
been able to identify a number of variant-disease associations, including several disease-associated
variants in the titin gene (Seidman and Seidman, 2011). Its limitations are that for cosegregation
to be detected, information on family members with and without the disease must be available.
Additionally, this method is most applicable to cases with high disease penetrance, although models
have been developed to deal with lower penetrance (Ott et al., 2015). This method cannot be applied
to de novo variants or somatic variants, as these are not inherited.
Association studies instead compare the incidence of variants in case and control groups, where
individuals in both groups are unrelated and cases and controls are matched for confounding factors
(i.e. ethnicity) (Lewis and Knight, 2012; Tsao and Florez, 2007). The assumption is made that variants
associated with disease will be enriched in the case group over the control group. A number of
approaches exist to calculating this enrichment, however, most commonly a Fisher exact test is used,
and the results subjected to correction for multiple testing. Moreover, it is generally assumed that
the impact of variants is additive, and thus each variant can be treated as an independent variable.
Using this approach, provided the cohort of cases and controls is large enough, it is possible to
detect variants with incomplete penetrance, such as those which may be associated with complex
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disease (Lewis and Knight, 2012). However, if causes of a disease are genetically heterogeneous,
specific disease-associated variants will not be particularly enriched in the disease cohort, and are
thus likely to go undetected.
Both of the above approaches can be combined with a hypothesis-driven or a hypothesis-free
approach (Donaldson et al., 2016). In hypothesis-driven approaches, prior information about a
disease is used to prioritise particular "candidate" genes for investigation (Patnala et al., 2013). This
information is generally retrieved from the literature and/or relevant databases. For example, genes
which are associated with a pathway known to be associated with a disease may be prioritised
(Patnala et al., 2013). This approach allows for greater statistical power, however has the disadvantage
that any completely novel associations cannot be detected. Hypothesis-free approaches, on the other
hand, are unbiased but may lack statistical power in detecting disease associations. These approaches
generally involve either genome- or exome- wide investigation (Kitsios and Zintzaras, 2009). In
contrast, hypothesis-driven approaches are more often restricted to the targeted set of "candidate"
genes, thereby reducing costs. However, these may also involve genome-wide investigation, in
which prior knowledge is used to weight results (Bakir-Gungor et al., 2014).
Genome-wide association studies and linkage studies have, to date, used primarily microarray
chips to identify variants (Sazonovs and Barrett, 2018). These have the advantage of comparatively
low cost, and, due to linkage disequilibrium, 2 to 4 times (Donaldson et al., 2016) more single
nucleotide polymorphism (SNP) genotypes can be assigned than directly detected, using imputation
software (Sazonovs and Barrett, 2018), such as PLINK (Chang et al., 2015; Purcell et al., 2007). The
disadvantages here are that any single nucleotide variants (SNVs) which are rare or unique will
be absent from these microarrays. With the decreasing cost of NGS technology, many studies are
moving towards the use of exome and genome-wide sequencing. Here trade-offs between sequencing
depth (and therefore the quality of variant calls), and cost must be considered (Sazonovs and Barrett,
2018).
A number of problem cases still exist. De novo variants, defined as variants which are present in
a child but not in either parent, are difficult to classify. Such variants have been linked to a number
of diseases, including neurodevelopmental disorders. Although these can be detected by sequencing
parent-child trios, establishing which de novo variants play a causative role in an observed phenotype
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can be challenging. This is due to the fact that other individuals with the same condition are unlikely
to share the causal variant (Acuna-Hidalgo et al., 2016). A similar problem is observed in the case of
somatic cancer variants. As cancers are genetically heterogeneous, although some driver mutations
are shared between individuals, a number are thought to be rare or personal and are thus difficult
to detect (Hou and Ma, 2014). Additionally, we have already been introduced to the problem case
of diseases whose genetic causes are heterogeneous. Furthermore, as stated earlier, it is generally
assumed that the impact of variants is additive, however, it is clear that this is an oversimplification.
From a biological viewpoint, as gene products, proteins, do not function in isolation but interact
with one another as part of a complex system, it seems unlikely that the combined impact of variants
will be equal to the sum of its parts. Indeed, a number diseases are known to be digenic (caused by
a combination of variants in two genes), such as those catalogued by the DIDA database (Gazzo
et al., 2016), and, in Section 1.3.2 we will be introduced to disease-associated titin variants with
compound heterozygous inheritance. Moreover, the known phenomenon of compensatory variants
provides evidence that variant-phenotype relationships are not always linear (Baresić et al., 2010).
The combinatorial impact of variants we discuss here is termed epistasis. This is particularly difficult
to detect, as although a number of algorithms have been developed, exhaustive approaches are
computationally costly. Moreover, statistical power can be elusive due to the tendency towards
large p-values and small numbers of observations (Wei et al., 2014).
These problem cases, with the exception of de novo variants and somatic cancer variants, can
offer a partial explanation to the phenomenon of "missing heritability", otherwise termed the "dark
matter" of genome-wide association (Manolio et al., 2009). As already outlined, this phenomenon
occurs when a phenotype is observed to be largely heritable, but only a small portion of this
heritability can be attributed to known genetic factors. An often used example is human height; this
has a heritability of approximately 80 %, yet despite extensive study, only 5 % of this heritability can
currently be explained (Visscher, 2008). At the crux of the matter is understanding how much of this
missing heritability can be attributed to common variants with, mainly, small effect sizes (coined the
’common variant common disease’ hypothesis) or rare variants with large effect sizes (Gibson, 2012).
Indeed, known examples suggest both ends of the spectrum are possible: observed odds ratios for
the majority of common variant-disease associations are between 1.1 and 1.4, whereas odds ratios
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for rare variant-disease associations are frequently greater than 2, or cannot be calculated due to
the absence of the rare variant from the control cohort (Bodmer and Bonilla, 2008). In contrast, a
handful of well-known cases exist where common variants have a large impact on phenotype, the
classic example being that of sickle cell disease (Luzzatto, 2012). These cases appear to occur only
where there is an advantage to being a heterozygote; for example, heterozygosity for the sickle
cell allele confers resistance to malaria. It is also likely that any small effect sizes of rare variants
go undetected by statistical methods. On a practical note, the detection of rare variants with large
effect sizes offers more immediate diagnostic and therapeutic value than detecting common variants
with small effect sizes. A variant must have a large effect size for the development of a targeted
therapeutic to be commercially viable (Manolio et al., 2009). Likewise, variants with small effect
sizes have little diagnostic use, as they can only suggest that individuals are slightly more or less
likely to develop a disease (Manolio et al., 2009; Reich and Lander, 2001). In this work, we try to
understand better the distinction between the characteristics of common and rare variants, and
focus, in particular, on deciphering the impact of rare titin variants. We do this by considering the
effect of SAVs on protein structure and function, which we feel to be of fundamental importance
in untangling the issues discussed here. It should not be forgotten that non-coding variants can
play an important role in disease (Zhang and Lupski, 2015); however, the consideration of these is
beyond the scope of this work.
1.2 The impact of SAVs on protein structure and function
The twenty amino acids are the building blocks from which proteins are constructed. This gives
rise to 190 possible different single amino acid variants (SAVs), where one amino acid is swapped
for another, and a lower number (75) of these result from nsSNVs, as not all amino acids can be
transformed into one another by changing a single nucleotide of their codon. In reality, the number
of possible impacts is much higher, as protein sequences fold into highly complex tertiary structures.
Therefore a multitude of factors must be considered in order to understand the effect of SAVs on
protein structure and function.
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1.2.1 The localisation of SAVs in 3D space
From studies which map disease-associated variants to 3D protein structures, it has become widely
established that disease-associated SAVs are enriched in both protein cores and protein interaction
interfaces, but depleted on protein surfaces and inter-domain disordered regions (David et al., 2012;
de Beer et al., 2013; Engin et al., 2016; Gao et al., 2015; Gong and Blundell, 2010; Gress et al., 2017; Lu
et al., 2015; Petukh et al., 2015). Recent work suggests that the apparent enrichment in interaction
interfaces could be due to a bias in studies towards disease-associated proteins and their structures
(Gress et al., 2017); we address this issue in Chapter 3. There is also evidence to suggest that disease-
associated variants impact on post-translational modifications (PTMs) and functional sites more than
neutral variants (de Beer et al., 2013; Gao et al., 2015; Gong and Blundell, 2010; Holehouse and Naegle,
2015). Furthermore, it has been shown that disease-associated variants, although not enriched in
DNA-binding proteins, are enriched at DNA-binding interfaces, whereas somatic cancer mutations,
although not specifically enriched at DNA-binding interfaces, are enriched in DNA-binding proteins
(Gress et al., 2017). Beyond the consideration of localisation to specific regions, it has also been
shown that "neutral" population variants are more dispersed throughout 3D protein structures,
whereas disease-associated variants tend to form clusters (Sivley et al., 2018). Although recurrent
somatic cancer variants generally show patterns similar to population variants, significant clustering
of these variants is seen in a subset of proteins (Sivley et al., 2018). This observation has been
harnessed by a number of algorithms which make use of clustering on 3D structure to detect cancer
driver variants (Porta-Pardo et al., 2017). The spatial dispersion of population variants generally
reflects avoidance of the core and important functional sites. Indeed, one example is the depletion
of population variants near PTMs, with this depletion being particularly marked for PTMs which
cluster in sequence space (Reimand et al., 2015).
1.2.2 The physicochemical impact of SAVs
At the physicochemical level, it has been shown that the distribution and impact of amino acid
changes due to disease-associated mutations are distinct from those of neutral mutations. Generally,
disease-associated mutations result in more drastic changes in hydrophobicity, charge, size, shape,
1.2 The impact of SAVs on protein structure and function 17
and hydrogen bonding networks, whereas neutral mutations more frequently conserve properties
of the wild-type (WT) (Alexov and Sternberg, 2013; de Beer et al., 2013; Gong and Blundell, 2010;
Petukh et al., 2015). Changes in charge can disrupt salt bridges, and the introduction of charged or
hydrophilic residues to the core of a protein can result in structural destabilisation (see Fig. 3.2a).
Furthermore, large differences in the size and/or shape of a buried residue will either result in
steric clashes, or the formation of undesirable structural voids (Al-Numair and Martin, 2013). More
specifically, disease-associated mutations are enriched in changes from the wild-type amino acids
cysteine, tryptophan and glycine (Petukh et al., 2015; Vitkup et al., 2003). These play important
structural roles, with cysteine able to form disulfide bonds, tryptophan being the largest amino
acid, involved in hydrophobic, cation-pi and pi-stacking interactions, and glycine the smallest, most
flexible amino acid (Gao et al., 2015; Makwana and Mahalakshmi, 2015). Disease-associated mutant
amino acids are most enriched in mutations to proline and cysteine (Gao et al., 2015). Mutations to
cysteine may result in the formation of unwanted, disruptive, disulfide bridges, whereas the rigid
proline is known as a helix breaker and can also disrupt hydrogen bonding in turns. Interestingly,
disease-associated mutations to proline are only enriched in ordered secondary structural elements,
and not in disordered coil regions (Gao et al., 2015). Consistent with disease-associated mutations
having a greater impact on protein structure and function, are observations that disease-associated
variants result in greater changes to the folding and binding free energies of proteins than neutral
variants do. These conclusions have been made possible by experimental data available from the
ProTherm (Gromiha and Sarai, 2010) and SkemPi (Jankauskaite et al., 2018) databases. However, it
must be considered that these data are likely biased towards the study of disease-associated variants
and variants of interest to protein engineering.
1.2.3 The impact of SAVs on functional sites
The impact of variants can also be better understood by considering the local context around the
affected residue. Mutations at or close to functional sites (e.g. metal-coordinating sites, such as the
zinc-coordinating site in p53 that resides near the p53-TP53BP2 interface (Fig. 1.1b)) (Gorina and
Pavletich, 1996), or post-translational modification sites can disrupt these (Reimand et al., 2015).
Such mutations can be either gain of function, i.e. result in greater enzymatic activity, or loss of
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function. Disease mutations which disrupt PTMs can result in the rewiring of signalling networks
(Reimand et al., 2015) and can impact on protein-protein interactions (Lu et al., 2016a; Petschnigg
et al., 2017).
1.2.4 The impact of SAVs on protein flexibility and disorder
It has been shown that population variants are enriched in disordered inter-domain protein regions,
whereas disease-associated variants, in contrast, are more enriched in ordered domain regions (Lu
et al., 2015). This is likely due to the fact that disordered regions are subject to less structural and
functional constraint. However, this is an oversimplification, as intrinsically disordered regions can
play an important biological role; for example in signalling, disorder to order transitions, protein
interactions and in the transmission of allosteric signals. Furthermore, such proteins are often tightly
regulated, with functions which can be tuned via PTMs (Babu et al., 2011; Dunker et al., 2015; Fong
and Panchenko, 2010). Beyond pure intrinsically disordered regions, the degree of regional flexibility
is particularly important to a protein’s dynamics in the event of conformational transitions. Indeed,
there are examples of disease-associated mutations which impact on protein flexibility, thereby
altering the equilibrium between different conformers of a protein. A particular case of this is
demonstrated by mutations in allosteric proteins (Pandini et al., 2012; Weinkam et al., 2013), such as
somatic cancer mutations in phosphofructokinase-1 (Webb et al., 2015), which can impact on the
conformational equilibrium between effector bound and unbound forms. Moreover, the impact may
not result in a simple re-weighting of conformations observed in the wild-type, but can also result
in the exploration of new conformations (Weinkam et al., 2013).
1.2.5 From the atomistic to the macroscopic level
The atomistic impact of variants on protein structures will ultimately exert its effect at the macro-
scopic system level. A network of protein-protein, protein-nucleotide and protein-ligand interactions
make up this system. Variants which localise to the core of a protein may disrupt tertiary structure
(Fig. 1.1a), and have the potential to abrogate association with all interaction partners (node removal),
whereas mutations which localise to interaction interfaces may disrupt specific interactions (edges
in the network, Fig. 1.1c) (Jubb et al., 2017; Laskowski and Thornton, 2008; Yi et al., 2017). Variants
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Fig. 1.1 Molecular mechanisms of genetic variants which affect PPIs. Here we take the example of
the human p53 protein (encoded by TP53 gene), first zooming out ("-" sign) to look at its directly
interacting proteins (purple circle), then zooming in ("+" sign) to study atomistic details of the
mutated residues (green circles). The same colour code is used in both the PPI network and the
structures, which show two structural complexes of p53 (in salmon), one with the pro-apoptotic
protein p53 binding protein-2 (in cyan, encoded by TP53BP2, PDB 1ycs (Gorina and Pavletich, 1996))
and the other with the anti-apoptotic protein Bcl-xl (in violet-red, encoded by BCL2L1, PDB 2mej
(Follis et al., 2014)). Four categories of mutations were shown here (a-d, see main text), with the
wild-type residues highlighted on the structures. All mutations have been observed in cancers,
curated from both the COSMIC database (v83, http://cancer.sanger.ac.uk/cosmic) (mutations in ≥
100 cases were considered) and the literature (Cho et al., 1994; Nishi et al., 2013; Tomita et al.,
2006). Their effects on PPIs were assessed to be either stabilising (in orange) or destabilising (in
green) in silico (Nishi et al., 2013) or in vitro (Cho et al., 1994; Tomita et al., 2006). Structures were
visualized and rendered in PyMol (v1.8.2.1). Network was compiled through STRING-db (v10.5,
https://string-db.org) (high-confidence interactions, score > 0.95) and visualized in Cytoscape.
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which destabilise a protein may also result in pathogenicity through loss of specific, for example
enzymatic, functions, or the accumulation of toxic aggregates. Examples being the cardiovascular
disease predisposing T560M mutation, found in human lipoxygenase A, which disrupts a hydro-
gen bonding network connecting the mutation to the active site (Schurmann et al., 2011), and the
Charcot Marie tooth disease associated L16P mutation in peripheral myelin protein 22, which leads
to protein misfolding and aggregation (Sakakura et al., 2011). A subtle difference must be noted
between those variants which destabilise the folded form of the protein and those which impact on
folding kinetics (Zhang et al., 2012). Conversely, it has also been shown that deleterious missense
variants can exert a stabilising effect. For example, the H101Q CLIC2 mutation, associated with
X-linked intellectual disability with cardiomegaly, stabilises the CLIC2 protein; thereby preventing
conformational changes which are necessary for its transition between soluble and membrane forms
(Takano et al., 2012; Witham et al., 2011).
Experiments have shown that the majority (approximately two-thirds) of disease-associated
variants perturb PPIs but preserve protein stability (Sahni et al., 2015), contingent with them
specifically affecting interaction interfaces. Such interface mutations can alter binding affinity, or,
more rarely, result in novel interactions (Sahni et al., 2015). The p53 protein, a known cancer driver,
offers examples of both variants which disrupt the core of a protein (Fig. 1.1a) and variants which
affect specific interfaces, such as the p53-TP53BP2 interaction interface (Fig. 1.1c) (Cho et al., 1994;
Gorina and Pavletich, 1996; Nishi et al., 2013; Tomita et al., 2006).
Cancer driver mutations offer an ideal example to illustrate how such types of genetic variants
can affect PPIs. Here, differences in the protein regional enrichment in somatic mutations between
subsets of cancer driver genes have been observed. Proteins encoded by oncogenes have been found
to be enriched in variants which localise to both protein interaction interfaces and functional sites,
while those encoded by tumour suppressor genes have been found to be enriched in variants which
are found in the core of a protein (Engin et al., 2016; Stehr et al., 2011). Moreover, Engin et al. (2016)
found that the interfaces of tumour suppressors annotated as activating interfaces are enriched in
destabilising mutations, in comparison to such interfaces of oncogenes, thereby offering mechanistic
insight into the differences between the two classes of cancer drivers.
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A single protein may have multiple interfaces; additionally, it may use particular interfaces to
interact with multiple proteins. p53, for example, employs different interfaces to bind with TP53BP2
and the anti-apoptotic protein Bcl-xl (Fig. 1.1d) (Follis et al., 2014; Gorina and Pavletich, 1996). In
a number of pleiotropic proteins (those associated with multiple biological functions) (Chesmore
et al., 2016), mutations associated with distinct diseases have been observed to cluster on different
interfaces (Mosca et al., 2015; Wang et al., 2012). On the contrary, different variants which localise
to the same PPI interface can result in the same/similar phenotypes (Mosca et al., 2015; Wang et al.,
2012). Interestingly, disease-associated mutations which abrogate a greater number of interactions
have been correlated with earlier disease onset (Sahni et al., 2015). On the other hand, it has been
observed that common variation is depleted in multi-binding promiscuous interfaces (Fornili et al.,
2013). Other studies into conformational dynamics have shown protein interfaces to be more rigid;
furthermore, those interfaces which harbour disease-associated variants were demonstrated to
be even less flexible (Butler et al., 2015). Here it must be taken into consideration that protein
interactions are heterogeneous in both structural and physicochemical properties, therefore this
trend may not hold for all protein interaction interfaces. Indeed it has been shown that, in some
cases, flexibility can play an important role; in particular where partner binding is mediated by a
continuous epitope, as well as in interactions involving intrinsically disordered proteins, where
disorder-to-order transitions may occur (Jubb et al., 2015). In such cases, it has been demonstrated
that mutations which decrease the level of disorder in the unbound conformation or change the
propensity for secondary structure formation upon binding, can be pathogenic (Yates and Sternberg,
2013).
Protein interaction interface regions can be further divided into rim regions, which are similar
in composition to the rest of the surface, and core regions which are more hydrophobic in nature.
Interface core regions have been found to be most highly enriched in disease-causing SAVs, whereas
neutral SAVs appear to localise preferentially to rim regions. Hotspot residues, which provide the
largest energetic contribution towards binding have, unsurprisingly, been found to be enriched in
disease-associated SAVs (David and Sternberg, 2015).
Missense variants may also impact on protein-nucleic acid interaction interfaces. Such mutations
can lead to altered gene regulation, translation, RNA editing and DNA replication and repair
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(Gommans et al., 2009; Pires and Ascher, 2017; Zhang et al., 2012). This has been particularly noted
in the case of cancer, for example, certain p53 mutants demonstrate impaired binding to DNA
response elements (Muller and Vousden, 2013). Of note, disruptive mutations may occur on either
the interface of the protein or the nucleic acid. For example, it has been found that cancer mutations
are enriched in DNA-cohesin binding sites (Katainen et al., 2015).
1.2.6 Proteomics and transcriptomics data
Insights into the behaviour of proteins and related transcripts, in their cellular environment, can be
obtained through the use of mass spectrometry and RNAseq technologies. Interestingly, correlations
between measured protein abundances and mRNA levels are incomplete, for example, a review by
Maier et al. (2009) reports Spearman correlations ranging between 0.45 and 0.75. This discrepancy
between transcript levels and protein abundance can be attributed to biological processes, such as
those associated with translation, mRNA stability, and protein turnover, in addition to technical
error and noise (Maier et al., 2009). Despite these incomplete correlations, it has been shown that
both proteins which are highly transcribed, and those which are abundant, evolve at a slower
rate. Presumably, as any mutations which result in destabilisation or aggregation will impact on a
larger quantity of protein in the crowded cellular environment, leading to greater cellular toxicity.
Interestingly such correlations, between protein evolutionary rate and abundance, are strongest for
proteins expressed by tissues with a high neuron density (Drummond and Wilke, 2008). This can be
attributed to the greater potential for misfolded proteins and aggregates to lead to toxicity, due to
the long neuronal life-span over which these can build up. It has also been shown that the surfaces
of more abundant proteins have a lower "stickiness" than less abundant proteins (Levy et al., 2012).
This property has been investigated using the "stickiness" index, which is based on the propensity
of an amino acid to occur at protein-protein interaction interfaces. This suggests that there is a
greater need for abundant proteins to avoid non-specific interactions. Furthermore, it has been
observed that evolutionary mutations which result in large "stickiness" changes are less common
on the surfaces of abundant proteins. Observed correlations between stickiness and abundance
are higher for the Escherichia coli proteome than the human and yeast proteomes. This is likely
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due to the fact that the compartmentalisation of eukaryotic cells results in non-linear relationships
between protein concentration and abundance (Levy et al., 2012).
Recent developments in mass spectrometry-based proteomics now enable the measurement
of a number of protein properties, beyond abundance, such as thermal stabilities and half-lives
(Leuenberger et al., 2017; Mathieson et al., 2018). Data derived by such techniques have shown
that proteins with high thermal stability are more abundant. In light of the discussed correlations
of abundance with evolutionary rate, this suggests that more abundant proteins have evolved to
become more stable, due to the potentially detrimental effects large quantities of aggregated or
misfolded proteins would have on the cell. It has also been shown that essential proteins have higher
thermal stability than non-essential proteins, and that stable proteins are enriched in functions
distinct to those of unstable proteins. Specifically, the Picotti lab has shown that stable proteins are
enriched in ribosomal, RNA-binding and protein biosynthesis processes, whereas unstable proteins
are enriched for cofactor and DNA-binding proteins (Leuenberger et al., 2017).
We believe that these measured properties of proteins, in particular their abundance and stability,
could give insight into the potential impact of localised missense variants. The correlations of
evolutionary rate with this data, suggests that this may be the case; however, to the best of our
knowledge, the relationship of these features with the enrichment of missense variants has not been
investigated. We explore these possibilities in Chapter 3.
1.3 Titin
1.3.1 Titin structure and function
The giant protein titin spans half a cardiac sarcomere from the Z-disk to the M-line, and plays a
pivotal role in sarcomeric function and stability. Notably, the I-band region is characterised by
its elastic properties (Gigli et al., 2016) and maintains resting tension, whereas the A-band region
has been suggested to act as a blueprint for thick filament assembly, although recent research
suggests that a better description is that of a wrapper which restricts the length of the thick
filament (Kellermayer et al., 2018). Although titin is known to be involved in numerous interactions,
including interactions with the thick filament proteins myosin and myosin binding protein C in the
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A band region (Chauveau et al., 2014b), only a handful of these have been structurally characterised.
These are titin’s interactions with telethonin at the beginning of the Z-disk, and both obscurin and
obscurin-like protein at the end of the M-line.
Titin is modular in structure, being comprised primarily of the globular immunoglobulin and
fibronectin type-III (Fn3) domains. Notably, titin’s immunoglobulin domains are classified as be-
longing to the intermediate-set (I-set), as they have loop regions which are intermediate in length
between variable-set (V-set) and constant-set (C1) domains (Kenny et al., 1999). Ig domains are
found throughout the length of titin, whereas Fn3 domains localise only to the A-band region,
where, along with the Ig domains they form super-repeat patterns (see Fig. 1.2). These comprise
of 7 and 11 domains in regions termed the D-zone and C-zone respectively. The only departures
from these patterns are at the beginning and end of the A band. Evolutionary analysis has shown
that domains at particular positions within the super-repeat are more closely related to one another
than to domains at other positions (Kenny et al., 1999). Interestingly the spacing of the D-zone
repeats, at a length of 43 nm, matches the periodicity with which myosin binding protein C interacts
with titin, supporting the molecular blueprint hypothesis (Kenny et al., 1999). Additionally, a single
pseudokinase domain is found at the beginning of the M-band region, which acts as a mechanosensor
(Bogomolovas et al., 2014). Both titin Fn3 and Ig domains share a similar beta sandwich structure
with a conserved hydrophobic core (Meyer and Wright, 2013). The major difference between these
two domain types is in the topology (see Fig. 1.2). It has also been shown that titin Ig domains have
higher mechanical stability than titin Fn3 domains, however, even titin Fn3 domains have a higher
mechanical stability than those of the extracellular protein tenascin. Furthermore, domains from
the A-band region have been shown to have lower mechanical stability than those from the I-band
region, throughout which stability increases from the N to C terminal end. The lower stability of
A-band domains is perhaps indicative of the fact these are most likely stabilised by their numerous
interactions with the thick filament (Rief et al., 1998). Interestingly, when I-band Ig domains are
divided into more stable and less stable domains, particular sequence motifs unique to each group
have been found (Garcia et al., 2009). The ability of titin’s I-band Ig domains to unfold and refold in
response to physiological stretch forces contributes to the spring-like properties of this region (Li
and Linke, 2017; Meyer and Wright, 2013). Despite their discussed differences, both titin Fn3 and Ig
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Fig. 1.2 a) Schematic of titin’s localisation within the sarcomere; a single titin molecule (green) spans
half a sarcomere from the Z-disk to the M-line. The I-band region of titin acts as an elastic spring,
and interacts with proteins of the thin filament, whereas the A-band region interacts with the thick
filament proteins myosin and myosin binding protein C. b) Titin A-band domain organisation. c)
C-terminal domains of the A-band (Ig-158, Ig-159, Fn3-132), PDB structure 2nzi. Structures were
visualised using the UCSF Chimera software (Pettersen et al., 2004). d) The topology of titin Ig (blue)
and Fn3 (orange) domains.
domains fold independently and are stable at room temperature. Moreover, crystal structures are
generally easy to obtain, although it has not yet been possible to obtain a crystal structure for the
HMERF hotspot domain Fn3-119 (Meyer and Wright, 2013). In addition to these globular domains,
titin contains a flexible PEVK region, so named for its amino acid composition, which is a hotspot
for interactors, including tropomyosin and actin (Chauveau et al., 2014b).
A number of different titin isoforms exist, seven of which are documented in the RefSeq database
(O’Leary et al., 2016). The longest isoform is the inferred complete (IC) isoform; although this has
no known biological relevance, this provides a useful reference point for the positional numbering
of other isoforms. The major biologically relevant isoforms are the N2A, N2B, and N2AB variants.
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These differ in length due to differential splicing in the I-band region, with the shortest isoform
being the cardiac-specific N2B isoform. Specifically, the skeletally expressed N2A isoform contains
the N2A exons, the N2B isoform contains the N2B exons and a reduced number of PEVK region
exons, and the N2BA isoform contains both the N2A and N2B exons. The Z-disk, A-band, and M-line
regions are, in contrast constitutively spliced in. Additionally novex-1 and -2 isoforms are similar
to the N2B isoform but contain unique 125 and 192 amino acid stretches respectively. Finally, a
unique isoform, called novex-3, contains an alternative terminal out of frame exon, which cannot be
mapped to the reference IC isoform (Chauveau et al., 2014b).
1.3.2 Disease-associated titin variants
Due to titin’s large size, associations of titin variants with disease phenotypes was, mainly, not
feasible until the advent of NGS technology. Since then a number of rare titin variants have been
associated with disease (Savarese et al., 2018). Most notably hotspots in the domains Ig-169 and
Fn3-119 have emerged for the diseases tibial muscular dystrophy/limb-girdle muscular dystrophy
2J (TMD/LGMD-2J) and hereditary myopathy with early respiratory failure (HMERF) respectively
(Chauveau et al., 2014b; Savarese et al., 2016). As well as missense variants a number of truncating
variants in titin have been identified, and are now known to be one of the primary causes of dilated
cardiomyopathy (DCM) (Schafer et al., 2017). Although truncating variants are also present in
approximately 1 % of the general population, it has been found that those variants which lead to the
DCM phenotype localise to exons which are constitutively spliced in, as these cannot be "rescued"
by differential splicing (Schafer et al., 2017). Moreover, high-resolution cardiac scans have revealed
eccentric cardiac remodelling in those nominally "healthy" individuals who possess truncating
variants in constitutively spliced in exons (0.5 % of the population), thereby exposing a phenotypic
continuum (Schafer et al., 2017). In the last few years, compound heterozygous mutations have
been associated with severe paediatric titinopathies, including novel forms of core myopathy with
heart disease (Chauveau et al., 2014a). Although only a handful of cases have been characterised,
these generally involve the inheritance of a rare titin missense variant in trans with a truncating
variant. One proposed hypothesis is that the truncating variant cannot give rise to a functional titin
molecule, and thereby unmasks the deleterious nature of the missense variant. A number of variants
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have also been identified in the titin kinase (TK) domain, one of which was initially associated
with the disease HMERF (Pfeffer et al., 2014), however as this is in linkage with a Fn3-119 hotspot
mutation, it is now assumed that this SAV, may at most, be a phenotype modifier. Interestingly, one
of the compound heterozygous paediatric titinopathy patients lacks a functional TK domain, due to
the possession of a truncating variant, which leads to the loss of almost the entire portion of the
C-terminal domain of titin, and a missense W34072R (W260R) TK variant which leads to loss of
function (Chauveau et al., 2014a). Please note that here titin variants are notated according to their
position in the full length IC isoform with their domain position given in brackets. Including the
mutations discussed here, a total of 42 disease-associated missense variants exist with evidence in
the literature. These are associated with a variety of myopathies and cardiomyopathies, including
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and arrhythmogenic right
ventricular cardiomyopathy (ARVC) (Laddach et al., 2017). Additionally, 3 variants, with in-house
evidence providing disease associations, can be added to this total. An in-depth discussion of
titin-associated pathologies is beyond the scope of this work, for a detailed review of the subject
refer to Chauveau et al. (2014b). Suffice to suggest that the impact of titin variants is complex, due
to the variety of phenotypic manifestations, and is likely influenced by both the use of different titin
isoforms, and distinct cellular environments found in different muscle types (i.e. skeletal and cardiac
muscles).
A number of published studies have attempted to elucidate the molecular mechanisms underlying
mutations of the Fn3-119 and Ig-169 hotspots. Work by Hedberg et al. (2014) established that the
P31709R (P2R), C31712R (C5R), W31729 (W22C), and P25L (P31732L) mutations lead to impaired
solubility of the Fn3-119 domain, whereas common population variants in this domain had no such
impact. This parallels in-house data which suggests disease-associated Fn3-119 variants can have a
spectrum of impacts on the stability of the domain. Similarly, the biophysical impact of the TMD
associated missense mutants, 35946P (H50P), L35956P (L60P), and I35947N (I51N) has been studied
by Rudloff et al. (2015). In addition, they investigated the impact of an indel, referred to as the
FINmaj variant, which results in the sequence change 35927EVTW→VKEK (31EVTW→VKEK).
Again their results showed a range of impacts, with the FINmaj and L35956P (L60P) mutants
remaining unfolded at room temperature, the 35946P (H50P) mutant remaining folded at room
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temperature but demonstrating reduced stability, and the I35947N (I51N) mutant showing only
minimal destabilisation. Of the two unfolded mutants, only the FINmaj mutant had a tendency to
form aggregates. Similarly, all variants, with the exception of the I35947N (I51N) mutation, had
a negative impact on binding to the domain’s interaction partner, obscurin. Given these findings,
the authors suggest that the I35947N (I51N) mutant may not be causative of TMD, but co-inherited
with an actual causal allele. However, to date, no other explanatory allele has been proposed, and
it seems unlikely for a non-causal allele, identified by co-segregation, to localise to the structural
TMD hotspot.
In addition to mutational hotspots, several isolated mutations have been investigated in the
globular Ig and Fn3 domains. The V49M (V54M) Ig-1 mutation, near the beginning of the Z-disk,
provides one such example. Here a computational approach was taken and a variety of techniques
explored. These included the use of variant impact predictors, protein-protein docking to explore
the Ig1-telethonin interface, and molecular dynamics simulations (50 ns). Results from this study
suggest that the mutation may result in decreased affinity to telethonin, through destabilisation of
the domain and alterations to its secondary structure composition (Kumar et al., 2017).
The majority of variants discussed so far appear to have a destabilising impact, which in some
cases has the additional effect of decreasing or abrogating binding-partner affinity. In contrast, the
four variants known to be associated with HCM exhibit gain of function effects, resulting in the
upregulation of interactions. Specifically, the R740L mutation in the Z-disk increases alpha-actinin
binding affinity (Satoh et al., 1999), the S4116Y mutation increases binding affinity to DRAL/FHL2
(Matsumoto et al., 2005) and both the R9744H and R8500H mutations increase the titin/T-cap
interaction affinity (Arimura et al., 2009). These mutations are only notated according to their
position in the IC isoform as they do not occur within globular domains.
Importantly, hundreds of rare titin missense variants of unknown significance have been iden-
tified in disease cohorts. These include patients with HCM (Lopes et al., 2013), peripartum car-
diomyopathy (van Spaendonck-Zwarts et al., 2014), DCM (van Spaendonck-Zwarts et al., 2014), and
other diseases associated with sudden cardiac death (Campuzano et al., 2015). This highlights the
necessity for the development of robust methods to classify rare titin variants.
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1.4 Predicting the impact of missense variants
After the analysis of genomic data, typically 100 to 1000 variants (Li et al., 2013) may emerge
as suspects for playing a role in a disease phenotype. These may have been identified through
enrichment, co-segregation or rare variant/candidate gene analyses, as outlined in Section 1.1. At
this stage, it becomes necessary to understand the likely impact of these variants. Here the initial
use of computational predictors is desirable, as results from these can be used to further narrow
down candidate variants for wet lab analysis. Moreover, computational results can be used to design
more targeted wet lab experiments. For example, if a variant is predicted to impact on protein
stability, assays for probing this in vitro can be designed. Conversely, if a variant is predicted to
impact on protein-protein interaction affinity, wet-lab techniques which probe this will be more
appropriate. A number of computational approaches to predicting the impact of SAVs exist, which
we will discuss here.
Three main ingredients are required for the creation of variant impact predictors. These are 1)
benchmark data which comprises of variants with known or ’labelled’ impact; 2) input features; 3) a
method or algorithm which can transform these features into a prediction. We will discuss each of
these ingredients in turn. Finally, we will draw our attention to recent experimental validations
of variant impact predictors, which suggest that these computational methods require further
improvement.
1.4.1 Benchmark datasets
The majority of benchmark datasets label variants with known disease associations as deleterious,
and "common" population variants as neutral. A summary of the major benchmark datasets is
given in Table 1.1. Deleterious variants are generally obtained from the UniProt (The UniProt
Consortium, 2018) and ClinVar (Landrum et al., 2016) databases. Neutral population variants are
obtained from either UniProt (The UniProt Consortium, 2018) or dbSNP (Sherry et al., 2001), where
neutral variants have generally been defined as those with a minor allele frequency (MAF) > 0.01
or 0.05 (as data for more individuals have become available the commonly used thresholds have
decreased) (Grimm et al., 2015; Ponzoni and Bahar, 2018). Such neutral variants in dbSNP, at the time
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these data sets were constructed, originated from the 1000 genomes project. This contains data for
2502 nominally healthy individuals. As these datasets have been constructed at different time points
and contain only partially overlapping data, one strategy has been to amalgamate unique variants
to create larger benchmark datasets (Ponzoni and Bahar, 2018). One issue here is that some variants
which were previously believed to play a causal role in disease phenotypes are now believed to be
phenotypically neutral. This initial misclassification can be attributed to coinheritance (linkage)
with a variant which actually plays a causal role. An example of this phenomenon is the titin
kinase variant discussed in Section 1.3.2, initially believed to play a causal role in HMERF. Now it is
known that this variant is simply coinherited with the causal variant, which localises to the HMERF
hotspot domain Fn3-119. Another issue is that a number of variants were previously believed to be
common, due to the undersampling of particular populations. Now that genetic data exists for a
greater number of individuals, this no longer proves to be the case. Finally, a large assumption the
vast majority of these datasets make is that common variants are non-pathogenic and have similar
properties to rare non-pathogenic variants. As discussed in Section 1.1, the distinction between rare
and common variants is not fully understood. Indeed, it has been highlighted by Li et al. (2013) that
rare neutral variants are more difficult to separate from disease-associated variants than common
neutral variants are. Moreover, distinguishing disease-associated rare variants from rare neutral
variants is closer to the real task at hand, as most identified candidate variants are rare.
An alternative approach is to predict whether a variant will impact on protein molecular function,
rather than establishing whether it is deleterious or not. This approach was taken in the construction
of the benchmark dataset for the SNAP2 predictor (Hecht et al., 2015). A number of sources were used
in the creation of this dataset, including the Protein Mutant Database (Kawabata et al., 1999). This
database extracts data from the literature onmutant proteins and, amongst other annotations, records
whether a change in activity or stability is reported. The SNAP2 dataset also takes information
from enzymes which have the same EC classification and > 40 % sequence identity. Here it is
assumed that any amino acid differences between pairwise alignments of such enzymes constitute
functionally neutral mutations (Hecht et al., 2015).
In a similar vein, a number of predictors aim to decipher whether variants are destabilising.
Here benchmark datasets are extracted from the ProTherm (Gromiha and Sarai, 2010) and SkemPi
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Name Deleterious subset Neutral subset
HumVar (Adzhubei
et al., 2010)
22,196 disease-associated mutations from
UniProtKB.
21,119 common nsSNPs (MAF > 0.01) from
UniProtKB annotated as non-damaging.
ExoVar (Li et al., 2013) 5,340 disease-associated alleles with known impact
on molecular function from UniProtKB
4,752 rare alleles (MAF < 0.01) from dbSNP build
131, with no known disease association and at




19,335 missense variants from the PhenCode
database
21,170 nsSNPs with allele frequency < 0.01 and
chromosome sample count> 49 from dbSNP build
131, with no known disease-associations.
predictSNP (Bendl
et al., 2014)
19,800 disease-associated variants from a large
number of databases (SwissProt, HGMD, HumVar,
Humsavar, dbSNP, PhenCode, IDbases, 16 locus-
specific databases).
24,082 neutral variants from a large number of
databases (SwissProt, HGMD, HumVar, Humsavar,




36,440 disease-associated variants from the
UniProtKB/Swiss-prot database.
40,193 variants with no known disease-associations




Non-redundant union of deleterious SAVs
which can be mapped to a PDB structure
from the HumVar, ExoVar, VariBenchSelected,
predictSNPSelected and SwissVarSelected datasets.
Non-redundant union of neutral SAVs which can
be mapped to a PDB structure from the HumVar,
ExoVar, VariBenchSelected, predictSNPSelected
and SwissVarSelected datasets.
Table 1.1 Benchmark datasets used in variant impact prediction. Adapted from (Grimm et al., 2015).
(Jankauskaite et al., 2018) databases. The ProTherm database contains data which describes the
impact of missense variants on the stability of monomeric proteins, whereas the SkemPi database
has analogous information for protein complexes. It must be considered that all such datasets,
which amalgamate experimental data from different sources, are likely biased in coverage towards
commonly studied proteins and disease-associated variants.
The recent increase in experimental saturation mutagenesis datasets has enabled the use of these
as benchmark datasets. These have the advantage that the impacts of each mutant are experimentally
validated and associated with a magnitude. Furthermore, the impact of a range of different mutations
at a particular protein position can be explored. Here the proviso is that mutations may impact on
different functions from those which are measured (Gray et al., 2018).
In selecting benchmark datasets it is important that two types of circularity are avoided, as these
can falsely inflate the performance of a predictor (Grimm et al., 2015). Type one circularity arises
when variants in the training set and testing set overlap. This is most frequently a problem in the
creation of meta-predictors; those predictors which rely on the combined outcome of a number of
other predictors to reach their final prediction. Here it is essential that data to train the individual
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predictors is not used to assess the meta-predictor. The SwissVarSelected, VariBenchSelected and
predictSNPSelected datasets have been particularly designed to overcome this problem, as they
consist of variants which are not part of the major previously created benchmark datasets (Grimm
et al., 2015).
Type two circularity arises when all benchmark variants which localise to particular protein
belong to the same class (i.e. all variants are either classed as neutral or deleterious) (Grimm et al.,
2015). This is problematic as a predictor can achieve good performance simply by classifying all
benchmark variants which localise to a particular protein as deleterious or neutral. However, in
reality, it is likely that variants will fall into both classes. One solution has been to create benchmark
datasets only using proteins to which both classes of variants localise (Ponzoni and Bahar, 2018).
Unfortunately, this does little to ameliorate the problem if the ratio of variants from each class,
which are found in a particular protein, is still severely biased. This problem is further exacerbated
by properties intrinsic to the datasets. Once mapped to available structures, almost all of these
contain a larger proportion of disease-associated than neutral variants (Ponzoni and Bahar, 2018);
this is unlikely to reflect the true distributions of deleterious and neutral SAVs.
1.4.2 Features and methods
Prediction of the impact of missense variants rests on the premise that deleterious variants exhibit
properties which are distinct from those of neutral variants. Therefore, a step preliminary to
prediction is to uncover such segregating properties, which are referred to as features. We have
seen that disease-associated variants differ in their impact on protein structure in a number of
ways. However, predicting variant impact from structure alone poses several problems. Firstly, the
structural coverage of the proteome is incomplete (see Fig. 1.3), therefore limiting the applicability of
these methods. Secondly, due to the diverse ways in which variants can impact on protein structure,
a "one size fits all" approach cannot be used (Tang and Thomas, 2016). These problems have led to the
more extensive use and development of sequence-based predictors. Such predictors rely primarily
on evolutionary information (see Fig. 1.3), based on the notion that mutations at structurally and
functionally important sites will be subject to negative selection. Although these have had much
success, several issues have been encountered. One problem is that functionally important sites are
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Fig. 1.3 Sequence-based variant impact predictors achieve high coverage of the human proteome
(~21,000 proteins) and are most commonly based on evolutionary methods. Structure-based predic-
tors explicitly take the physicochemical environment of a mutation into account; the coverage of
such predictors (~15,000 proteins) has been greatly expanded by homology modelling (statistics taken
from Bienert et al. (2017) for the human proteome). PDB structure 2y9r is depicted, as visualised by
the UCSF Chimera software (Pettersen et al., 2004).
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not always conserved between homologs, as paralogs can specifically evolve to perform different
functions. This is particularly the case for certain families of enzymes, where homologs catalyse
the same class of reaction but the exact substrates differ (Das et al., 2015; Furnham et al., 2016;
Stone and Sidow, 2005). Therefore substrate specificity determining residues are not conserved
throughout the class. Another problem encountered is that of compensated pathogenic deviations.
Here, a variant which is pathogenic in one species is present as the wild-type residue in another
species, where its effects are ameliorated by a compensatory mutation. As the mutated residue type
is present at the specific position in the alignment, its pathogenic impact is unlikely to be predicted.
This is of considerable concern as at least 4 % of human Mendelian disease-associated variants are
known to be compensated pathogenic deviations (Azevedo et al., 2016). Moreover, even though the
best performing sequence- and structure-based methods have comparable success, sequence-based
methods offer little insight into potential mechanisms underlying variant pathogenicity. In the
following sections, we will summarise key aspects of both sequence and structure-based approaches.
Representative predictors which fall into both classes are summarised in Table 1.2.
Name Key features Predictive output Model type
SIFT (Ng and Henikoff, 2001) sequence-based predictor
(evolutionary information)
deleteriousness probabilistic











SNAP2 (Hecht et al., 2015) sequence- and structure-
based
functional impact neural-network
mCSM (Pires et al., 2014b) structure-based predictor ∆∆G SVM






REVEL (Ioannidis et al., 2016) meta-predictor deleteriousness random forests
Table 1.2 Representative methods for variant impact prediction.
Sequence-based approaches
Sequence-based approaches initially used substitution matrices derived from homologous proteins,
such as the well known BLOSUM62 matrix (Henikoff and Henikoff, 1992). Although these give a
rough idea of the likely impact of an amino acid substitution, it soon became clear that a residue’s
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propensity for deleterious mutations is also highly position specific. This led to the development of
predictors such as PolyPhen (Sunyaev et al., 2001) and SIFT (Ng and Henikoff, 2001), which derive
evolutionary features from multiple sequence alignments of the query protein and homologs. These
are the foundations on which the majority of sequence-based predictors are built, with differences
lying in the construction of the alignment (generally BLAST or HMM-based), the weighting of
each position in the alignment and the calculation of a score which reflects the likelihood of a
specific mutation (Tang and Thomas, 2016). More recent developments attempt to tackle the issue
of paralogs obscuring conservation, by either filtering sequence alignments to retain only orthologs
(Thomas and Kejariwal, 2004), or by using algorithms to detect whether subfamilies diverge (Reva
et al., 2011). Of particular interest is the recently developed predictor EVmutation, which creates
a global probabilistic model which takes epistatic effects into account, and is able to predict the
impact of combinations of mutations (Hopf et al., 2017).
In addition to evolutionary-based features, physicochemical sequence-based properties, such as
amino acid hydropathy, polarity, charge and side-chain volume, can be calculated; with an early
example being the use of the Grantham scale (Grantham, 1974). This physicochemical approach is
exemplified by the MAPP algorithm (Stone and Sidow, 2005) which elegantly combines evolutionary
and physicochemical information, with the key step being the calculation of a weighted matrix of
physicochemical properties from a multiple sequence alignment, followed by the comparison of this
matrix to those properties calculated for the mutant.
Structure-based approaches
Structure-based approaches fall into two major classes; those which use potential energy functions
to predict the impact of mutations and those which combine features calculated from 3D protein
structure using a machine learning-based approach.
Potential energy functions used by the first class of predictors can be either statistics-based,
physics-based or a combination of the two. The Fold-X software (Schymkowitz et al., 2005), for
example, uses a physics-based potential, PopMusic (Dehouck et al., 2009) a statistics-based potential
and Rosetta (Kellogg et al., 2011) a combined physics and statistics-based potential. An early approach
from the Blundell lab, SDM, combines evolutionary and structural information, in its potential energy
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functions, by using structural environment-specific substitution tables (Pandurangan et al., 2017).
In comparison, physics-based potentials include terms to account for properties such as van der
Waals forces, electrostatics, solvation energy, hydrogen bonds, and steric clashes. The weights of
such functions may be knowledge-based or learnt from experimental data, for example, FOLDEF (a
method based on the FOLD-X energy function) weights energy terms using empirical data from
protein engineering experiments (Guerois et al., 2002). Most approaches, which explicitly model
a mutation, assume a fixed backbone, although some, such as Rosetta allow for the sampling of
backbone conformations (Kellogg et al., 2011). The vast majority of these methods result in a
prediction of the change in Gibbs free energy upon mutation, however, the predictor HoTMuSiC
uses statistics-based potentials to predict changes in melting temperature (Pucci et al., 2016). This is
argued to be a more difficult task than predicting the impact of a mutation on the Gibbs free energy,
as it requires an understanding of how this quantity (∆∆G) varies with temperature.
Those algorithms which instead include structural features can either result in a prediction of
deleteriousness or impact on stability. PolyPhen-2, for example, incorporates the structure-based
features B factor and solvent accessibility, in its prediction of variant deleteriousness (Adzhubei
et al., 2013, 2010). The SAAPdb pipeline uses a more extensive range of structural features, including
the analysis of structural clashes and the formation of structural voids (where a larger amino acid
is replaced by a smaller amino acid) (Hurst et al., 2009). Other structural information used by a
number of predictors, includes annotations describing the 3D location of features such as structural
domains, binding sites, post-translational modifications and disulphide bridges (Venselaar et al.,
2010). These are generally retrieved from databases such as UniProt. When protein structure is
available, the predictor I-mutant uses the residue composition within a 9 Å sphere of the mutated
residue (Capriotti et al., 2005). The predictor mCSM, in comparison, uses a novel graph-based method
to extract atomistic distance patterns from the WT structure, upon which its prediction is based
(Pires et al., 2014b). This approach has now been extended to assessing the impact of variants on
protein-protein, protein-ligand, and protein-nucleotide interactions. Earlier graph-based approaches
include the predictor BONGO (Cheng et al., 2008), which uses a weighted residue-residue interaction
network to infer the essentiality of residues and predict the impact of mutations.
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Importantly the applicability of these algorithms can be increased through the use of homology
modelling. Indeed a handful of predictors, such as HOPE (Venselaar et al., 2010) and VIPUR (Baugh
et al., 2016) incorporate this process in their pipeline.
Protein dynamics and flexibility
As discussed in Section 1.2.4, variants can impact on protein flexibility and dynamics. Beyond the
incorporation of crystallographic B-factors (Adzhubei et al., 2013) and sequence-based metrics of
flexibility, the use of such features in the prediction of the impact of missense variants has been
underexplored. One of the few methods to model protein flexibility is Vipur (Baugh et al., 2016),
which uses the Rosetta software to model backbone rearrangements. Recently, work from the Bahar
lab has shown that incorporating structural dynamics information, derived from elastic network
models, can improve the accuracy of prediction (Ponzoni and Bahar, 2018). However, as the dynamic
features are based solely on Cα network models, the chemical nature of the change is not modelled.
Thus this dynamic information only allows discrimination between positions which are more or
less likely to harbour deleterious mutations.
Atomistic molecular dynamics has been used to assess small numbers of "case study" variants.
This approach has been applied, in particular, to cases where variants are proposed to impact
on allosteric communication (Carluccio et al., 2013). Generally, less computationally expensive
predictive methods are employed to prioritise several variants for further study using molecular
dynamics techniques. Such molecular dynamics-based investigations have found that potentially
deleterious variants generally result in increased flexibility, radius of gyration and solvent accessible
surface area (Doss and Nagasundaram, 2012; Kumar and Purohit, 2014; Pires et al., 2017); although
particular mutations, such as the V617F JAK2 SAV, have been shown to confer a rigidifying effect.
Generally, changes in hydrogen bonding networks have also been observed (Doss and Nagasundaram,
2012; Kumar and Purohit, 2014; Pires et al., 2017). One study performed atomistic molecular dynamics
to assess the impact of 57 mutations on the TGFBR2 kinase domain, however, here simulations
were limited to two nanoseconds, indicating that structural refinement rather than an exploration
of dynamics was achieved (Zimmermann et al., 2017). A few larger scale studies exist which have
used alchemical free energy simulations (Seeliger and de Groot, 2010) and free energy perturbation
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methods (Steinbrecher et al., 2017) to predict the impact of mutations on the free energy of protein
folding, however, differences in protein conformational equilibrium and flexibility have not been
explored using MD simulations on this scale. Despite the current limited use of molecular dynamics
simulations in the prediction of the impact of missense variants, it has been proposed that these
hold promise for assessing variants of unknown impact (Oliver et al., 2016).
Functional and network features
In addition to sequence and structure-based approaches, some success has resulted from using
functional and protein-protein interaction network information as predictive features. SuSPect, for
example, uses the protein-protein interaction network degree centrality of the protein a variant
localises to, to predict the variant’s impact (Yates et al., 2014). This is based on the fact that disease-
associated variants are believed to localise to proteins with more interaction partners - those proteins
which are hubs in the network. Caution must be taken, as the high centrality of disease proteins
in protein-protein interaction networks may result from bias due to the fact that they are more
frequently studied (Vidal et al., 2011). Other approaches use functional annotations, such as Gene
Ontology terms (Capriotti et al., 2013). It is important to note that, although these functional and
network features provide additional information in the prediction of variant impact, such protein-
level information may lead to an increased probability of type 2 circularity (as discussed in Section
1.4.1).
1.4.3 Combining features and methods
Unless features themselves constitute a predictive value, as is the case for a number of the early
evolutionary methods (i.e. the PSIC score of PolyPhen (Sunyaev et al., 2001)), these must be
transformed into a prediction of impact. This can be done using either empirical scoring functions
or machine learning-based methods. Empirical scoring functions rely on knowledge of the system
and can be less reliable if this is incomplete. Machine learning-based methods, in contrast, can infer
their functional form from the data and are able to predict non-linear relationships (Wójcikowski
et al., 2017). It has been argued that machine learning techniques can be "black boxes" which do not
allow insight into how predictions are arrived at, however, the majority of classical machine learning
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algorithms allow information to be extracted about the relative importance of different features
for making predictions. This may allow for insights which would not otherwise be accessible. A
number of machine learning algorithms have been applied to SAV impact prediction, including
logistic regression (Baugh et al., 2016), support vector machines (Pires et al., 2014b), random forests
(Ponzoni and Bahar, 2018) and neural networks (Ancien et al., 2018).
With the large number of predictors now available, predictors can be combined to form meta-
predictors. Again these may be combined empirically, or the results from these predictors themselves
input into a machine learning algorithm. Examples of such predictors include Condel (González-
Pérez and López-Bigas, 2011), CADD (Kircher et al., 2014) and REVEL (Ioannidis et al., 2016).
Although such meta-predictors have been shown to generally out-perform individual predictors,
this performance assessment can be inflated by type 1 circularity, as discussed in Section 1.4.1.
1.4.4 Success of predictors
Although the majority of predictors have been shown to perform well on benchmark datasets, a
number of recent studies have suggested that predictions do not map well to the actual consequences
of missense variants. A seminal study by Miosge et al. (2015) bred mice to homozygosity for 33
potentially disruptive de novo single nucleotide variants (30 missense and 3 truncating) in 23
essential immune system genes. Knockout mice for these 23 genes display clear phenotypic readouts.
Although only 4 of 30 missense variants resulted in an altered phenotype, 20 of the variants were
predicted to be deleterious by the majority of computational predictors used, which included
PolyPhen-2, Sift, and CADD. As the authors considered the possibility of phenotypic masking and/or
compensation they went on to investigate the in-vitro impact of all possible p53 variants on its
transactivation activity. Again, a large proportion of variants predicted to be deleterious (42 %
PolyPhen, 45 % CADD) had little impact on p53-promoted transcription. Similarly, Andersen et al.
(2017) identified 11 rare variants in 6 genes associated with the interferon induction pathway in
patients with herpes simplex encephalitis. Using a HEK293T cell-based system deficient in the
protein of interest, they reconstituted with the wild-type or mutant protein by transient transfection,
and induction of beta-interferon was assessed using a co-transfected reporter plasmid. An analogous
assay was used for variants in the IFNLR1 gene; here naturally occurring variants from the 1000
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genomes project were investigated. The results showed that only a single variant from the herpes
simplex cohort reduced interferon induction, similarly only one of the 1000 genomes project variants
lowered activity of IFNLR1, which still remained at ∼ 50 %. However, the majority of computational
predictions gave overestimates of the number of deleterious variants (Gray et al., 2018). These
results, taken together, indicate that a large portion of computational predictors may lack specificity.
This lack of specificity could arise from the fact that predictors are generally trained to separate
common from disease-causing variants, and therefore struggle to separate rare deleterious variants
from rare neutral variants.
Furthermore, the fact that computational approaches struggle to predict the impact of particular
mutations is highlighted by experimental saturation mutagenesis studies (Baugh et al., 2016). In
one such study positions in the LacI protein were classified as toggle or rheostat positions (Miller
et al., 2017). Here toggle positions are defined as those at which the impact of a mutation is binary,
whereas at rheostat positions a gradient in variant impact exists. It was found that, whilst predictors
performed well at toggle positions, they were poorly able to distinguish between rheostat positions.
Another recent study attempted to use saturation mutagenesis data to train their predictor (Baugh
et al., 2016). Although they achieved better performance than other methods on such data, they
noted poor performance for three of the twelve studied datasets. No rationale underlying this poor
performance could be found.
These facts suggest that, despite the plethora of predictive methods which exist, it is imperative
that these methods are improved, in order to better reflect experimental data. We believe this
improvement can be brought about by the development and use of better benchmark datasets, and a
more comprehensive understanding of which features segregate deleterious from neutral variants,
as opposed to deleterious from common variants.
1.5 Contributions of this thesis
In light of the information reviewed here, we sought to contribute towards improving the impact
prediction of missense variants. We approached this problem by trying to reach a better understand-
ing of which features can be used to distinguish between neutral and deleterious variants on three
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levels, as illustrated in Fig. 1.4. Specifically, we explore protein-level properties, including function,
expression, stability and abundance, in Chapter 3, the structural localisation of variants in Chapters
2-4, and the physicochemical impact of variants, including their effect on protein dynamics, in
Chapter 4. We focus, in particular, on the titin protein, as variants which localise to this protein can
be especially difficult to classify. Additionally, recent NGS studies have uncovered a large number of
titin variants of unknown significance (see Section 1.3.2). It must be noted that all work presented
in this thesis is associated with human genes/proteins.
The first step towards a better understanding of the impact of variants is their correct and
comprehensive annotation; an instruction manual must include a catalogue of its parts. To this
end, we developed a web application TITINdb, which we present in Chapter 2. This contains
comprehensive annotation of titin variants from the literature, the 1000 genomes project (Auton
et al., 2015) and the gnomAD database (Lek et al., 2016). The creation of this resource involved the
large-scale modelling of titin domains. This greatly increased the structural coverage of titin and
enabled the application of both sequence and structure-based methods to the impact prediction
of titin missense variants. All these results are available through the TITINdb interface (http:
//fraternalilab.kcl.ac.uk/TITINdb/), along with the results of in silico saturation mutagenesis.
From our application of currently available impact predictors to titin variants, in Chapter 2,
it becomes clear the results do not agree with one another. Moreover, the large number of rare
variants which are predicted to be deleterious suggests that these predictors may lack specificity; in
agreement with the literature discussed in Section 1.4.4. This motivated us to reach an improved
understanding of the characteristics of missense variants in health and disease, and led us to perform
a multidimensional analysis of the properties of population variants from the gnomAD database
(Lek et al., 2016), somatic cancer variants from the COSMIC database (Forbes et al., 2015) and
germline disease-associated variants from the ClinVar database (Landrum et al., 2016). Throughout
this analysis, we further segregated population variants into common and rare subsets, in order
to better understand the distinction between these. Uniquely, we integrated our analysis with
available transcriptomic and proteomics data. Clear differences between the datasets emerge; these
include observations which build upon those already reported in the literature but derived using
more extensive data, in addition to novel observations. The results of this work are presented in
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Fig. 1.4 Separating deleterious from neutral variants can be seen as a three-step process. This
involves establishing whether a protein a variant localises to is likely to harbour pathogenic muta-
tions, whether the 3D position of a variant suggests it may be disease-causing, and whether the
physicochemical nature of the mutation suggests it is deleterious.
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Chapter 3. A by-product of this analysis has been the creation of the ZoomVar database (http:
//fraternalilab.kcl.ac.uk/ZoomVar/), an online tool which allows users to annotate variants according
to their localisation to protein structure and protein-protein interaction sites, in addition to the
calculation of the enrichment of missense variants in different protein structural regions.
Through the work presented in Chapter 3, it becomes apparent that although features can be
used to separate disease-associated from population variants, as the feature distributions for these
two classes overlap, problem cases remain. For example, although disease-associated variants are
clearly enriched in protein cores, and population variants depleted in these regions, a small portion
of population variants are found in protein cores. This leaves us with a problem - how can we
distinguish rare disease-associated variants from rare neutral variants if they have superficially
similar characteristics? We explore this problem in Chapter 4, where we turn to protein dynamics,
due to the promise this holds (discussed in Section 1.4.2). Initially, we sought to incorporate dynamics
features from elastic network models in the prediction of variant impact, as we believed this would
improve performance. As work from the Bahar lab (Ponzoni and Bahar, 2018) recently proved
this to be the case, we decided to extend our work to the investigation of coarse-grained and
atomistic molecular dynamics approaches. Here we focussed on whether modelling the chemical
nature of the change, by calculating features which describe differences between wild-type and
mutant trajectories, could improve impact prediction. To test this we used a dataset constructed
of titin variants with known disease associations and population titin variants (the majority of
which are rare). We believe this is the first example of work which uses features derived from
molecular dynamics simulations within a machine learning-based framework for predicting the
impact (deleterious/neutral) of missense variants. Moreover, we believe this approach offers much
scope for future development, as discussed in Chapter 5.
Chapter 2
TITINdb
Missense variants which localise to the giant protein titin are particularly difficult to classify. As
discussed in Section 1.3.2, since the advent of NGS technology a number of titin variants have been
associated with both skeletal and cardiac forms of myopathy (Chauveau et al., 2014b; Hastings et al.,
2016; Helle and Parikh, 2016; Savarese et al., 2016). However, due to titin’s large size, even most
healthy individuals possess rare or unique titin variants (Lopes et al., 2013); therefore distinguishing
disease-associated variants from neutral variants is a non-trivial task. To complicate matters further,
it has recently been shown that certain titin variants can be pathogenic in particular constellations
or act as phenotype modifiers (Evilä et al., 2014). For example, in recent years novel paediatric
forms of core myopathy with heart disease have been associated with the inheritance of a rare titin
missense variant in trans with a truncating variant (Chauveau et al., 2014a). As a large number
of titin variants of unknown significance exist (Campuzano et al., 2015; Lopes et al., 2013; van
Spaendonck-Zwarts et al., 2014), the correct evaluation of these could contribute towards elucidating
the problem of missing heritability. However, at the start of this project, the in silico assessment of
such variants was hampered by the large size of the titin protein and discrepancies in titin domain
boundaries and numbering, in addition to the incomplete structural coverage of titin (Laddach
et al., 2017). To overcome these problems, and to facilitate the interpretation of titin missense
variants, we created the web application TITINdb. This integrates titin structure, variant, sequence
and isoform information, along with pre-computed predictions of the impact of non-synonymous
single nucleotide variants. Key steps in the creation of this tool included defining titin domain
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boundaries and the large scale homology modelling of titin Fn3 and Ig domains, in order to allow
for the structural mapping and further in silico assessment of titin missense variants.
This chapter consists of the paper "TITINdb-a computational tool to assess titin’s role as a
disease gene" published in the journal Bioinformatics which describes this resource. The project was
conceived by Prof. Franca Fraternali and Prof. Mathias Gautel. I carried out all the work, under their
guidance, including homology modelling, analysis, creation and deployment of the web application,
and writing of the paper. It should be noted that references for the paper and its supplementary
materials are included separately and directly succeed each of these. All references also feature in
the bibliography of this thesis.
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Abstract
Summary: Large numbers of rare and unique titin missense variants have been discovered in both
healthy and disease cohorts, thus the correct classification of variants as pathogenic or non-
pathogenic has become imperative. Due to titin’s large size (363 coding exons), current web appli-
cations are unable to map titin variants to domain structures. Here, we present a web application,
TITINdb, which integrates titin structure, variant, sequence and isoform information, along with
pre-computed predictions of the impact of non-synonymous single nucleotide variants, to facilitate
the correct classification of titin variants.
Availability and implementation: TITINdb can be freely accessed at http://fraternalilab.kcl.ac.uk/
TITINdb
Contact: franca.fraternali@kcl.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The giant protein titin, encoded by the gene TTN, is 35 991 amino
acids in length [inferred complete (IC) isoform], weighs over
4000 kDa and spans half a sarcomere. Since the advent of next gen-
eration sequencing (NGS) technology, a number of titin missense
variants, both recessive and dominant, have been associated with
disease (both skeletal and cardiac forms of myopathy) (Chauveau
et al., 2014a; Hastings et al., 2016; Helle et al., 2016; Savarese
et al., 2016), including those which can lead to sudden cardiac death
[e.g. hypertrophic cardiomyopathy (HCM)]. Unfortunately, due to
titin’s large size, even the majority of healthy individuals possess one
or more rare titin missense variants (Lopes et al., 2013). This results
in the paradox that rare titin variants are commonly found; there-
fore, pathogenicity cannot be inferred from frequency alone. To
complicate matters further, it has recently been shown that certain
titin variants can be pathogenic in particular constellations or act as
phenotype modifiers (Evil€a et al., 2014). One such scenario is the in-
heritance of a truncating variant along with a rare or unique mis-
sense variant in compound heterozygosity [as has been observed in
childhood core myopathy with heart disease, with rare recessive mu-
tations also found in the general population (Chauveau et al.,
2014b)]. In light of this information, we believe the assessment of
the impact of non-synonymous single nucleotide variants (nsSNVs)
at the molecular level to be essential, and propose that in silico
analyses can be used to prioritise variants for further experimental
investigation. We have created TITINdb to facilitate such
prioritization.
2 Implementation and features
TITINdb includes disease-associated nsSNVs reported in the litera-
ture as well as population nsSNVs from the gnomAD database (Lek
et al., 2016) and 1000 genomes project (Auton et al., 2015).
Additionally, in silico saturation mutagenesis has been performed to
allow users to access predictions for the impact of any possible sin-
gle amino acid variants (SAVs). As experimental structures were
only available for 23 of titin’s 302 globular domains (132 Fn3, 169
Ig, 1 Kinase), an automated pipeline based on the Modeller software
(Webb and Sali, 2016) was set up to model all 279 domains without
structure (see Supplementary Figure S3 for more details). As major
bioinformatics resources did not agree on titin domain numbers and
boundaries, we found it necessary to define these prior to modelling.
VC The Author 2017. Published by Oxford University Press. 3482
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As illustrated in Supplementary Figure S6, the TITINdb pipeline has
greatly increased the structural coverage of titin domains and the
quality of the coverage.
Sequence-based prediction of the impact of all nsSNVs was per-
formed using the Condel software (Gonzalez-Pe´rez and Lopez-
Bigas, 2011). The in silico assessment of the impact of nsSNVs using
structural information was performed using the DUET software
(Pires et al., 2014a) for all known nsSNVs which map to domain
structures, additionally the mCSM software (Pires et al., 2014b) was
used to predict the impact of all possible SAVs. Where experimental
structures of titin domains in complex with binary interaction part-
ners exist, mCSM was also used to predict the impact of SAVs on
protein–protein binding affinity. Other structural analysis provided
by the application includes computation of the quotient solvent ac-
cessible surface area [Q(SASA)] of all residues which map to struc-
ture [calculated using POPS (Cavallo et al., 2003)] and predictions
of which residues are involved in protein–protein interactions [cal-
culated using SPIDDER (Porollo et al., 2007)]. Of note, however, is
the absence of experimental, molecularly resolved protein–protein
interaction data for most of titin’s domains, precluding detailed im-
pact analysis on protein–protein interactions. Additionally, nsSNVs
are annotated with functional site information from UniProt (The
UniProt Consortium, 2017), including residue modifications.
Representative structures for each domain were used in the com-
putation of all structural analyses, apart from the calculation of
Q(SASA). This was calculated separately for each structure. A list of
structure representatives can be found in the Supplementary Tables
S1 and S2.
The application enables users to perform a number of visual-
izations, which include viewing population nsSNVs as distributions
on structures, colour-coded by minor allele frequencies.
Additionally, users are able to confidentially upload their own struc-
ture for nsSNV visualization (this may be useful if a group has an
unpublished crystal structure or believe their own model to be of
better quality).
All structures and in silico analyses can be freely accessed and
downloaded. Additionally, we provide quality assessment of the
models (in the form of zDOPE scores and per-residue DOPE plots)
(Shen and Sali, 2006) along with the alignments used for homology
modelling.
Video tutorials showing the use of TITINdb can be found at
http://fraternalilab.kcl.ac.uk/TITINdb/tutorials/
3 Applications
3.1 Investigating disease associated nsSNVs
A potential application of TITINdb that involves investigating SNVs
associated with specific diseases is shown in Figure 1 and further
explored in section S2.1 of the Supplementary Materials. The facility
to search by disease enables the detection of patterns or hotspots
characteristic of variants associated with particular diseases. Two
known nsSNV hotspots exist: one in domain Fn3-119 associated
with hereditary myopathy with early respiratory failure (HMERF)
(Pfeffer et al., 2015) and one in Ig-169 associated with tibial muscu-
lar dystrophy, limb-girdle muscular dystrophy 2J (TMD/LGMD2J)
(Chauveau et al., 2014a; Hackman et al., 2002; Savarese et al.,
2016).
TITINdb facilitates the visualization of nsSNVs associated with
these diseases on structure (see Fig. 1); for both conditions nsSNVs
can be observed to cluster in 3D space. In each case it can also be
clearly seen that the distribution of disease associated nsSNVs on
3D structure is distinct from the distribution of population nsSNVs
from the gnomAD database. Furthermore it becomes clear that all
disease-associated nsSNVs discussed here are fairly buried (as indi-
cated by a burgundy colour); therefore, it appears likely that they
may disrupt protein stability. From the pre-calculated in silico ana-
lysis, it can be seen that all these disease associated nsSNVs are pre-
dicted to be destabilizing by DUET (Pires et al., 2014a). TMD
associated nsSNVs are also predicted, by mCSM (Pires et al.,
2014b), to disrupt the interaction between titin and obscurin, albeit
by varying magnitudes; this has been validated experimentally
(Fukuzawa et al., 2008; Rudloff et al., 2015). Interestingly the
I35947N variant is predicted to have the least impact on the titin-
obscurin interaction affinity (mCSM score -0.17 kcal/mol) out of all
the TMD associated variants; this correlates with in vitro experi-
mental observations where negligible differences have been found
between this variant and wild-type titin (Fukuzawa et al., 2008;
Rudloff et al., 2015). Additionally, the majority of HMERF associ-
ated nsSNVs are predicted to be deleterious by Condel (Gonzalez-
Pe´rez and Lopez-Bigas, 2011), whereas only half the TMD
associated nsSNVs are predicted to be deleterious. This highlights
the need to take into consideration multiple sources of information,
as provided by TITINdb, when predicting the potential impact of
nsSNVs, and does not exclude experimental validation on a case-
by-case basis.
Despite being a hotspot for HMERF associated nsSNVs, no ex-
perimental PDB structures or models are currently publicly avail-
able for the domain Fn3-119. Therefore, TITINdb has made
possible the visualization of HMERF nsSNVs on structure and the
in silico prediction of their impact at the molecular level. Multiple
PDB structures exist for the domain Ig-169 (commonly referred to
as M-10), to which TMD associated nsSNVs localize. Here, users
can select which structure they wish to use to perform nsSNV
visualization.
3.2 Investigating NGS nsSNV data
An application of TITINdb we believe to be particularly useful is the
analysis of variants from NGS data. Specifically, the tool can be
used in the prioritization of rare variants observed in disease cohorts
for further experimental investigation. An example of such a variant
is the P13979S titin N2B (isoform) nsSNV, which is published in the
Supplementary Information associated with the article from Lopes
et al. (2013), and further described in Section S2.2 of the
Supplementary Materials. The nsSNV is found in 3/143 patients
with HCM, leading to a cohort minor allele frequency (MAF) of be-
tween 0.01 and 0.02 (details on zygosity are not available).
A notable feature of TITINdb is the ability to search by different
isoform positions. Tools such as ANNOVAR (Wang et al., 2010)
enable researchers to map variants from genomic to protein coordin-
ates, however, depending on the protocol followed, variants may be
mapped to different isoforms. For our nsSNV of interest, the N2B
isoform coordinate is reported, thus the ‘search by position’ facility
allows it to be mapped to both other major isoforms and the pos-
ition within the affected domain. Additionally, it can be seen that
the nsSNV localizes to residue position 5 of domain Fn3-55 and is
present in all isoforms apart from the novex-3 isoform; therefore it
is expressed in both cardiac and skeletal muscle.
TITINdb allows easy access to information concerning the
nsSNV’s potential impact. Structurally, it can be seen that the af-
fected residue has a Q(SASA) of 0.1 (this information is provided in
the table on the nsSNV page), indicating that it is buried and that
the nsSNV could potentially cause disease through destabilization of
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the underlying domain. It can also be seen, from predictions by the
software SPPIDER (Porollo et al., 2007), that the affected residue is
not predicted to be involved in protein-protein interactions and thus
is unlikely to cause disease through the disruption of these.
On comparison to known nsSNVs it can be seen that the nsSNV
is present in both the 1000 genomes data and the gnomAD database
with MAFs of 3.7036E-03 and 9.98403E-04. This indicates the vari-
ant is rare but present in a small proportion of nominally healthy in-
dividuals. From the MAF values it can be deduced that the variant is
enriched in the HCM cohort (which we know has a MAF between
0.01 and 0.02). This suggests that the variant is either neutral,
disease-causing with incomplete penetrance, recessive, or that a
small number of nominally healthy individuals have undiagnosed
HCM.
Structure (DUET)- and sequence (Condel)-based predictions of
the impact of the nsSNV can be observed. The DUET score of
2.703 kcal/mol suggests the variant is highly destabilizing and sup-
ports the hypothesis derived earlier from the Q(SASA) that the vari-
ant could potentially lead to disease by disrupting the domain
structure. Furthermore, it can be seen that the variant is also pre-
dicted to be deleterious by Condel.
As no experimental structures exist for the domain Fn3-55, 3D
visualization and access to pre-computed structural analyses are
made possible by the homology model provided as part of TITINdb.
One salient feature is that, if nsSNVs are pinned on structure from
the sequence, any related/identical nsSNVs rise to the top of the
nsSNV table and become highlighted in either yellow (surface) or
red (buried) according to their Q(SASA) (see Supplementary Figure
S2); the pinned nsSNVs also follow this colour scheme.
The results indicate that, although the analysed nsSNV is highly
likely to affect the domain structure, it is unclear whether this will
contribute to the disease phenotype (primarily as the mutant titin
may not be expressed in vivo in heterozygous cases).
Further information concerning applications of TITINdb can
be found in the Supplementary Materials. In particular, it is hoped
that the tool will enable clinicians to perform the information-
based assessment of variants from patient data, and assist biolo-
gists in the prioritization of domain structures for biophysical
characterization.
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TITINdb enables users to:
• access pre-computed predictions of the
impact of gnomAD, 1000 genomes and
disease-associated nsSNVs calculated using
Duet (Pires et al., 2014b) and Condel
(Gonza´lez-Pe´rez and Lo´pez-Bigas, 2011)
• access pre-computed predictions of the
impact of any possible single amino acid
variants (SAVs) which localise to titin
domain structures, calculated using mCSM
(Pires et al., 2014a), and the impact of any
possible nsSNVs calculated using Condel
(Gonza´lez-Pe´rez and Lo´pez-Bigas, 2011)
• access pre-computed predictions of the impact
of any possible SAVs on protein-protein
binding affinity calculated using mCSM (Pires
et al., 2014a) (where experimental structures
for titin domains in complex with interaction
partners exist)
• visualise nsSNVs on structure and save images
as PNG files
• visualise 3D nsSNV distributions on structure
from the 1000 genomes project, gnomAD and
disease-associated nsSNVs
• download all nsSNV information for nsSNVs
which localise to a titin Ig, Fn3 or kinase
domains as a CSV file
• explore disease hotspots through the facility to
”search by disease”
• access structural analysis, i.e. the Q(SASA)
for each residue (computed using POPS
(Cavallo et al., 2003)) and predictions of
which residues take part in protein-protein
interactions (computed using SPPIDER
(Porollo et al., 2007))
• access Uniprot (The UniProt Consortium,
2017) functional site annotations, including
residue modifications
• download structures and models of titin Ig,
Fn3 and kinase domains as PDB files
• assess model quality by using zDOPE
score, per residue DOPE score plots and
query-template alignments
• upload structures/models for nsSNV
visualisation
• translate between isoform amino acid positions
for all seven titin isoforms with RefSeq
sequences (IC, N2AB, N2A, N2B, novex-1,
novex-2, novex-3)
S2 Case studies
Mutations which result in amino acid changes
can be broadly divided into two classes: those
which are present in the population and which
are generally not phenotypically deleterious, or
those which are causative of disease. Certain
mutations may also be unclassified, and of
uncertain effect. For titin this is frequently
the case when nsSNVs are observed in disease
cohorts but a causative link with the condition
has not been established. In TITINdb we present
analyses of nsSNVs which fall into the ”classified”
classes, to enable users to better understand
the properties of such nsSNVs, and in order to
facilitate the classification of currently unclassified
nsSNVs; a graphical summary of this can be
seen in Fig. S1. The two classes are, however,
not mutually exclusive. Some disease-associated
nsSNVs may demonstrate incomplete penetrance
or may be recessive (e.g. in compound
heterozygosity (Evila¨ et al., 2014; Chauveau et al.,
2014a)), or play a modifier role in disease.
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Conversely, it is possible that certain nsSNVs
may be misclassified due to nominally healthy
individuals harbouring undiagnosed disease, or
linkage disequilibrium existing between variants
which are actually disease-causing and those which
are not. Indeed, it must be remembered that
the gnomAD database, although not expected
to be enriched in disease-associated nsSNVs,
does contain genetic information from disease
cohorts, although individuals with severe paediatric
disease have been filtered out (Lek et al., 2016).
Nevertheless, the gnomAD database is expected
to contain rare recessive disease-causing TTN
mutations similar to any gene, e.g. recessive
autosomal CFTR mutations causing cystic fibrosis
(frequency of heterozygous carriers between 1% and
3.5% depending on population (Strom et al., 2011))
or recessive X-linked DMD mutations causing
Duchenne muscular dystrophy (carrier frequency
0.18% Mundy et al. (2016)). The main difference
is that such recessive mutations are expected to
be more numerous in titin due to the large size of
the coding sequence (>100kb). In silico saturation
mutagenesis has also been carried out to enable
users to predict the impact of novel nsSNVs.
In the following case studies, we show how
TITINdb allows the exploration of disease
associated nsSNVs, and how the application can
be used to facilitate the classification of new
nsSNVs.
S2.1 Investigating disease associated
nsSNVs
TITINdb allows the user to search by disease;
currently 12 myopathies have associated titin
variants. This enables the detection of patterns
or hotspots characteristic of variants associated
with particular diseases. Two known nsSNV
hotspots have been investigated in the main
text: one in domain Fn3-119 associated with
hereditary myopathy with early respiratory failure
(HMERF) (Palmio et al., 2014; Pfeffer et al.,
2012; Ohlsson et al., 2012; Toro et al., 2013;
Izumi et al., 2013; Vasli et al., 2012; Uruha
et al., 2015) and one in Ig-169 associated with
tibial muscular dystrophy/limb-girdle muscular
dystrophy 2J (TMD/LGMD2J) (Pollazzon et al.,
2010; Van den Bergh et al., 2003; Hackman et al.,
2002; Evila et al., 2016). Here, we present an
additional example, which investigates nsSNVs
associated with dilated cardiomyopathy (DCM).
This disease is primarily associated with titin
truncating variants (Schafer et al., 2016). There
are, however, a number of nsSNVs which are also
associated with this condition.
On searching for dilated cardiomyopathy (DCM)
associated nsSNVs (Itoh-Satoh et al., 2002; Gerull
et al., 2002; Herman et al., 2012; LIU et al., 2008;
Roncarati et al., 2013; Matsumoto et al., 2005),
it can be seen that these do not appear to form
a distinct hotspot as observed for both TMD and
HMERF, and, although two of the thirteen nsSNVs
localise to the domain Ig-30, they are situated at
opposite ends of the domain. It can be noted that
these nsSNVs are both found in gnomAD and one is
also found in the 1000 genomes project; indicating
that these nsSNVs are unlikely to demonstrate
complete penetrance. Upon visualisation on the
available model of Ig-30, it can be seen that the
affected residues are also both located on the
surface of the protein, with the S4780N nsSNV not
predicted to be destabilising. This suggests that
pathogenicity could be a result of the disruption
of protein-protein interactions. Indeed, from the
SNV table it can be seen that both residues affected
by these nsSNVs are predicted to take part in
protein-protein interactions.
From this example and those in the main
text, it can be seen that inferring titin nsSNV
pathogenicity can be a complex task; however, even
with the sparse association of titin nsSNVs with
disease, emerging patterns/hotspots are already
discernible and further work will aid in the
classification of currently unclassified nsSNVs.
S2.2 Investigating NGS nsSNV data
Hypertrophic cardiomyopathy (HCM) is a clinically
heterogeneous disease in which the walls of the
heart become thickened, in particular the wall of
the left ventricle (Pantazis et al., 2015). It is caused
by cardiac sarcomere mutations with incomplete
penetrance (Seidman and Seidman, 2011) and is
one of the leading causes of sudden death in
young adults, affecting approximately 1 in 500
individuals (Maron et al., 1995). A number of rare
and unique missense variants have recently been
found in a cohort of HCM patients (Lopes et al.,
2013), however how many of these play a causative
2
51
Figure S1: Summary showing how the information in TITINdb can be used to assess unclassified
nsSNVs. This can be done in several ways, for example by comparing nsSNV properties to known
SNVs, of which there are currently 51 disease-associated nsSNVs and a larger number of population
nsSNVs (19741 in the gnomAD database and 1982 in the 1000 genomes data). There is an overlap of
24 nsSNVs between disease-associated nsSNVs and population nsSNVs (from the 1000 genomes project
and gnomAD database); this is most likely due to the incomplete penetrance of some disease-associated
SNVs. Information based assessment can also contribute to the classification of unclassified SNVs
through structure- and sequence-based predictions of their impact, and properties of their location on
3D structure.
role in the disease is currently unclear. In the
main text we show one possible use of TITINdb
through the analysis of the P13979S titin N2B
nsSNV which is published in the supplementary
information associated with the paper from Lopes
et al. (2013). The visualisation of this particular




Figure S2: Visualisation of the P13979S titin N2B nsSNV on the Fn3-55 domain structure. The red
colour indicates the nsSNV affects a buried residue. The nsSNV can be compared to the gnomAD
distribution of nsSNVs (shown in orange).
S3 Methods
S3.1 Data
1000 genomes titin variant data was obtained in
VCF format using the online data slicer (Auton
et al., 2015). Variants were mapped to isoform
and position using ANNOVAR (Wang et al.,
2010). gnomAD variant data was obtained from
the gnomAD web server (Lek et al., 2016) in
Variant Dataset Format and titin nsSNVs were
extracted using Hail (Ganna et al., 2016). Titin
related disease nsSNVs were obtained from ’A
rising titan: TTN review and mutation update’
(Chauveau et al., 2014b). Disease nsSNVs reported
in the literature discovered since the publication
of Chauveau et al. (2014b) were queried for on
PubMed using the terms ”(”titin”[All Fields]) AND
(”snp”[All fields])”,”(”titin”[All Fields]) AND
(”mutation”[All fields])” and ”(”titin”[All Fields])
AND (”variant”[All fields])”.
Data from the 1000 genomes project originates
from 2504 nominally healthy individuals. The
gnomAD database represents a much larger
number of individuals (138632) and is aggregated
from a number of studies, including the 1000
genomes project. It does not only include
healthy individuals; however individuals with
severe paediatric diseases have been filtered from
the dataset. Therefore the gnomAD database is
unlikely to be enriched in variants associated with
severe diseases and is likely to be indicative of a
population distribution of variants.
Titin functional site information was obtained
from UniProt (The UniProt Consortium, 2017).
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S3.2 Defining titin domain
boundaries
HMMER (Finn et al., 2011) was used to
scan the protein sequence of titin IC variant
(NP 001254479.2), obtained from the RefSeq
database (Pruitt et al., 2012) against Pfam seed
libraries (Finn et al., 2014). Where hits overlapped
the hit with the lowest E-value was accepted. When
the lowest E-value hit for a region was greater
than 0.0001 additional evidence was required to
accept a hit, such as an existing experimental
structure or homology to other titin domains of
the same type. This homology was assessed by
creating an HMM from all titin domains of the
same type (which had been identified with an
E-value <0.0001) and rescanning the titin protein
sequence against this HMM. If identified domains
were detected with an E-value <0.0001, upon
scanning against this titin-specific HMM, they were
considered homologous.
Sequences of titin domains defined in this way,
including an extra 5 amino acids upstream and
16 amino acids downstream of the Pfam defined
boundary, were aligned using T-coffee (Notredame
et al., 2000) (separate alignments were created for
titin Fn3 and Ig domain sequences).
Sequence logos were also created from these
alignments using Weblogo (Notredame et al., 2000).
Additionally, sequence logos were created from the
Pfam I-set and Fn3 seed alignments. It should be
noted that all titin Ig domains are determined to be
of the I-set type when defined by scanning against
Pfam seed alignments.
Comparisons were made between sequence
logos derived from aligned titin domain sequences
and those derived from Pfam seed alignments.
Where the two types of sequence logo appeared
to differ substantially or the domain boundaries
did not appear to be clearly defined by sequence
conservation, the boundaries were mapped
onto available experimental 3D structures and
information from this mapping used to redefine
titin domain boundaries. It must be noted
that differences between sequence logos, and
clarity of the initial domain boundaries, were
assessed heuristically by eye. Additionally,
the redefinition of domain boundaries was
accomplished heuristically by setting these visually
to cover the entire globular portion of the mapped
domain structures.
S3.3 Mapping of titin isoforms
Stretcher (Myers and Miller, 1988) was used to
align all titin isoforms to the IC variant. Isoform
sequences were obtained from RefSeq (Pruitt et al.,
2012). Positions were mapped according to these
alignments.
S3.4 Modelling of titin domains
An automated homology modelling pipeline was
set up. The pipeline takes a fasta file of
domain sequences as input and uses only publicly
available PDB structures as templates. The overall
modelling process can be seen in Fig. S3A and
a flow diagram detailing the template selection
process is depicted in Fig. S3B. The template
search, modelling and model assessment were
performed using Modeller (Webb and Sali, 2016),
the alignment of query and templates performed
using 3DCoffee (O’Sullivan et al., 2004), and the
overall pipeline produced using Python 2.7. Models
were selected based on zDOPE score. zDOPE
score is a normalised atomic distance-dependent
statistical potential based on a sample of native
structures (Shen and Sali, 2006). Lower zDOPE
scores indicate better models with zDOPE scores
below -1 indicating the distribution of atomic
distances is similar to that in the sample of native
structures.
The I-TASSER server (Zhang, 2008) was used
to model Ig-112 as a satisfactory (negative)
zDOPE score was not obtained using the homology
modelling pipeline.
S3.5 Validation of models
The modelling pipeline described in Section S3.3
was used to model all models with existing
experimental structures. However so as to exclude
the already solved structure from the templates, all
hits with an identity >95% were excluded during
template selection.
To validate the models these were compared to
the representative experimental structures detailed
in Table S1 in a similar manner to Sa´nchez and Sali
(1998) as well as the Critical Assessment of Protein
Structure Prediction experiments (Cozzetto et al.,
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Figure S3: Flow-diagrams showing A an outline of the modelling pipeline and B template selection
criteria. Qualifying templates refer to those templates which are selected for the modelling procedure.
2009). Sequence alignments between structures
and models were calculated using Muscle (Edgar,
2004) and, structural superpositions guided by
the sequence alignments as well as per residue
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Table S1: PDB structures used for the structural
investigation of nsSNVs.
domain PDB ID method resolution/ A˚
Ig-1 2a38 X-RAY 2.00
Ig-2 2a38 X-RAY 2.00
Ig-10 1g1c X-RAY 2.10
Ig-18 5jdd X-RAY 1.53
Ig-19 5jdd X-RAY 1.53
Ig-20 5jdd X-RAY 1.53
Ig-84 5j0e X-RAY 2.00
Ig-94 1waa X-RAY 1.80
Ig-156 3lcy X-RAY 2.50
Ig-157 3lcy X-RAY 2.50
Ig-158 2j8h X-RAY 1.99
Ig-159 2j8h X-RAY 1.99
Ig-160 2bk8 X-RAY 1.69
Ig-163 3qp3 X-RAY 2.00
Ig-164 1tnn NMR NA
Ig-166 3puc X-RAY 0.96
Ig-169 3knb X-RAY 1.40
Fn3-3 4o00 X-RAY 1.85
Fn3-62 1bpv NMR NA
Fn3-66 3lpw X-RAY 1.65
Fn3-67 3lpw X-RAY 1.65
Fn3-132 2nzi X-RAY 2.90‘
RMSD calculations were performed using Theseus
(Theobald and Wuttke, 2006).
S3.6 In silico assessment of the
impact of nsSNVs
The in silico assessment of known nsSNVs
occurring within Ig and Fn3 domains was
performed using DUET (Pires et al., 2014b). This
tool exploits structural information and is based
on a consensus of mCSM (Pires et al., 2014a),
a graph-based method combined with machine
learning to predict free energy changes resulting
from single point mutations, and SDM (Topham
et al., 1997) which uses environment-specific
substitution tables. The prediction of impact for all
possible SAVs which localise to domain structures
was carried out using mCSM (Pires et al., 2014a);
this algorithm was chosen as its speed enables the
prediction to be carried out for the large number of
such possible SAVs (492271). Where experimental
structures were available these were used for the
assessment. Where no experimental structures
were available the model with the lowest zDOPE
score was used. See Table S1 for experimental
structures used in the in silico assessment of
nsSNVs. The impact of nsSNVs on protein-protein
binding affinity was also predicted using mCSM
(Pires et al., 2014a) where experimental structures
of titin domains in complex with binary interaction
partners exist. See Table S2 for structures used
in the assessment of the impact of nsSNVs on
protein-protein binding affinity.
Assessment of all nsSNVs was performed
using the method Condel (Gonza´lez-Pe´rez and
Lo´pez-Bigas, 2011). This method is purely
sequence-based and uses the weighted average of
the normalised scores of 5 methods: Log R Pfam
E-value, MAPP, Mutation Assessor, Polyphen2
and Sift (Gonza´lez-Pe´rez and Lo´pez-Bigas, 2011).
S3.7 Definition of structural
elements
Interface and core regions were defined using POPS
(Cavallo et al., 2003). Residues with a Q(SASA)
(quotient solvent accessible surface area)> 0.3 were
defined as being surface residues and those with
a Q(SASA) ≤ 0.3 defined as core residues. Here
Q(SASA) is defined as the quotient of the SASA
(solvent accessible surface area) and Surf (surface
area of the isolated residue).
Putative PPI interface regions were predicted
using SPPIDER II (Porollo et al., 2007) with
a balanced trade-off between sensitivity and
specificity (SPPIDER estimates this based on
a control data set of 149 protein chains with
no sequence homology), using representative
structures (see Table S1). SPPIDER II
predicts interface residues with 74.18% accuracy,
60.30% recall, 63.72% precision, and a Matthews
correlation coefficient (MCC) of 0.42.
S3.8 Creation of a titin database
A database was set up to integrate titin structural,
variant and disease information. The database was
created using SQLite and DJANGO. nsSNVs from
the 1000 genomes project, ExAC and the paper ‘A
rising Titin: TTN review and mutation update’
(Chauveau et al., 2014b), as well as information
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Table S2: PDB structures used for the investigation of the impact of nsSNVs on protein-protein binding
affinity.
domain PDB ID method resolution / A˚ interaction partner
Ig-1 1ya5 X-RAY 2.44 TCAP
Ig-2 1ya5 X-RAY 2.44 TCAP
Ig-169 3knb X-RAY 1.40 OBSL1
Ig-2 4c4k X-RAY 1.95 TCAP
concerning structures modelled by the pipeline and
PDB structures were loaded to the database.
S3.9 Web server implementation
TITINdb is a python-based application
implemented using the DJANGO framework.
JSmol is used to visualise protein structures. It is
hosted on an Apache2.2.15 web server.
S4 Results
S4.1 Comparison of the calculated
properties of categorised
nsSNVs/SAVs
A comparison of the calculated properties of
categorised nsSNVs/SAVs which feature in
TITINdb can be seen in Fig. S4. The top left
plot compares the log-transformed distribution
of gnomAD frequencies for nsSNVs found in the
1000 genomes project with the log-transformed
distribution of gnomAD frequencies for nsSNVs
associated with disease (a small pseudocount
of 3.6E-6 has been added to each frequency to
allow for log transformation). It can be seen
that although the two subsets are significantly
different the MAF values show a large overlap.
Here the caveat must be taken that data from
1851 individuals from the 1000 genomes project
is a subset of the gnomAD data set. However, as
data from the 1000 genomes project only accounts
for 1.3% of the data in gnomAD it is considered
unlikely that this will have a large impact on the
MAF values observed in gnomAD. These results
suggest that not all pathogenic variants can be
distinguished from non-disease causing variants by
differences in MAF.
The top right plot shows the distributions of
Condel scores for nsSNVs from the 1000 genomes
project, the gnomAD database, saturation
mutagenesis, and disease-associated nsSNVs.
The disease-associated nsSNVs are predicted to
be significantly more deleterious than nsSNVs
the other subsets. nsSNVs from saturation
mutagenesis are predicted to be significantly
more deleterious than those from the 1000
genomes project and gnomAD database (from
Fig. S4 it is clear the difference is very small
and significance reached due to the large size of
the dataset), however significantly less deleterious
than disease-associated variants.
In the bottom left plot it can be seen that
disease-associated nsSNVs localise to residues with
a significantly lower Q(SASA) than nsSNVs and
SAVs from all other subsets. SAVs from saturation
mutagenesis localise to residues with a significantly
lower Q(SASA) than variants from the 1000
genomes data or ExAC database, however it is clear
that the difference is very small and significance
reached due to the large size of the dataset.
The bottom right plot shows the distribution
of mCSM scores (predicted impact on stability in
kcal/mol, negative values indicate destabilisation)
for variants from each subset of the data. Here
it can be seen that disease-associated nsSNVs are
predicted to be significantly more destabilising
than nsSNVs from the 1000 genomes project,
the gnomAD database and SAVs from saturation
mutagenesis.
Please note that saturation mutagenesis has
explored all variants (SAVs) which can be achieved
by a single amino acid change through mCSM
and POPs, however only those variants (nsSNVs)




Figure S4: A comparison of the properties of titin nsSNVs from the 1000 genomes project and gnomAD
database with disease-associated nsSNVs and nsSNVs/SAVs from saturation mutagenesis. It can be seen
that disease-associated nsSNVs are predicted to be both significantly more destabilising and significantly
more deleterious than nsSNVs/SAVs from the other subsets. It can also be seen that disease-associated
SNVs localise to residues with a significantly lower Q(SASA). Significance calculated using pairwise
Mann-Whitney tests with Bonferroni correction (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).
S4.2 Titin domain boundaries
We find titin has 169 Ig domains in contrast to the
previously reported 152 (Chauveau et al., 2014b).
This discrepancy arises from both the previous
use of shorter isoforms to define domains rather
than the reference IC isoform, and the failure to
integrate available experimental evidence. Domain
Ig-94 is identified with an E-value of 0.0079 which
is higher than the set threshold of 0.0001, but
is validated by the experimental PDB structures
(1WAA, 1TIU and 1TIT) which exist of this
domain. Ig-88, Ig-89, Ig-90 and Ig-98 were also
identified with E-values higher than the threshold
(0.00079, 0.00026, 0.0022 and 0.0005); however
when the titin sequence was scanned using an
HMM created from an alignment of all (165) other
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titin Ig domains, these domains were identified
with significantly low E-values (5.9E-11, 1.2E-12,
2.9E-10, 7.4E-12). The mapping of all titin isoform
protein sequence positions to the reference IC
isoform has enabled the instigation of a consistent
naming scheme for domains in which Ig domains
are sequentially numbered from 1 to 169 and Fn3
domains numbered sequentially from 1 to 132.
Sequences logos (see Fig. S5) showing aligned
titin Fn3 sequences, differ substantially from such
logos depicting Pfam seed alignments (as assessed
heuristically by eye); particularly towards the end
of the sequence where the conservation drops of
gradually. Therefore the correct boundaries do
not appear to be clearly defined from sequence
alone. When mapped onto available structures,
for example in the case of the Fn3 dimer 3LPW
(bottom Fig. S5), it becomes clear that the Pfam
defined boundaries do not cover entire titin Fn3
domains. Due to this information, it was decided
the Pfam defined Fn3 domain boundaries were not
accurately determined. Therefore Fn3 domains
were initially identified using Pfam/HMMER and
the sequences of these domains, including an
extra 5 amino acids upstream and 16 amino
acids downstream of the Pfam defined boundaries,
were aligned using T-coffee. This alignment
was cut heuristically (see Section S3.2) using
structural information from available titin Fn3
crystal structures, in particular 3LFPW. An HMM
was created from this alignment and titin scanned
again using this HMM to redefine titin Fn3 domain
boundaries.
S4.3 Modelling of titin Ig and Fn3
domains
A pipeline was set up as described in the methods
section to perform the homology modelling of titin
Fn3 and Ig domains. Fig. S6 shows the structural
coverage of titin by experimental crystal/NMR
structures from the PDB, existing models from
the ModBase database (Pieper et al., 2009), and
models produced by the TITINdb pipeline.
It can be seen in Fig. S6 that our pipeline has
greatly increased both the structural coverage of
domains and the quality of the coverage (lower
zDOPE (Shen and Sali, 2006) scores indicate better
structures with native structures expected to have
a zDOPE score around -1). Here, for each domain
sequentially along the length of titin, existing
experimental structures are represented by purple
diamonds and blue hexagons, ModBase models are
represented by blue bars and models created by
the TITINdb pipeline are represented by red bars.
The closest identity each domain shares with an
experimental PDB structure is annotated along the
top x-axis.
Model validation was performed by modelling all
domains for which experimental structures already
exist, however excluding structures with >95%
identity from template selection. The models
were then compared to solved structures for the
relevant domain as described in the methods
section, in a similar manner to Sa´nchez and Sali
(1998) and Cozzetto et al. (2009). Cumulative
distribution plots for the RMSD (root-mean-square
deviation) for the comparison between models and
representative structures are shown in Fig. S7A (Ig
domains) and Fig. S7C (Fn3 domains). It can be
seen that a large proportion of modelled residues
have RMSD values lower than 1A˚ indicating that
the modelling has predicted the actual structure
with a high degree of accuracy. For 82% of the
models >60% of their residues fall within 1A˚ of the
solved structure and for 65% of the models >70% of
their residues fall within 1A˚ of the solved structure
(see Table S4.3). As experimental structures have
only been solved for 5 titin Fn3 domains, summary
statistics are perhaps less informative, however for
80% of these >70% of residues lie within 1A˚ of
the solved crystal structures. For this small sample
size, the Fn3 models generally show less deviation
in terms of alpha carbon (Cα) RMSD from the
solved structures than the Ig models do. This is
perhaps a result of the proportionally lower loop
content of the majority of titin Fn3 domains when
compared to titin Ig domains; as loop regions tend
to be more flexible and less conserved these tend to
result in larger RMSD values.
In the majority of cases, those residues with
the highest RMSDs when compared to solved
structures localise to loops; as discussed this
is unsurprising due to the inherently greater
flexibility of loop regions. The exception to this is
the model for Ig-19, shown aligned to the crystal
structure 5JDD in Fig. S7A-I, which, from the
cumulative RMSD distribution appears to have
been modelled with the least success. On closer





























































































































































































































































































































































of the backbone aligns closely to the crystal
structure however the loop prior to the C-terminus
is not as tight as in the crystal structure which
results in misplacement of the final β sheet. On
observation of the alignment between the query and
template sequences (see Fig. S8) it can be seen that
the quality of the alignment drops for the portion of
the sequence which corresponds to the C-terminal β
sheet which perhaps explains the poor accuracy of
modelling this region. The other immunoglobulin
model which appears less accurate judging by the
RMSD values is Ig-164, shown aligned to the NMR
structure 1TNN in Fig. S7A-II. Here, as expected,
the beta sheet core regions show close alignment
to the solved NMR structure 1TNN, however the
loop regions show large differences, in particular a
short helical stretch can be seen in the loop between
beta sheets E and F in the model which is not
present in the structure. Interestingly, the model
was built using only crystal structures as templates,
and all the crystal structures available for titin
Ig domains show such a short helical segment in
their analogous loops; however none of the NMR
structures demonstrate this property. Therefore it
is likely that the helical structure does not form in
solution due to competition with the surrounding
solvent for hydrogen bond formation with partially
exposed residues. This indicates that the higher
RMSD values observed in the loop regions for
this domain may be an indicator of conformational
differences caused by the distinct environments in




Table S3: Percentage of domains for which models have a particular percentage of residues within 1A˚
of the solved experimental structure after structural superposition. The analysis was performed using
17 domains for Ig domains and 5 domains for Fn3 domains (see Table S1 for domains and experimental
structures used for validation).






















Figure S7: Cumulative RMSD plots for models aligned to representative structures A for Ig domains
B for Fn3 domains. Alignments of Ig models with representative structures coloured by RMSD can be
seen for two of the least successful cases (I Ig-19 aligned to 5JDD and II Ig-164 aligned to 1TNN) and
two of the most successful cases (III Ig-2 aligned to 2A38 and IV Ig-163 aligned to 3QP3). A similar
method of model assessment has been used by Sa´nchez and Sali (1998) and Cozzetto et al. (2009)
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Figure S8: Alignment of query sequence and templates for the domain Ig-19, obtained using T-coffee
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Missense variants in health and
disease impact on distinct functional
pathways and proteomics features
3.1 Introduction
In this chapter, we zoom out from our focus on titin variants to perform a large-scale analysis of
the properties of missense variants in health and disease. Chapter 2 has shown that titin variants
remain difficult to classify, with predictors frequently offering conflicting interpretations. Moreover,
the problem of missing heritability, discussed in Chapter 1, remains unsolved, suggesting that a
number of variant-disease associations cannot be detected by current statistical methods.
Due to these observations, it becomes increasingly pressing to understand the molecular charac-
teristics of variants in health and disease; including differences in the characteristics of driver and
passenger somatic cancer mutations, and in the impact of rare and common population variants.
Analyses of the localisation of variants to protein structure, taking into account their proximity to
functional sites (e.g. post-translational modifications, or PTMs) (David et al., 2012; Engin et al., 2016;
Gao et al., 2015; Gress et al., 2017; Laddach et al., 2018; Lu et al., 2016b), have shown to be effective
in uncovering the impact of variants at the molecular level (Pires et al., 2014b). In the field of cancer
research, protein structure-based methods have been used to successfully predict cancer driver
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genes (Porta-Pardo and Godzik, 2014; Porta-Pardo et al., 2015b), as validated by a recent large-scale
study by Bailey et al. (2018). Despite such success, this does not appear to have been applied to other
classes of variants (i.e. population and Mendelian disease-associated variants). Only a few studies
(Gress et al., 2017; Sivley et al., 2018) have taken advantage of the recently available large-scale data,
and compare, using structural bioinformatics methods, disease-associated variants with somatic
cancer variants, and variants found in the general population. Furthermore, recent papers propose
that previously observed trends, which suggest that somatic cancer single amino acid variants (SAVs)
are enriched in protein-protein interaction sites, could be due to biases caused by the tendency
of disease-associated variants to localise to those proteins which are most experimentally studied
(Gress et al., 2017). Therefore robust statistical methods to treat these comparisons are urgently
needed. Additionally, as discussed in Section 1.2.6, large proteomics and transcriptomics datasets
have been generated in recent years, but, to the best of our knowledge, studies which incorporate
this information in the analysis of the impact of genetic variants are yet to appear.
These factors have motivated us to undertake an integrative analysis which compares disease-
associated variants, including somatic cancer variants and germline disease-associated variants,
with variants found at different frequencies in the general population. A unique feature of our
analysis is in addressing the interplay between atomistic and macroscopic features. Here we define
atomistic features to be those features associated with the precise localisation of SAVs to proteins
and protein structure, and macroscopic features to be properties of the proteins to which variants
localise (e.g. abundance and function). In particular, we have made use of recently published protein
half-life data (Franken et al., 2015), along with protein abundance (Wang et al., 2015), thermal
stability (Mathieson et al., 2018) and transcriptomics data (GTEx Consortium, 2013), to uncover
underexplored biophysical and biochemical principles governing the impact of variants.
It must be noted that Joseph Ng has contributed to the analyses presented in this chapter.
Specifically he contributed to the analysis of variant enrichment in oncogenes and tumour suppressor
genes presented in Section 3.3.2; performed the DNA-binding domain case study presented in Section
3.3.4; curated the drug-protein mappings used in Section 3.3.4; obtained the gene expression data
from the GTEx database, used in Section 3.3.5; and calculated the gene-wise proportion of samples
with an RPKM equal to zero (see Section 3.2.1).
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3.2 Methods
The analysis of the properties of missense variants in health and disease has necessitated the
collection of variant data from available databases, and the mapping of this data to proteins and
protein structures/structural homologs. These have been annotated with structural features (e.g.
core, surface and interface regions, proximity to post-translational modifications (PTMs)) to allow
for the analysis of variant enrichment in protein structural regions. Structural annotations, including
residue level mappings of protein-protein interaction sites, have been stored in the ZoomVar database
(http://fraternalilab.kcl.ac.uk/ZoomVar). Additionally, a number of other annotations have been
collated in order to investigate the properties of variant-enriched proteins/domains, including
proteomics, transcriptomics and functional features, as well as protein structural architectures. The




ClinVar (dbSNP BUILD ID 149) variant data (Landrum et al., 2016), COSMIC coding mutations (v80)
(Forbes et al., 2015) and gnomAD exome data (Lek et al., 2016), all mapped to the GRCh37 genome
build, were obtained in variant call format (VCF). The ClinVar dataset contains variants submitted
through clinical channels. Only variants with CLINSIG codes 4 and 5 (probably pathogenic and
pathogenic) were selected for further analysis. To ensure the quality of our dataset, we selected only
variants with "variant suspect reason code" of 0 (unspecified). Additionally, all variants labelled as
being somatic were filtered from this dataset. All variant datasets were mapped to Ensembl protein
sequences (Aken et al., 2016) using the Variant Effect Predictor (VEP) (McLaren et al., 2016), and
further mapped to canonical UniProt sequences and the respective structures/homologs.
Protein-protein interaction networks
A large non-redundant protein-protein interaction network (UniPPIN) (Chung et al., 2018) was
used. This incorporates non-redundant data amalgamated from IntACT (Orchard et al., 2014),
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BioGRID (Chatr-Aryamontri et al., 2017), STRING (Szklarczyk et al., 2015), DIP (Xenarios et al.,
2002) and HPRD (Peri et al., 2004), as well as recent large-scale experimental studies (Havugimana
et al., 2012; Huttlin et al., 2015; Rolland et al., 2014). Although the data from STRING contains
computationally predicted interactions, some of which may be false positives, we deem it unlikely
that many incorrectly predicted interactions will have structural coverage. As we only analyse those
interactions further which can be mapped to structure, we believe our analysis is unlikely to be
compromised by false positives in the set of computationally predicted interactions.
Protein sequences and structures
The biounit database of the Protein Data Bank (PDB) was downloaded on 28/04/2017. For mapping
purposes, in this study, both the canonical UniProt human protein sequences (Poux et al., 2017) (for
mapping to structures and protein-protein interaction networks) and Ensembl protein sequences
(Aken et al., 2016) (for mapping variant datasets) were used.
Gene and protein annotations
Gene sets for KEGG pathways were obtained from the MSigDB database (Subramanian et al., 2005).
Oncogene and tumour suppressor gene annotations were taken from Supplementary Table S2A
from Vogelstein et al. (2013) 1. Cancer drivers were taken from the Cancer Gene Census (CGC)
(COSMIC v84). Genes from both tiers 1 and 2 were included. Conversions between gene symbols,
Entrez gene identifiers and UniProt accession numbers were performed using the biomaRt package
(Durinck et al., 2005). A list of DNA-binding domains was obtained from the review by Vaquerizas
et al. (2009). These domains were mapped from InterPro (Finn et al., 2017) IDs to PFAM IDs using
conversion tables in PFAM (v31) 1.
Protein-drug interaction mapping
A mapping of protein-drug interactions was obtained from DrugBank (v5.0.11) (Wishart et al., 2018)
(under "Target Drug-UniProt Links") and filtered for human proteins 1. Drugs were mapped to a
PFAM domain-type if at least one domain of that type occurs in a protein a drug is known to interact
1Work done by Josef Chi-Fung Ng (Fraternali laboratory)
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with. It is, of course, possible that a drug may only interact directly with another domain-type within
the protein. However, if only domain-drug interactions with supporting structural information are
accepted, the data becomes both sparse and biased towards structurally resolved domains.
Protemics and transcriptomics data
Protein thermal stability and half-life data were obtained from separate large-scale studies by the
Savitski lab (Franken et al., 2015; Mathieson et al., 2018). Gene expression quantification (Reads Per
Kilobase of transcript per Million mapped reads [RPKM]) counts per sample (v6p) was downloaded
from the GTEx portal (GTEx Consortium, 2013) and grouped by tissue, according to the sample
metadata provided 1. For each tissue type, we quantified the gene-wise proportion of samples with
an RPKM equal to zero 1. Only those genes with zero counts in < 10 % of samples were retained for
our analysis. Protein abundance data (protein per million [ppm]), integrated for each tissue/sample
type were obtained from PaxDb (Wang et al., 2015).
3.2.2 ZoomVar Database
Identification of resolved structures/homologs
Canonical UniProt human protein sequences were assigned resolved structures/homologs from the
PDB biounit database (Berman et al., 2003) using BLAST (Altschul et al., 1997). BLAST searches were
carried out using both the entire protein sequences and domain sequences, which were defined by
scanning UniProt sequences against the PFAM seed library (Finn et al., 2016) using HMMER (Finn
et al., 2011). Hits were only accepted with sequence identity > 30 % and E-value < 0.001. T-COFFEE
(Notredame et al., 2000) was used to obtain a residue level mapping of queries to structure hits. The
quotient solvent accessible surface area [Q(SASA)] of each structure residue was computed using
POPS (Cavallo et al., 2003).
Mapping of Ensembl proteins
Ensembl protein sequences were mapped to UniProt protein sequences (Poux et al., 2017), using
the UniProt ID mapping. Additionally, if UniProt and Ensembl sequences were not of the same
length, the sequences were aligned using T-COFFEE (Notredame et al., 2000) to obtain a per residue
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mapping. Stretcher (Myers and Miller, 1988) was used to align those sequences which were too long
to align using T-COFFEE.
Identification of interaction complexes
For each interaction in our protein-protein interaction network, resolved binary interaction com-
plexes and homologues were identified using the BLAST search results. As an example, if protein A
and B are annotated as interacting in UniPPIN, and their structure homologues A’ and B’ are located
in a resolved structural complex (and at least one residue from each protein is involved in a shared
interface), residues from A and B are mapped onto A’ and B’ to infer their interaction interface.
The partner-specific regression formula from HomPPI (Xue et al., 2011) was used to assign a
score and zone to each interaction interface inferred in this way:
IC Score = β0 + β1logEV al + β2PositiveS + β3FracAA′ + β4FracBB′ (3.1)
The formula uses the following terms:
logEV al = log(EV alAA





FracAA′ = FracA · FracA′ (3.4)















Here EV alAA′ and EV alBB′ represent the BLAST E-values between protein A and A’, and
between B and B’ respectively; PositiveSAA′ and PositiveSBB′ are the analogous BLAST positive
scores. Similarly LALAA′ and LALBB′ are the lengths of the BLAST alignments.
The parameters β0, β1, β2, β3 and β4 have values -0.505, 0.001, 0.009, 0.341 and 0.205 respectively.
Zone boundaries defined by HomPPI are given in Table 3.1.
Zone Property Threshold
Safe Zone PositiveS ≥ 70 %
FracAA′ ≥ 80 %
FracBB′ ≥ 80 %
logEV al ≤ -50
Twilight Zone 1 PositiveS ≥ 60 %
FracAA′ ≥ 60 %
FracBB′ ≥ 60 %
logEV al ≤ 1
Twilight Zone 2 PositiveS ≥ 55 %
FracAA′ ≥ 40 %
FracBB′ ≥ 40 %
logEV al ≤ 1
Dark Zone PositiveS ≥ 0 %
FracAA′ ≥ 0 %
FracBB′ ≥ 0 %
logEV al ≤ 1
Table 3.1 Zone boundaries for the inference of protein-protein interaction interfaces defined by
HomPPI (Xue et al., 2011).
Residues involved in interfaces were assigned using POPSCOMP (Kleinjung and Fraternali, 2005).
Only those residues with a change in SASA > 15Å2 were annotated as interface residues. Many
residues contribute only a very small surface area to the interface, and are thus likely to play a
less important role in binding affinity and specificity. Setting the threshold to (greater than) 15Å2
retrieves > 90 % of the interface surface area (91.1 % calculated from the PDB biounit database) and
removes residues with negligible individual contributions to this.
3.2 Methods 76
Determination of per-residue binding partners
A protein may interact with multiple other proteins. For each of these interactions, a maximum of
10 corresponding best hits (ordered by HomPPI defined score (Xue et al., 2011)), located in the best
populated zone, were considered. If a residue was located at the interaction interface, in at least
half of these structures, it was annotated as interacting with that specific protein, otherwise it was
annotated as non-interacting. This follows the HomPPI procedure to identify interface residues
(Xue et al., 2011).
Mapping of variant data
Variants in each dataset were annotated according to protein region localisation using the ZoomVar
database. For certain analyses the COSMIC data was divided into "driver" and "non-driver" subsets,
taking drivers as variants which map to all proteins from both tier 1 and tier 2 of the Cancer Gene
Census (CGC) (COSMIC v84). The non-driver subset contains all other variants.
Definition of regions
We defined several types of protein and domain regions as described below.
Interface regions were considered to be composed of residues which bind to at least one protein
interaction partner. Core residues were defined as those with a Q(SASA) < 0.15. Surface residues
were defined as those with a Q(SASA) ≥ 0.15 which do not take part in protein-protein interaction
interfaces. These thresholds are identical to those used by Stehr et al. (2011).
Disordered protein regions were predicted using DISOPRED3 (Jones and Cozzetto, 2015). Intra-
domain ordered regions were defined as those regions predicted to be ordered which lie within
PFAM defined domains. Intra-domain disordered regions were defined as regions predicted to
be disordered which lie within PFAM domains. Inter-domain disordered regions were defined as
those regions not located within PFAM defined domains which are predicted to be disordered. Any
residues with structural coverage were filtered from the inter-domain disordered regions as it was
thought that these could potentially belong to domains which have not been defined by PFAM.
Although DISOPRED3 lacks sensitivity (0.147) it has high specificity (0.958) (Jones and Cozzetto,
2015). Therefore we have high confidence in the annotation of those regions which were predicted
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to be disordered. Furthermore, due to the large size of our dataset, we believe that this procedure
allowed for trends in the variant enrichment of disordered and ordered protein regions to be captured,
despite noise which was inevitably introduced due to prediction error.
Ubiquitination and phosphorylation sites were obtained from PhosphoSitePlus (Hornbeck et al.,
2004). Each site was mapped to the structural template with the highest identity. Regions close to
phosphorylation and ubiquitination sites were defined as those within 8 Å in 3D space. A cut-off of
8 Å has been frequently been used to define regions close to functional sites, for example by Stehr
et al. (2011).
Creation of ZoomVar database
All data, including per-residue mappings, were stored in the ZoomVar MySQL database (MySQL,
2008). A web interface and REST architecture was implemented, using the Django framework
(Django Software Foundation, 2017) to allow users to query this. It is available at http://fraternalilab.
kcl.ac.uk/ZoomVar.
3.2.3 Calculation of SAV enrichment
The binomial cumulative distributive function (see Equation 3.7) was used to assess the SAV enrich-
ments of individual proteins, domains or domain-types, and the 2-tailed binomial test was used to
assess the significance of enrichment/depletion. In this formula k is the number of observed SAVs
which localise to a region, n is the total number of SAVs which localise to all regions of interest
(all_regions) and p is ratio of the size of the region (number of amino acids) to the size of all_regions:








Hereafter, we refer to the binomial CDF as the variant enrichment score (VES).
The calculations were performed for the regions defined in Table 3.2. For each analysis at the
whole protein or whole domain level, all UniProt proteins/domains (except for immunoglobulin and
T cell receptors), which contained SAVs in any of the datasets analysed, were considered to be the
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background proteome (all_regions). Proteins belonging to immunoglobulin and T cell receptor gene
family products were filtered from all analyses (HGNC definition (Yates et al., 2017)), to avoid the




PFAM domain-type all PFAM domain-types
protein region union of all regions of a particular protein
domain region union of all regions of a particular domain
PFAM domain-type region union of all regions of a particular PFAM domain-type
Table 3.2 The anatomy of the protein levels considered in our analysis. N.B. at the protein region,
domain region and domain-type region levels, if the region of interest is the ”core”, the union of
all regions will be the ”core”, ”surface” and ”interface”. The same logic applies to other regions of
interest (see Fig. 3.1).
For all calculations of enrichment and simulations involving protein or domain regions (e.g.
core, surface and interface), only those proteins/domains which posses the region of interest and
to which SAVs localise (although not necessarily to the region of interest), were considered. For
example, to calculate the enrichment of SAVs at the core of a protein, the protein must have a core
region of size > 0. Moreover, a region of a protein cannot be enriched in SAVs, in comparison to the
rest of the protein, if no SAVs from a particular dataset localise to that protein.
The overall SAV enrichment of protein regions, for each data set, was also calculated using a





Here 95 % confidence intervals were estimated via bootstrapping (10,000 iterations). The 2-
tailed significance of enrichment/depletion was estimated by simulation. 10,000 simulations were
carried out for each dataset, in which the number of variants which localise to a given protein was
kept constant, but their location within the protein randomised. The regional density of variants
was calculated for each simulation and compared to the actual value in order to derive a p-value.
Simulations were performed in this way, keeping the number of SAVs which localise to each protein
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Fig. 3.1 The regions used for the analysis of variant enrichment at the protein region, domain region
and domain-type region levels (as defined in Table 3.2)
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fixed, in order to overcome bias which stems from the assumption that variants are uniformly
distributed throughout the proteome.
3.2.4 Further protein structural analyses
Calculation of protein topological network features
Graph representations for protein structures, with mapped SAVs, were constructed. Here protein Cα
atoms are represented by nodes in the graph, and nodes are connected if Cαs are< 10 Å apart in 3D
space. Similar graph representations are routinely used to create elastic network models of proteins.
One class of such models is the Gaussian network model (GNM); the default cut-off distance used by
GNMs is commonly 10 Å (Bakan et al., 2011). Therefore we use this cut-off in the creation networks
here. Topological network features were calculated using the python package NetworkX (Hagberg
et al., 2008). Specifically, we calculate the degree, degree centrality, betweenness centrality and
closeness centrality of residues (nodes) to which variants localise. The degree of a node is defined
as the number of nodes it is connected to, and the fraction of connected nodes constitutes its degree
centrality. Betweenness centrality BC is defined as the number of pairwise shortest paths which
pass through a node:
BC(u) =
∑
s, t ∈ V σ(s, t|u)
σ(s, t) (3.9)
Here V is the set of nodes, σ(s, t) is the total number of shortest paths, and σ(s, t|u) is the
number of shortest paths which pass through the node u.
Closeness centrality CC is the reciprocal distance of the sum of the shortest paths from all other
n− 1 nodes to node v:
CC(u) = n− 1∑n−1
v=1 d(v, u)
(3.10)
Where d(v, u) is the distance of the shortest path between nodes v and u.
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Calculation of protein core density
The density of residue packing in protein cores may impact on their ability to accommodate
missense variants. To investigate this, a non-redundant set of representative structures for the
UniProt canonical proteome was collated. Here, structures from the ZoomVar database were mapped
in order of identity. Additional structures were only added to represent a protein if at least 50 % of
the residues they covered were not mapped to a structure with higher identity. Protein core density
was only calculated for those proteins with a single mapped structure. This was to avoid problems
associated with determining the core density for multi-domain proteins. The number of Cα contacts
(< 8 Å) for each core residue [Q(SASA) < 0.15] was counted. The mean number of contacts for all
core residues within a protein was used as a proxy for protein density, the assumption being that
protein cores with greater density will have a higher number of Cα contacts. Only protein cores
which comprise of > 4 residues were analysed, as it was considered density could not be accurately
calculated for very small cores. It was also considered that if this threshold was set too high, the
data would become too sparse to observe trends. However, the results presented in Section 3.3.5
remained consistent for all cut-offs between > 2 and > 8 residues, with only small differences seen
outside these cut-offs (see Appendix A1).
3.2.5 Enrichment analysis of gene sets and domain architecture sets
Gene set enrichment
Enrichment analyses were performed using Gene Set Enrichment Analysis, using the implementation
provided by the R FGSEA package (Sergushichev, 2016). Given an enrichment statistic for each
query gene, the GSEA algorithm outputs a score per gene set, which quantifies the enrichment of
query genes in the sets examined. This is then normalised by the size of the gene set, to give a
normalised enrichment score (NES).
We utilise the centred VES, as the enrichment statistic which is input into the GSEA algorithm.
Here, the centred VES is simply obtained by subtracting 0.5, therefore proteins with the expected
number of SAVs have a centred VES of 0. At the whole protein level only sets with n ≥ 25 were
considered. At the protein subregion level, variant enrichment data exists for a smaller number of
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proteins, due to incomplete structural coverage of the proteome. In order to perform a complete
comparison between pathway enrichment at different levels, all pathways analysed at the whole
protein level were also analysed at the protein subregion level.
Definition of pathway clusters
The pathway normalised enrichment scores (NESs), calculated at the whole protein level for each
dataset, were used to perform K-means clustering of KEGG pathways (Kanehisa et al., 2017). The R
package NbClust (Charrad et al., 2014) was used to determine the optimum number of clusters.
CATH architecture enrichment analysis
PFAM domains (Finn et al., 2016) were assigned CATH domains (Sillitoe et al., 2015) using the
per-residue mapping of structures to domains, from both data sets, available from the SIFTs resource
(Velankar et al., 2013). A minimum of 50 residues, which mapped to both a particular CATH domain
and a particular PFAM domain were required to assign a PFAM domain to a CATH domain. This
threshold was used in order to prevent spurious assignments. If a PFAM domain appeared to map
to more than one CATH domain, the majority vote, from the residue level mapping, was used.
Using these assignments PFAM domains were mapped to CATH architectures, guided by the CATH
hierarchy, to create "domain sets" for each architecture.
Architecture enrichment analysis was performed as for gene set enrichment analysis, however
here the domain-type, and domain-type region centred VESs (for each PFAM domain-type) were
used as the enrichment statistics. Additionally, as we were interested in the enrichment of individual
architectures only "domain" sets of size n ≥ 25 were considered at all levels.
3.2.6 Analysis of expression, abundance, density, and stability data
Spearman correlations of protein-wise and region SAV enrichments with expression levels (RPKM),
abundance (ppm), half-life (hours), thermal stability (Tm), and density (mean contacts of core α
carbons) were calculated. Additionally, gene set enrichment analysis was performed as in Section
3.2.5, but using the metrics in Table 3.3 as enrichment statistics.
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thermal stability Tm - mean(Tm)
abundance log(ppm + 1) - mean(log(ppm + 1))
expression log(median(RPKM) + 1) - mean(log(median(RPKM) + 1))
half-life log(hours) - mean(log(hours))
Table 3.3 Proteomics and transcriptomics-based metrics used as enrichment statistics for GSEA
analysis.
Here it can be seen that the mean value for each quantity of interest was subtracted to obtain
values centred around 0, allowing both pathway enrichment and depletion to be assessed.
3.2.7 Statistics and data visualisation
The majority of data analyses were performed in the R statistical programming environment. All
corrections for multiple testing have been done using the Benjamini-Hochberg method in R (p.adjust
function). Bootstrapping was performed using the boot package (function boot) (Canty and Ripley,
2017). Spearman correlations were performed using the SpearmanRho function of the DescTools
package (Signorell, 2017). Heatmaps were produced with either the heatmap.2 function in the
gplots package (Warnes et al., 2016) or the ComplexHeatmap package (Gu et al., 2016), in which
clustering, wherever shown, was performed with hierarchical clustering (hclust function) using
default parameters unless otherwise stated. Circos plots were generated with the Circos package
(Krzywinski et al., 2009). Additionally, binomial CDFs were calculated and two-tailed binomial tests
performed using the NumPy package in Python (Oliphant, 2006).
3.3 Results
We present a multidimensional analysis of single amino acid variants (SAVs) observed in the general
population (gnomAD database) (Lek et al., 2016), in comparison to somatic cancer-associated SAVs
from the COSMIC database (Forbes et al., 2015) and disease-associated SAVs from the ClinVar
database (Landrum et al., 2016). Throughout this analysis we further divide the gnomAD data into
its constituent common (MAF ≥ 0.01) and rare (MAF < 0.01) variants, to investigate whether there
are differences between these two subsets.
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We ask whether the enrichment of variants is associated with specific structural features and
functional pathways, and whether results differ for population and disease-associated variants. In
particular we investigate the interplay between variant enrichment and proteomics features; for
example, we explore whether disease-associated variants are found more frequently in the cores
of less thermally stable proteins, as these might be more easily sufficiently destabilised to lead
to complete/partial unfolding. Such exploration of the interplay of these atomistic features with
macroscopic features is novel in the field. Finally, we use these features to understand whether
rare population variants demonstrate characteristics which are more similar to common population
variants or disease-associated variants.
Our analysis explores the enrichment of SAVs at different levels, constituting what we define as
a protein-centric anatomy of variants in health and disease, as illustrated in Fig. 3.2. We employ a
similar approach to that used in the prediction of cancer driver genes (Porta-Pardo et al., 2015a):
the SAV enrichment of individual proteins/regions has been modelled using a binomial distribution
(Methods Equation 3.7), whereas global trends in the distribution of SAVs have been investigated
by calculating SAV density (Methods Equation 3.8). The binomial cumulative distribution function
quantifies the enrichment of variants (Fig. 3.2g) and is referred to as the Variant Enrichment Score
(VES). This is assessed statistically using a two-tailed test (see Section 3.2.3). Additionally, the
significance of the enrichment/depletion of SAVs, in terms of their density, is assessed by comparison
to simulated SAV distributions, in which the number of SAVs is kept identical to that observed in the
data, but their positions within the protein are randomised. This goes beyond similar studies (e.g.
(David et al., 2012; Engin et al., 2016; Gao et al., 2015)) and addresses possible biases in our current
knowledge of protein structures and interactions.
A summary of the numbers of SAVs investigated in each dataset is given in Table 3.4, and a more
detailed breakdown is given in Appendix A2.
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Fig. 3.2 Enrichment statistics are calculated at different levels. At the protein region level, the number
of SAVs in a region is compared to the number of SAVs in the rest of the protein. Regions are defined
as: a) core, surface and interface regions of a protein; b) regions close to functional sites, and; c)
regions predicted to be ordered or disordered which lie either within or outside of PFAM defined
domains. d,e) At the protein/domain level the number of SAVs in a protein or domain is compared
to the number of SAVs in the whole dataset which localise to defined proteins/domains. f) At the
domain-type level the number of SAVs in a particular PFAM defined domain-type is compared to
the number of SAVs which localise to all domains. g) The calculation of enrichment at the different
levels is statistically assessed using the binomial distribution. The binomial cumulative distributive
function constitutes a Variant Enrichment Statistic (VES) with value range 0 to 1, which quantifies
enrichment.
3.3 Results 86
Region Common Rare COSMIC ClinVar
protein 54571 3806698 1731030 21272
surf 12151 966409 491179 8558
interact 403 38108 22205 768
core 2789 296291 152356 5194
intra-ord 20650 1575286 755683 14620
intra-dis 2984 197482 96914 1211
inter-dis 17352 1045997 439437 1128
phos 1661 158192 82364 2362
ubiq 440 52250 25778 607
Table 3.4 Numbers of SAVs which localise to different protein regions in the studied datasets. Data
shown for common and rare population variants from the gnomAD database, somatic cancer variants
from the COSMIC database and disease-associated variants from the ClinVar database.
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3.3.1 Disease-associated and population variants impact on different functional
pathways
We first investigated whether variants from each dataset impact on proteins which are involved in
distinct functional pathways. To do this we performed KEGG (Subramanian et al., 2005) functional
pathway analysis, by ranking proteins using their whole-protein VESs (see Fig. 3.2d) calculated for
each dataset, and using the Gene Set Enrichment Analysis (GSEA) algorithm (Subramanian et al.,
2005) (see Section 3.2.5).
The pathway enrichment data, for each mutation dataset, were subjected to clustering and
Principal Component Analysis (PCA) (see Section 3.2.5). In Fig. 3.3a it can be seen that variant
enrichment segregates pathways into three clusters. Strikingly each pathway cluster appears to
have distinct characteristics. The cluster visualised in orange is primarily composed of terms
associated with cancer, growth and proliferation, whereas that coloured pink contains pathways
associated with splicing, transcription, translation and metabolic terms. Pathways associated with
sensory perception and the immune response are found in the final "green" cluster. A handful of
metabolic pathways also localise to this cluster, however, these appear to be more associated with
environmental response and adaptation than those pathways found in the "pink" cluster; for example,
pathways associated with the metabolism of drugs and xenobiotics are found here. For brevity, the
"orange", "pink" and "green" clusters will be termed the "proliferative", "nucleotide processing" and
"response" clusters respectively, for the remainder of this text. A list of pathways assigned to each
cluster is given in Appendix A3.
This visualisation (Fig. 3.3a) also reveals that both the common and rare subsets of the gnomAD
database associate tendentially with the "response" cluster, whereas COSMIC data localises between
the clusters associated with response and proliferation. ClinVar data associates with the "nucleotide
processing" cluster, between both the "response" and "proliferation" clusters. Strikingly, the popula-
tion variant datasets (gnomAD rare and common) are clearly separated from the disease-associated
variant datasets by the first principal component (PC1), whereas COSMIC variants are separated
from ClinVar variants along the third principal component (PC3) (see Fig. 3.4).
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These trends of functional distinction are further visualised in the Circos plot (Fig. 3.3b). Here
it can be clearly seen that the gnomAD data only shows significant enrichment for pathways
belonging to the "response" cluster, whereas the COSMIC data shows enrichment for pathways
belonging to this cluster and those belonging to the "proliferative" cluster. The ClinVar dataset
displays enrichment for pathways belonging to all three clusters; uniquely showing enrichment for
pathways within the "nucleotide processing" cluster.
We went on to extend this analysis to the protein region level (Fig. 3.5). Here we find that
proteins enriched in gnomAD variants at the surface (Fig. 3.3c) are significantly enriched in pathways
belonging to the "proliferative" cluster. Moreover, this enrichment is shared between common and
rare variants (albeit not significant for common variants in individual pathways after FDR correction).
Proteins with surfaces enriched in disease-associated variants (from COSMIC and ClinVar) are,
contrastingly, not enriched in "proliferative" cluster pathways. However, no such pattern emerges
for the protein core and interface (Fig. 3.3d), possibly suggesting that population variants avoid
disrupting the function of proliferation-related proteins by preferentially localising to the surface.
Interestingly, the "nucleotide processing" cluster does not show such amarked enrichment of variants
which localise to the surface in the gnomAD database, perhaps indicating that these pathways are
more robust to disruption than those in the proliferative cluster. These data show that there is
clearly an interplay between variant localisation at the macroscopic level (functional pathways) and
the atomistic level (structural regions).
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Fig. 3.3 Functional analysis of proteins according to variant enrichment. Gene set enrichment for
KEGG functional pathways was performed by ranking proteins using their whole protein VESs,
which quantify the variant enrichment of a protein in comparison to the whole proteome. The
analysis was performed separately for common population variants (common), rare population
variants (rare), somatic cancer variants (cosmic) and disease-associated variants (clinvar). a) At the
whole protein level, KEGG pathways form 3 identifiable clusters (K-means), as visualised projected
on the first two principal components of the PCA. Each cluster has been assigned a colour for
visualisation purposes; these colours correspond to those used in b) and c). COSMIC, ClinVar and
gnomAD (rare/common) data can be clearly separated by pathway enrichment, as evidenced by the
visualisation of factor loadings (arrows). b) Enrichment for each dataset, at the whole protein level
(as in a), visualised on a Circos plot, with results for each dataset occupying a quarter of the plot.
Pathways are coloured and ordered by cluster membership defined in a) and c). The Normalised
Enrichment Score for each pathway is plotted as a bar graph (the further from the centre, the more
positive) in the middle layer of the plot. In the outermost layer of the plot, significant enrichment
(dark grey) or depletion (light grey) of a pathway (q-value < 0.05) is depicted. In the centre of
the plot, links indicate enrichment (p-value < 0.05) shared between datasets. c) Pathway terms
visualised by cluster, sized by their cluster uniqueness score. This is defined as the average of the
Euclidian distances (calculated in 4D) to the two other cluster centres. Each cluster has been titled
("proliferative", "nucleotide processing" or "response") to reflect its pathway composition.
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Fig. 3.4 Functional analysis of proteins according to variant enrichment. Gene set enrichment, for
KEGG functional pathways, was performed by ranking proteins using their whole protein VESs,
which quantify the variant enrichment of a protein compared to the whole proteome. The analysis
was performed separately for common population variants (common), rare population variants (rare),
somatic cancer variants (cosmic) and disease-associated variants (clinvar). A 3D PCA representation
shows that at the whole protein level KEGG pathways form 3 identifiable clusters (K-means), as
projected onto the first three principal components. Each cluster has been assigned a colour for
visualisation purposes, and has been titled ("proliferative", "nucleotide processing" or "response")
to reflect its pathway composition. It can be seen that the gnomAD rare/common data are clearly
separated from disease-associated data (cosmic/clinvar) by the first principal component, whereas































































































































































































































































































































































































































































































































3.3.2 Population and disease-associated variants localise to different protein re-
gions
We then zoomed in to view trends in the enrichment of variants at the atomistic level. Specifically, we
catalogued the enrichment of variants in core, surface and interface regions; intra-domain ordered
regions (intra-ord), intra-domain disordered regions (intra-dis), and inter-domain disordered regions
(inter-dis); and regions close to (≤ 8Å) of phosphorylation sites and ubiquitination sites.
In agreement with previous research, we find disease-associated (ClinVar) variants to be enriched
in both protein cores and interfaces, but depleted on protein surfaces (see Fig. 3.6a) (David et al.,
2012; Engin et al., 2016; Gao et al., 2015; Gress et al., 2017). This reflects the disruption, caused
by such mutations, of structurally and functionally important protein regions. GnomAD variants
(both common and rare) and somatic non-driver variants display the opposite trend, most likely
as variants which localise to protein surfaces are less likely to impact on protein structure and
function than either core or interface mutations. Somatic driver variants follow trends closer to
ClinVar variants, with slight, but significant, depletion on the surface, but enrichment in the core.
Protein interfaces are enriched in disease-associated variants but depleted of gnomAD rare variants.
GnomAD common variants appear neither significantly enriched nor depleted, however this may
result from the relative sparsity of the data; fewer variants are shared between many individuals (this
is clearly evidenced by the numbers in Table 3.4). Interestingly, COSMIC non-driver variants appear
depleted in interacting interfaces. However, it becomes clear that they are actually significantly
enriched when compared to simulated null distributions (Fig. 3.6a). It is likely that a small number of
proteins which harbour a large number of variants at interface regions dominate this variant set, as
evidenced by the overlaps of 95 % confidence intervals of the observed and simulated distributions;
these may be putative cancer driver genes (see Appendix A4), as a number of known driver genes are
enriched in variants in protein interface regions (Bailey et al., 2018; Engin et al., 2016; Porta-Pardo
et al., 2015a). Indeed, the enrichment of variants in such regions has been used by Porta-Pardo et al.
(2015a) to identify cancer driver genes.
A more detailed per-protein analysis can bring finer granularity into the comparison of variant
enrichment. Therefore we look at a curated list of oncogenes and tumour suppressor genes (TSGs)
3.3 Results 93
(see Section 3.2.1) (Vogelstein et al., 2013). As stated in Section 3.1, these analyses were performed
in collaboration with Joseph Chi-Fung Ng (Fraternali laboratory).
Several studies have suggested that proteins encoded by oncogenes (which are activated upon
mutation) and tumour-suppressor genes (TSGs, which are inactivated upon mutation) tend to be
enriched in mutations in different protein regions (Engin et al., 2016; Gress et al., 2017; Stehr et al.,
2011). We found that clustering based on VESs broadly classifies these proteins into two groups, one
comprising of proteins enriched in mutations mainly at protein-protein interaction interfaces and
protein surfaces, and another group of proteins generally enriched in mutations in the core (some of
these proteins also show enrichment in mutations in interacting interfaces but, nonetheless, a clear
depletion at the surface is evident) (Fig. 3.6b). Interestingly, we observe a statistically significant
(Fisher-exact test p-value = 0.004199) segregation of these two groups in terms of cancer driver
status: the first group of proteins are mainly (17 out of 24) products of oncogenes, and the other
mainly those of TSGs (17 out of 25). These results are consistent with the hypotheses that activating
mutations in oncogenes are likely to affect particular functions by impacting on specific interactions,
whilst inactivating mutations in TSGs abrogate protein function (Engin et al., 2016; Stehr et al.,
2011). Taking the oncogenes and TSGs as two separate groups, the GSEA result confirms a similar
trend; moreover, it can also be seen that the disease-associated datasets (ClinVar and COSMIC) show
opposite patterns of enrichment in comparison to the gnomAD data (see Fig. 3.7) (Engin et al., 2016;
Gress et al., 2017; Stehr et al., 2011). These results confirm that our approach reproduces previous
results and highlights clear robust trends.
On analysis of variant enrichment in ordered and disordered regions, we again observe clear
segregation between disease and population variants (see Fig. 3.6a). ClinVar and COSMIC variants
are depleted in inter-domain disordered regions and enriched in intra-domain ordered regions. In
contrast, gnomAD variants (both rare and common) appear enriched in inter-domain disordered
regions and depleted in intra-domain ordered regions. GnomAD common and rare variants show
similar trends to one another, which are distinct to those of disease-associated variants. These
results suggest that variants are more likely to be pathogenic if they fall within ordered domain
regions.
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Fig. 3.6 The localisation of missense variants to protein regions. a) The density of missense variants
in different protein regions. Shown for common population variants (common), rare population
variants (rare), somatic cancer variants (cosmic) and disease-associated variants (clinvar). Observed
densities (pink), and densities derived from simulated null distributions (turquoise) are shown. Error
bars depict 95 % confidence intervals; for observed densities, these were obtained by bootstrapping.
Significance was calculated by comparison of observed values to simulated null SAV distributions
(significance level indicated by: * q-value < 0.05, ** q-value < 0.001, *** q-value < 0.0001). b)
Enrichment of cosmic missense variants in protein core, surface and interface regions, across a list of
annotated oncogene and tumour suppressor gene (TSG) products. The genes were grouped into two
clusters using hierarchical clustering (see dendrogram by rows), with the pie charts enumerating
the number of oncogenes (orange) and TSGs (blue) in each cluster.
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Fig. 3.7 The enrichment of tumour suppressor and oncogene gene sets in common population
variants (common), rare population variants (rare), somatic cancer variants (cosmic) and disease-
associated variants (clinvar). Enrichment calculated using the GSEA algorithm using the Variant
Enrichment Score (VES) as the enrichment statistic. The VES is calculated to describe the variant
enrichment of a protein in comparison to the entire proteome, and the variant enrichment of a
protein region (core, surf or interact) in comparison to the rest of a protein. Tumour suppressor
gene and oncogene gene sets were defined as described in Section 3.2.1.
The density of variants close to PTMs is also shown in Fig. 3.6a. Here, ClinVar variants appear
enriched when considering the density of SAVs close to phosphorylation sites, but not significantly
so in comparison to simulations. The large bootstrap confidence interval suggests this may be due
to the sparsity of the data available. A similar observation is seen for COSMIC driver variants;
however, COSMIC non-driver variants, which appear depleted according to variant density, are
significantly enriched close to phosphorylation sites in comparison to simulated null distributions.
This indicates that, in agreement with a number of other studies (Olow et al., 2016; Reimand et al.,
2013), the disruption of phosphorylation sites may play a particularly important role in cancer. In
contrast to phosphorylation sites, all data sets appear depleted of variants close to ubiquitination
sites.
These analyses conclude that the enrichment of missense variants at various structural features
consistently segregate population variants from disease-associated ones. For the majority of struc-
tural regions defined here, the greatest, most consistent distinction is always seen between common
and ClinVar variants, given that the data is not too sparse.
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3.3.3 Population and disease-associated variants have different topological struc-
tural network properties
Here we ask whether variants from different datasets have distinct topological properties according
to their structural localisation. We define these topological properties by representing protein
structures at networks, in which nodes consist of Cαs, and those Cαs within 10 Å of one another
are connected by edges. Due to this representation, we are able to calculate topological network
properties of the residues to which variants localise. Such properties give insight into the connectivity
and neighbourhood of the affected residues.
The results of the analysis are depicted in Fig. 3.8. Given that we find protein cores to be enriched
in ClinVar variants, it is perhaps unsurprising that we find these variants to localise to residues with
a significantly higher degree (are more highly connected), than do variants from the other datasets
(pairwise Mann-Whitney test, see Appendix A5 for values). We also find that disease-associated
variants show significantly higher values for several other centrality measures. Interestingly, the
most significant difference between datasets (Kruskal-Wallis test, see Appendix A5), after degree,
is betweenness centrality. This metric can be seen to highlight bottlenecks within the network,
as it is a measure of the fraction of shortest paths which pass through a node. This suggests that
disease-associated variants may impact on residues which play an important role in communication
through the structural network. Conversely, disease-associated (ClinVar) variants localise to residues
with only slightly higher median degree centrality (the fraction of connected nodes) than population
variants, and slightly lower median degree centrality than COSMIC driver variants. This suggests
that disease-associated variants localise to residues with a higher degree as they occur in proteins
in which all residues are more highly connected. Although we see significant differences between
the datasets, it is clear there is a large overlap in their distributions of topological network features
(see Fig. 3.8).
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Fig. 3.8 Cα structural network topological features of variants. Proteins are transformed into
networks based on positions of Cα carbons. Network topological features for common population
variants (common), rare population variants (rare), somatic cancer variants (cosmic) and disease-
associated variants (clinvar) datasets are compared. Somatic cancer variants have been further
divided into variants which localise to proteins which are classified as drivers or non-drivers. See
Appendix A5 for associated statistics.
3.3.4 Towards a domain-centric landscape of variant enrichment
We then proceeded from the protein level to examine variant enrichment at the domain level. First,
we studied whether disease-associated SAVs would localise preferentially to domains with specific
architectures. We made use of the CATH protein domain classification system (Sillitoe et al., 2015)
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and focussed on the architectural level, which groups domains with similar secondary structural
orientations, thereby capturing tertiary structural features. We mapped PFAM domain definitions to
those used by CATH, and created domain sets (analogous to gene sets) for each CATH architecture.
Enrichment was calculated at both the domain-type level (i.e. localisation of SAVs to a domain-type,
for example fibronectin type-III (Fn3), in comparison to localisation of SAVs to all other domain-types,
see Fig. 3.2), and at the domain-type region level (i.e. localisation of SAVs to core residues within
a domain-type, for example all Fn3 core residues, in comparison to the localisation of SAVs to all
other residues within a domain-type).
As depicted in Fig. 3.9, the results show that, at the whole domain level, the data sets show similar
trends in variant localisation. A number of architectures, such as the Alpha Horseshoe architecture,
show depletion of variants in all data sets, in contrast to other architectures, for example the Beta
Sandwich and Irregular architectures, which show enrichment in all data sets. Few architectures,
such as the Alpha-Beta Barrel, which is enriched in the gnomAD rare data but depleted for the other
data sets, show markedly different patterns of enrichment at the domain architecture level. At the
protein region level, the picture diversifies with the ClinVar data generally showing enrichment
in architecture cores, although not significantly, in contrast to the other data sets which are more
frequently depleted of variants in this region. Interestingly, this trend is particularly marked for
the Alpha-Beta Barrel architecture. Thus, although gnomAD rare variants are enriched in this
architecture, it is clear that very few of these localise to this architecture’s core.
We moved on to compare variant localisation across protein domain-types, using PFAM domain
definitions. As depicted in Fig. 3.2, we calculated the variant enrichment at the amalgamated
whole-domain and region (core/surface/interaction sites) levels. A case study, performed by Joseph
Chi-Fung Ng (Fraternali lab), highlights striking patterns of variant enrichment. Here we focus on
DNA-binding proteins: a wealth of analyses have established the fundamental role of structural
properties in the interaction of these proteins with DNA (Luscombe and Thornton, 2002; Rohs
et al., 2010; Schneider et al., 2014). We considered a list of DNA-binding domains (DBDs) curated
in the literature (Vaquerizas et al., 2009), and compared their whole-domain and region VESs. Fig.
3.10 shows that DBDs vary considerably in their enrichment of disease-associated and population
variants. Visualisation of the whole-domain level enrichment statistics shows that some DBDs
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Fig. 3.9 The enrichment CATH architectures in PFAM domains according to SAV enrichment,
quantified as the variant enrichment score (VES). Here CATH architectures constitute domain sets,
analogous to gene sets, and the VES constitutes the enrichment statistic. The normalised enrichment
score (NES) for each architecture is shown on the y-axis of the plots. Results are depicted at the
domain level (the enrichment of a PFAM domain in comparison to all other PFAM domains) and
the domain region level (the enrichment of the core, surface or interface of a PFAM domain in
comparison to the rest of a PFAM domain). * indicates q-value < 0.05.
(e.g. Forkhead, Homeobox) are only enriched in COSMIC and ClinVar variants, while zf-H2C2_2
domains, which are numerous in zinc finger (ZNF) proteins, appear to be enriched only in rare
variants. Other DBDs, e.g. Myb_DNA_binding, appear depleted in all types of variants. Different
regional enrichment patterns are also observed: ClinVar mutations are typically enriched in the
core but devoid at the surface of these domains, whereas in the COSMIC data, as well as the two
nominally healthy datasets derived from the gnomAD database, variants which localise to the
surface are more common (Fig. 3.10).
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Characteristic patterns of variant enrichment also hold when we examine across all PFAM
domains, including, but not limited to, DBDs. Fig. 3.11 depicts the union of the top 20 most
variant-enriched domains for each data set. Here it can be seen that a small number of domains
appear enriched in variants in primarily only the COSMIC and ClinVar data sets. These include
known drug targets such as kinase and ion channel domains. A handful of domains, which are only
enriched in COSMIC variants, include the Cadherin_tail and Laminin_G_2 domain, both of which
are important in cancer (Garg et al., 2014; Jeanes et al., 2008). A larger number of domains are variant
enriched in both the COSMIC and gnomAD dataset (rare and common variants). Some domains (e.g.
Serpin, UDPGT, Collagen and EGF_CA) contain variants from all datasets or all datasets with the
exception of COSMIC. In such domains, it is likely that the precise structural localisation of a variant
determines whether it plays a pathogenic role. Intriguingly a few domain-types, such as NPIP and
NUT appear only enriched in common variants. This could suggest that these domains take part
in functions for which it is desirable to maintain diversity within a population; however, little is
known about either domain-type (PFAM, 2018a,b). Thereby the bias in study towards those domains
associated with disease, rather than those enriched in population variants, is further highlighted.
It also becomes apparent that the global trends in variant localisation to the core, surface and
interface regions, observed in Section 3.3.2 are recapitulated here. Again the majority domains are
enriched in gnomAD (rare and common) variants at the surface but ClinVar variants at the core.
Although COSMIC variants show a trend broadly similar to gnomAD variants, it is clear that a
larger proportion of domain-types are enriched at the core or interface. These include domain-types
with known cancer driver associations, such as the P53 and VHL domains (Semenza, 2006).
We wished to understand how the targeting of domains by drugs mapped to the landscape of
variant enrichment we observed. To investigate this we used the protein-drug mapping provided in
the DrugBank database, as detailed in Section 3.2.1. The curation of this list was performed by Joseph
Chi-Fung Ng. As already extensively pointed out (Santos et al., 2017), the targeting of domain-types
by existing drugs is highly biased towards a small number of domain-types, such as GPCRs and
kinase domains. Indeed, we observe a large number of drugs targeting proteins containing 7tm
(GPCR) domains. These domains are enriched in variants from the gnomAD and COSMIC database
but are devoid of disease-associated ClinVar variants. Interestingly it has recently been shown that
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genetic variants in such domains (GPCRs), identified in the general population, may be associated
with differential drug response between individuals (Hauser et al., 2018). Therefore we show that
our domain-centric landscape of variant localisation highlights, for each domain-type, implications
useful for both understanding variant impact and motivating therapeutic design (see Section 3.4).
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Fig. 3.10 Landscape of variant enrichment in DNA-binding domains (DBDs). Here all DBDs, as
curated in Vaquerizas et al. (2009), with structural coverage are considered, and their domain-region
level enrichment is depicted. Each row corresponds to a PFAM domain-type. Region (surface,
interface and core) enrichments (which compare the enrichment of a region from a PFAM domain-
type in comparison to other regions from that domain-type) are shown in the heatmaps for common
population variants (common), rare population variants (rare), somatic cancer variants (cosmic)
and disease-associated variants (clinvar). Grey cells correspond to the absence of interaction site
mappings (for interface data), or the absence of mutations in our dataset. Each row is annotated
with the number of domain instances of each type present within our data. A stacked bar graph
shows the enrichment at the whole domain level (the variant enrichment of a PFAM domain-type in
comparison to all PFAM domains) for each data set.
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Fig. 3.11 A domain-centric landscape of variant enrichment. Here the union of the top 20 most
enriched domains for each data set is depicted: each row corresponds to a PFAM domain-type. The
plots show, from the left to the right, heatmaps of regional (surface, interface and core) enrichments
for common population variants (common), rare population variants (rare), somatic cancer variants
(cosmic) and disease-associated variants (clinvar). These regional enrichments compare the variant
enrichment of a region from a PFAM domain-type in comparison to other regions from that domain-
type. Grey cells correspond to the absence of interaction site mappings (for interface data), or the
absence of mutations in our dataset. Domain instances and enrichment at the whole domain level
(the variant enrichment of a PFAM domain-type in comparison to all other domain-types) for each
data set are shown as stacked bars to the left of the plot. The number of drugs known to target
proteins containing each domain-type is depicted in the rightmost bar graph. Note the cut numeric
axis; the number of drugs which target the only outlier, the 7tm_1 domain, is noted on the plot.
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3.3.5 Proteomics and transcriptomics features associate with variant localisa-
tion
Proteins, of course, do not function in isolation but in the crowded environment of the cell. In our
analysis so far we have viewed proteins through their three dimensional and functional properties;
however, we have to consider that proteins may be present in the cell in different quantities, display
different turnover rates and possess different melting temperatures. All of these factors can crucially
affect the stability and the fitness of a protein to perform its function. Here we have made use
of large-scale proteomics data, including protein abundance data from PaxDb (Wang et al., 2015)
and data describing both protein half-lives and thermal stability from the Savitski lab (Franken
et al., 2015; Mathieson et al., 2018), together with transcriptomics data from the GTEx database
(GTEx Consortium, 2013), to explore relationships between these features and variant localisation.
Please note that the numbers of proteins and SAVs which underlie each comparison are described in
Appendix A6.
Our results show that the protein-wise enrichment of disease-associated variants displays
positive correlations with protein abundance, expression, half-life and thermal stability, whereas
population variants exhibit the opposite trend (see Figs 3.12-3.14). It is important to recall here
that the protein-wise enrichment of variants is calculated in comparison to the entire proteome (all
UniProt proteins which contain SAVs in any of the datasets; see Fig. 3.2d).
However, if we zoom into the enrichment of variants in the core of protein structures, in
comparison to all regions of proteins with resolved structure, rare population variants demonstrate
a positive correlation with abundance and thermal stability, whereas disease-associated variants
negatively correlate with this (see Fig. 3.12). These results prove robust across multiple tissue
types. Analogous correlations for variant enrichments at protein surfaces display roughly opposite
trends to those observed at the protein cores. Due to the relative sparsity of variants which map to
protein interfaces, we believe it is difficult to draw robust conclusions from any trends observed for
correlations of proteomics data with variant enrichment at protein-protein interaction sites.
Our results, at the "core" region level, for gnomAD rare and ClinVar variants suggest that
disease-associated variants might preferentially localise to the core of unstable proteins, as these
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might be more easily destabilised to a degree at which function is deleteriously impacted. This
possibility is further explored in the discussion. Similarly to the ClinVar data, the gnomAD common
data also show negative correlations for variants occurring at the protein core; this could potentially
give weight to the argument presented by Mahlich et al. (2017) that common variants could affect
molecular function more than rare variants. However, we believe this is more likely to be due to
the fact that very few common variants localise to protein cores, as shown by Fig. 3.6, resulting in
sparse statistics (i.e. the correlation is calculated over Variant Enrichment Scores which are already
very low).
One might expect that mutations would be less easily accommodated in cores of densely packed
proteins, which would have higher thermal stability. To assess this we calculate the mean number
of Cα contacts within 8 Å of core residues, as a proxy for protein density. We find a significant
correlation between this metric and protein thermal stability (vehicle_1: ρ = 0.1680595, q-value
= 1.464451e-12; vehicle_2: ρ = 0.1854869, q-value = 1.528586e-13). If we correlate this metric of
core density with the core Variant Enrichment Score, we find a significant negative correlation for
the gnomAD common dataset. No other datasets show significant correlations with core density,
however a clear trend emerges in which correlations become progressively more positive in the
order of gnomAD common, gnomAD rare, somatic non-driver, somatic driver and ClinVar (see
Fig. 3.15). This suggests variants may be more deleterious if they localise to a packed core. Again
the complexity of the interplay between features is highlighted, as the higher stability of proteins
with more packed cores suggests that destabilisation, to a degree which is physiologically relevant,
may be more difficult to achieve. Although core packing and thermal stability are correlated, the
correlation value (ρ) is low. Therefore, this feature is clearly not the only determinant of protein
stability.
The results we see at the whole protein level, where the disease-associated ClinVar data clearly
show a more positive correlation with Tm, are, at a first sight, more difficult to explain. However,
work by the Picotti lab (Leuenberger et al., 2017) has demonstrated that more stable proteins are
generally more abundant. In agreement with this, we find significant correlations between the
protein abundance and thermal stability data (see Appendix A7). Moreover, we do see significant
positive correlations of protein-wise variant enrichment with protein abundance, in our analysis
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(see Fig. 3.12b). This suggests that the preferential localisation of ClinVar variants to more stable
proteins could be attributed to the higher abundance of such proteins.
Interestingly, it can be seen that the trends observed at both the protein level and core region
level, are less pronounced for cell line data and break down for extracellular fluids (saliva and urine).
Moreover, the trend is most evident for tissues containing long-lived cell-types, such as the brain,
ovary and testis. Transcriptomics data (see Fig. 3.13) again reinforces this picture, albeit with less
contrast between data sets (particularly at the protein core).
Finally, we wanted to understand whether correlations with these proteomic and transcriptomic
features could be associated with the specific functional roles of the involved proteins. This was
achieved by investigating the association of these proteomic and transcriptomic features with
biological pathways, using the GSEA algorithm. For the majority of proteomic and transcriptomic
features, no clear associations with the functional clusters identified in Fig. 3.3 can be detected
(see Appendix A8). An exception to this is protein thermal stability: pathways which belong to the
"proliferative" cluster are clearly enriched in proteins of lower stability than the other two clusters
(see Fig. 3.10c). This suggests that proliferation-related proteins may be vulnerable to disruption
by mutations which localise to their already unstable cores. Moreover, this agrees with the idea
proposed in Section 3.3.1, that "proliferative" cluster proteins may be less robust to disruption.
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Fig. 3.12 The protein-wise enrichment of SAVs in comparison to protein abundance, expression and
stability. Spearman correlations for SAV enrichment (quantified as VESs) at different levels with a)
protein melting temperature (Tm) measured in 2 replicates and b) protein abundance (ppm) measured
in different tissues/sample-types. The VES is calculated to describe the variant enrichment of a
protein in comparison to the entire proteome, and the variant enrichment of a protein region (surf,
interact or core) in comparison to the rest of a protein. This is calculated for common population
variants (common), rare population variants (rare), somatic cancer variants (cosmic) and disease-
associated variants (clinvar). Error bars indicate 95 % confidence intervals. * indicates q-value <
0.05. c) Functional enrichment of proteins in KEGG pathways according to Tm calculated using the
GSEA algorithm. The Normalised Enrichment Score (NES) is shown on the y-axis. Pathways have
been mapped to the 3 clusters defined in Section 3.3.1 and have been named to reflect their pathway
composition.
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Fig. 3.13 The protein-wise enrichment of SAVs (VES) in comparison to protein abundance (ppm) and
expression (median count), measured in different tissues, at the a) "protein" level, b-d) "surf","core"
and "interact" levels. The VES is calculated to describe the variant enrichment of a protein in
comparison to the entire proteome, and the variant enrichment of a protein region (surf, interact
or core) in comparison to the rest of a protein. This is calculated for common population variants,
rare population variants, somatic cancer variants (cosmic) and disease-associated variants (clinvar).
Spearman correlations calculated using only those proteins present in both abundance and expression
data. Error bars indicate 95 % confidence intervals. * indicates q-value < 0.05.
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Fig. 3.14 The Spearman correlation of the enrichment of SAVs (VES) with protein half-life data
(hours), measured in different cell-types (2 replicas each). The VES is calculated to describe the
variant enrichment of a protein in comparison to the entire proteome, and the variant enrichment
of a protein region (core, interact or surf) in comparison to the rest of a protein. This is calculated
for common population variants, rare population variants, somatic cancer variants (cosmic) and
disease-associated variants (clinvar). Error bars indicate 95 % confidence intervals. * indicates
q-value < 0.05.
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Fig. 3.15 The Spearman correlation of the enrichment of SAVs in protein cores (VES) with a proxy
for protein core density (see Section 3.2.4). The VES has been calculated for common and rare
population variants, somatic cancer variants (cosmic) and disease-associated variants (clinvar). Error
bars indicate 95 % confidence intervals. * indicates q-value < 0.05.
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3.3.6 Rare variants are similar to common variants
Throughout the majority of analyses, performed both at the macroscopic and atomistic levels, the
greatest segregation of data can be seen between common and disease-associated variants. Rare
variants show characteristics more similar to common variants, both in terms of the functional
pathways they impact on, and in terms of the protein regions they localise to (core, surface and
interface, order and disorder). If more stringent minor allele frequency (MAF) thresholds are used
to define rare variants, their properties move towards those of disease-associated variants, but
still remain closest to those of common variants (see Figs 3.16-3.17). A visible separation between
common and rare variants, especially in the pathway analysis, can only be seen if an extreme MAF
cutoff (<0.00001) is used.
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Fig. 3.16 Rare variants display similar functional enrichments to common variants. Gene set en-
richment for KEGG functional pathways was performed by ranking proteins using their whole
protein VESs, which quantify the variant enrichment of a protein in comparison to the whole
proteome. The analysis was performed separately for common population variants (common), rare
population variants (rare), somatic cancer variants (cosmic) and disease-associated variants (clinvar).
As in Fig. 3.3a, at the whole protein level, KEGG pathways form 3 identifiable clusters (K-means),
as visualised projected on the first two principal components of the PCA. Each cluster has been
assigned a colour for visualisation purposes, and has been named to reflect its pathway composition.
The plots show that if increasingly stringent minor allele frequencies (MAFs) are used to define rare
variants, the functional enrichment of the rare dataset becomes slightly more similar to that of the
disease-associated datasets (clinvar and cosmic), but remains closest to that of the common dataset,
as revealed by factor loadings.
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Fig. 3.17 The density of rare mutations from the gnomAD data in different protein regions. Rare
variants have been defined using different MAF cut-offs, as shown on the x-axis. Both observed
densities (pink), and densities derived from simulated null distributions (turquoise) are shown. Error
bars depict 95 % confidence intervals; for observed densities, these were obtained by bootstrapping.
Significance was calculated by comparison of observed values to simulated null SAV distributions
(significance level indicated by: * q-value < 0.05, ** q-value < 0.001, *** q-value < 0.0001).
3.4 Discussion and conclusions
Throughout this work, we show that SAVs in the general population, considered ’nominally healthy’,
show properties distinct from those in disease cohorts, both at the macroscopic and atomistic levels.
Additionally, although we uncover a spectrum in the properties of variants, which ranges from
common population variants to disease-associated ClinVar variants, we find that the properties
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of rare variants remain close to those of common variants. These findings contrast with other
observations (Mahlich et al., 2017), which suggest that common variants have more impact on
molecular function than rare variants. Common variants appear closer in character to disease-
associated variants than to rare variants, only for certain proteomics properties, such as the thermal
stability and abundance of the variant enriched proteins, as discussed in Section 3.3.5. However, we
consider these results inconclusive, due to the sparsity of the data. Alhuzimi et al. (2018) suggest that
the properties of genes enriched in rare population variants are similar to those enriched in disease-
associated variants, and are thus good candidates for harbouring unknown disease associations.
Instead, we show that such proteins are, from the annotated functional pathways, most similar to
those enriched in common variants (Fig. 3.16). Moreover our results, which show that variants
maintained within a population impact on functions which are mainly associated with response
to the environment, such as sensory and immune-related functions (Figs 3.3a and 3.4), agree with
results from evolutionary studies reviewed by Quintana-Murci (2016), which used (primarily) a
genome-wide scanning approach to detect signals of positive selection.
We have dissected the levels of variant enrichment in diverse datasets and across different protein
levels (Fig. 3.2). Such a detailed anatomy of variant enrichment in health and disease provides a
unique link between the cataloguing of mutations, and understanding both their mechanistic and
functional effects. This supplies invaluable information to researchers studying specific proteins
or domains, or focusing on proteins involved in a particular function (e.g. DNA binding; Fig. 3.10).
By analysing the enrichment of variants in protein regions (core, surface, interface, disorder and
disorder, PTM vicinity), we recapitulate trends observed by previous studies (e.g. in the comparison
of oncogenes and TSGs; Fig. 3.6b) (David et al., 2012; Engin et al., 2016; Gao et al., 2015; Gress et al.,
2017; Stehr et al., 2011), but also shed light on the debate as to whether somatic cancer variants
are enriched in interface regions, by simulating null-distributions of variants. The simulations we
have performed show that it is essential to consider that variants from different datasets are not
uniformly randomly distributed throughout the proteome. Through density-based metrics we find
somatic cancer variants are not enriched in protein interfaces, however using a simulation-based
approach we do find an enrichment (Fig. 3.6a). A similar simulation-based approach was taken
by Gress et al. (2017), but they found no significant enrichment for COSMIC variants in interface
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regions. Whilst they analysed a filtered set of mutations likely to play a driver role, we investigated
all somatic variants and addressed separately mutations that localise to defined driver and non-driver
genes. Our enrichment calculations were rigorous, and directly compared against null (n = 10,000)
simulations to assess statistical significance.
Throughout this analysis, we have, of course, been limited by the number of proteins with
available structural data, although this has been enriched by considering homologous structures.
Our analyses have attempted to overcome biases which could result from the increased study (and
associated structural coverage) of disease-associated proteins, however we cannot fully anticipate
the structural properties of the unresolved portion of the proteome. It is likely that this is enriched
in proteins with higher flexibility/more disordered regions, which are more difficult to resolve
structurally. Therefore, it is possible that greater insight into the properties of missense variants
will be achieved as the structural coverage of the proteome increases. However, as the properties we
observe are in line with those from earlier studies which had access to a much smaller number of
protein structures and variants (e.g. that by Sunyaev et al. (2000)), we consider it unlikely increased
structural coverage of the proteome will drastically alter our results, unless techniques for resolving
proteins which contain a large portion of disordered/flexible regions continue to improve (Gibbs
and Kriwacki, 2018). We are also still limited by the structural coverage of protein interactions;
although enough data exists to uncover broad trends, our analyses at a finer granularity, which
probed protein-protein interaction sites, generally lacked statistical power. Moreover, it is likely that
a more detailed picture will emerge if variant localisations to proteins involved in different classes
of interactions are probed (e.g. transient vs permanent interactions). We envisage that the recent
advances in cryo-EM (Orlov et al., 2017), and the integration of structural data derived by a variety
of techniques (Burley et al., 2017), will further increase the structural coverage of the protein-protein
interaction network, enabling such finer-grained analyses in the future.
Our analysis at the macromolecular level, which probes associations between the enrichment
of variants and proteomic features, is, to the best of our knowledge, unprecedented, and has
only been made possible due to the recent release of large-scale proteomics data (Franken et al.,
2015; Leuenberger et al., 2017; Mathieson et al., 2018; Wang et al., 2015). We observe correlations
which suggest an interplay between variant enrichment, protein abundance and thermal stability.
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First, disease-associated variants localise preferentially to proteins which are highly expressed and
abundant (Fig. 3.12). These results complement a body of research which concludes that the rate of
protein evolution correlates negatively with protein expression and abundance (Zhang and Yang,
2015). The extent of this anti-correlation has been found to be tissue-specific; those tissues with
a high neuron density demonstrating the highest anti-correlation (Drummond and Wilke, 2008).
Consistent with this, we found the largest negative correlation for the protein-wise enrichment of
rare variants, from the gnomAD dataset, with protein abundance in the brain, and, interestingly also
in the ovary and testis, which both harbour long-lived germline progenitor cells (Fig. 3.12b; Fig. 3.13);
purportedly the lifespan of long-lived cells renders them more sensitive to the toxicity of misfolded
proteins. Second, we see a trend which suggests disease-associated variants preferentially localise
to the core in less thermally stable proteins, most probably as these are more easily destabilised to
an extent at which function is lost or impaired (Fig. 3.12a). Hence two competing trends emerge;
variants which localise to less abundant proteins have greater disruptive potential, conversely, those
which localise to thermally unstable proteins (which are normally less abundant (Leuenberger et al.,
2017)) may be able to deleteriously destabilise such proteins more easily. It is conceivable that the
chemical nature of the particular missense variant plays an important role here: e.g. if a variant at
the protein surface alters the "stickiness" of the protein and promotes non-specific interactions, this
is likely to be most detrimental if the affected protein is present in great abundance. This highlights
the importance of evaluating the interplay of macroscopic and atomistic features when estimating
the potential impact of variants on protein function and stability.
The relationship between variant localisation and protein stability is of importance, as a number
of algorithms have used the change in protein stability upon mutation (∆∆G) as a proxy for variant
impact. Our results indicate that the baseline stability of the wild-type protein may also be important
when considering the phenotypic relevance of a change in stability upon mutation. From their
analysis of the ProTherm database, Serohijos et al. (2012) found that mutations in more stable
proteins generally led to greater destabilisation. They interpret this as suggesting that proteins
which have evolved to become more stable are in a state closer to their peak stability, where any
changes will result in drastic destabilisation. Similarly, Pucci and Rooman (2016) used temperature
dependent statistical potentials to investigate the thermal stability of the structurome (all proteins
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with resolved structure), and concluded that mutations in proteins which are highly thermally stable
lead to a larger decrease in thermal stability, compared with those in less thermally stable proteins.
We believe that our results point to the fact that, even under a scenario in which mutations in
proteins with higher stability result in a greater change in stability, a mutation in an already unstable
protein is more likely to result in complete/partial unfolding under physiological conditions. These
factors should be brought into consideration when interpreting the impact of missense variants.
By investigating the interplay of macroscopic and atomistic features, such as pathway and
region enrichment, we show that greater insight into the properties of variants in health and disease
can be obtained. For example, as discussed in Section 3.3.1, it can be clearly seen that population
variants are most enriched on the surface of proteins which take part in pathways we have defined
as belonging to the "proliferative" cluster (Fig. 3.3d). Moreover, pathways belonging to this cluster
also appear to be enriched in proteins with less thermal stability (Fig. 3.12c), suggesting a possible
mechanistic basis underlying the localisation of variants (variants tend to localise to the surface and
avoid disrupting the core of these already unstable proteins). This indicates that the combinatorial
use of such features may aid in both improving the prediction of a variant’s impact on phenotype,
and in assessing the molecular mechanisms underlying this.
Ultimately, the goal should reach beyond the identification of variants which underlie a disease
phenotype, to the use of this information to inform the development of therapeutic strategies. Here
we envisage that our domain-centric landscape of variant enrichment (Fig. 3.11), which includes the
mapping of domain-targeting drugs, besides providing another feature for the characterisation of
variants, will allow for more informed decisions in selecting new therapeutic targets. This will allow
for the selection of domains to which multiple disease-associated variants localise, in order to give
scope for drug repurposing or redesign. Additionally, targets with few population variants could be
selected, to minimise differential drug response due to genetic differences between individuals. It
is, of course, likely that such a differential drug response may not only be associated with genetic
variants which localise to the target protein, but also a number of other factors, such as variants
which localise to interacting proteins and environmental conditions. Nevertheless, our analysis
provides a starting point for determining the actionability of disease-associated variants and domains.
As with all other analyses presented here it must be considered that our knowledge of protein-drug
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and domain-drug interactions is incomplete, and depends partially on the techniques which have
been used to study a drug, and the particular drug design and development processes involved. For
example, the mechanisms of action (and target binding) for a number of drugs, including paracetamol
(Mehta and Sharma, 2013), are unknown. It is possible that systematic biases could result from
this; for example drug-target interactions with a lower binding affinity may be less frequently
characterised.
In conclusion, this chapter highlights the complex interplay between different factors which may
determine variant pathogenicity, at both the macroscopic and atomistic levels. We believe that these
insights will prove important in the prediction of which variants drive disease phenotypes. Further
advancement in the structural coverage of the proteome, and the exploitation of high throughput
proteomics technologies, such as those pioneered by the Savitski and Picotti labs (Leuenberger et al.,
2017; Mathieson et al., 2018), will offer a finer-grained picture of features which segregate variants
in "health" and "disease".
Chapter 4
Predicting the impact of titin variants
using protein dynamics-based features
4.1 Introduction
As discussed in Chapter 3, despite the explosion of accessible genetic data the problem of missing
heritability still persists. A number of variants defy classification by purely statistical methods,
therefore their impact must be elucidated by a combination of computational and wet lab techniques.
Furthermore, the impact of a missense variant on structure and function must be discerned, if the
mechanism underlying a variant’s pathogenicity is to be understood. Such insights may inform
therapeutic strategies. Although a number of computational methods have been developed to assess
the impact of variants, it is clear these do not always match experimental outcomes. Moreover, as
discussed in Chapter 1, evidence suggests that existing methods lack specificity.
One important aspect of proteins’ functional roles is their dynamic behaviour; in fact proteins
are not static by nature, but in a perpetual state of motion within the cell. Therefore the impact
of a variant may act on particular conformational states and transitions between these. However,
we have seen in Chapter 1 that very few predictors use features associated with protein flexibility
or dynamics. Importantly, recent work from the Bahar laboratory has shown that incorporating
structural dynamics information derived from elastic network models can improve the accuracy
of prediction (Ponzoni and Bahar, 2018). However, as the dynamic features within this approach
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are based solely on Cα network models, the chemical nature of the change is not modelled. Thus
this dynamic information only allows discrimination between positions which are most likely to
harbour deleterious mutations. Atomistic molecular dynamics, as discussed in Section 1.4.2, may
enable more accurate modelling of the physicochemical nature underlying a residue’s flexibility, and
therefore allows for a more realistic representation of the impact of a variant on protein dynamics.
Yet, to date, atomistic molecular dynamics simulations have generally only been used to investigate a
small number of "case study" variants, or been applied over very short timescales to refine modelled
mutants (see Section 1.4.2). Here, an obstacle to the large-scale use of such simulations is their
computational cost. Because of this the use of coarse-grained methods, which contain approximate
but nonetheless realistic representations of amino acids, and are less computationally expensive,
would be desirable. However, it is not clear whether these are able to reflect the impact of mutations
on dynamics.
As the focus of this thesis is on titinopathies, we explore here whether population titin variants,
the majority of which are rare, can be distinguished from titin variants with known disease associa-
tions. In particular, we investigate the application of dynamics features to the task of predicting the
impact of these variants. We calculate elastic network features, for titin Ig and Fn3 domains, as in
the work by Ponzoni and Bahar (2018) however we go further to explore the use of coarse-grained
molecular dynamics using the CafeMol (Kenzaki et al., 2011), Martini ElNeDyn (Periole et al., 2009)
and Martini GO models (Poma et al., 2017), in addition to full atomistic molecular dynamics in
explicit solvent. Each of these models can be placed upon a spectrum which ranges from the Cα
representation (which explores only near-equilibrium dynamics) of elastic network models, to the
Cα representation with residue specific potentials of the CafeMol simulations (Kenzaki et al., 2011),
to the Martini representation in which groups of atoms are represented by virtual "beads" (de Jong
et al., 2013; Monticelli et al., 2008), and finally to full atomistic molecular dynamics simulations
(Meier et al., 2013; van Gunsteren et al., 2006, 2018)(see Fig. 4.1).
We ask whether atomistic molecular dynamics simulations are better able to distinguish between
disease-associated and (predominantly) rare population variants than coarse-grained models and
elastic network models. Furthermore, we compare the predictive power of features derived from
atomistic molecular dynamics simulations to those derived from ENMs and sequence-based features,
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Fig. 4.1 Different levels of granularity can be used to represent protein structures. These include, in
order of increasing detail, coarse-grained Cα representations, coarse-grainedMartini representations,
in which several atoms are grouped together to form virtual beads, and atomistic representations.
PDB structure 2y9r is depicted, as visualised by the VMD software (Humphrey et al., 1996).
by training random forest-based predictive models to classify disease-associated and population
variants. Finally, we compare the performance of these models to that of widely used predictors,
such as PolyPhen2 (Adzhubei et al., 2010) and FATHMM (Shihab et al., 2013).
Unfortunately, a perfect dataset to test whether rare non-pathogenic variants can be segregated
from rare pathogenic variants does not exist. Firstly, there is no guarantee that rare variants may not
have an undiscovered disease association. Moreover, disease-associated homozygous and compound
heterozygous variants can be present in healthy heterozygotes. The extent to which rare variants
may be associated with disease is a matter of active research and debate (Gibson, 2012; Kido et al.,
2018). Secondly, we cannot rule out the possibility that variants in our disease-associated set could
be incorrectly labelled, due to co-inheritance with a causative allele. However, we believe that this
detailed study of the impact of variants on the dynamics of these ubiquitous domains (Ig and Fn3)
may shed light on the proportion of rare variants which may have an impact on protein function.
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4.2 Materials and methods
4.2.1 Dataset
19 titin variants were selected based on their disease associations and localisation to the constitutively
spliced-in A-band and M-line regions of titin. These variants localise to 5 distinct titin domains.
For each domain, an equal number of variants with no known disease-associations were selected
from the gnomAD database, based on either having a WT solvent accessibility similar to the disease-
associated WT positions, or available biophysical data. The rationale being that, as the majority
of disease-associated variants have low solvent accessible surface areas (SASAs), surface exposed
population variants are easy to distinguish from these, and thus the use of dynamics-related features
is not necessary to achieve segregation. From the minor allele frequencies it can be seen that the
majority of selected SAVs are extremely rare; only the Fn3-90 I14V has a MAF above the cut-off
of 0.01, which is frequently used to define common variants. One additional population variant
was selected for the domain Fn3-90, due to the availability of associated in-house biophysical data 2
for two population variants from this domain. Selected deleterious and population variants are
detailed in Table 4.1 and Table 4.2. In particular, two of the domains, Ig-169 and Fn3-119, are hotspots
for disease-associated mutations. The domain Ig-169, also known as M10, is located at the end
of titin’s M-band region where it interacts with obscurin and obscurin-like protein. This domain
harbours variants associated with tibial muscle dystrophy (TMD) (Hackman et al., 2002; Savarese
et al., 2016) and limb-girdle muscular dystrophy 2J (LGMD2J) (Hackman et al., 2002; Savarese et al.,
2016). Similarly, the domain Fn3-119 harbours a number of variants associated with the disease
hereditary myopathy with early respiratory failure (HMERF) (Pfeffer et al., 2015). For all investigated
domains, variants are depicted mapped to structure in Fig. 4.2.
2Private communication, Roksana Nikoopour and Dr Martin Rees (Gautel laboratory)
4.2 Materials and methods 123
Fig. 4.2 The location of population variants (green) and disease-associated variants (magenta)
analysed in this study, mapped to structures for the titin domains Ig-169, Fn3-119, Fn3-7, Fn3-49 and
Fn3-90. One position (blue), in Ig-169, harbours distinct variants from the disease-associated and
population datasets. Structures were visualised using the UCSF Chimera software (Pettersen et al.,
2004).











Fn3-7 W22C 17471 0.10 M-DCM in-house model 4.00E-04 75∗ 43∗
Fn3-49 V81E (V77E) 22232 0.09 MmD-HD literature in-house 59∗ unfolded
Fn3-90 G88V (G84V) 27849 0.17 M-DCM in-house in-house 60∗ unfolded∗
Fn3-119 P2R 31709 0.15 HMERF literature model 50∗
Fn3-119 C5Y 31712 0.12 HMERF literature model 50∗
Fn3-119 C5R 31712 0.12 HMERF literature model 4.164E-06 50∗ 32∗
Fn3-119 W22R 31729 0.11 HMERF literature model 50∗
Fn3-119 W22L 31729 0.11 HMERF literature model 50∗
Fn3-119 W22C 31729 0.11 HMERF literature model 50∗
Fn3-119 P25L 31732 0.15 HMERF literature model 1.22E-05 50∗ 33∗
Fn3-119 N79K 31786 0.12 HMERF literature model 50∗
Fn3-119 G84V 31791 0.15 HMERF literature model 50∗
Fn3-119 G84R 31791 0.15 HMERF literature model 50∗
Fn3-119 G84D 31791 0.15 HMERF literature model 50∗
Ig-169 H54P (H50P) 35946 0.21 TMD literature 2y9r 58 37
Ig-169 I55N (I51N) 35947 0.14 TMD literature 2y9r 4.06E-06 58 53
Ig-169 L64P (L60P) 35956 0.11 TMD literature 2y9r 58 unfolded
Ig-169 T23P (T19P) 35915 0.32 TMD literature 2y9r 58
Ig-169 W38R (W34R) 35930 0.15 LJMD2J literature 2y9r 58
Table 4.1 Titinopathy associated variants analysed in this study. Note that a minority of these
are present in the gnomAD database at low MAFs. SAVs are numbered by their position in the
domain structure. TITINdb domain position numbering (Laddach et al., 2017) is included in brackets
where this does not match the numbering of the structure used here. In-house differential scanning
fluorimetry (DSF) data 2 is denoted by *. All other Tm measurments are from circular dichromism
(CD) data reported in (Rudloff et al., 2015). Titinopathies associated with these variants include
hereditary myopathy with early respiratory (HMERF), tibial muscular dystrophy (TMD), limb-
girdle muscular dystrophy 2J (LGMD2J), multi-minicore disease with heart disease (MmD-HD) and
myopathy with dilated cardiomyopathy (M-DCM).










Structure WT Tm Mutant
Tm
Fn3-7 A17T 16466 0.10 8.23E-06 model 75∗
Fn3-49 V42I (V38I) 31748 0.09 8.20E-06 in-house 59∗
Fn3-90 I14V (I10V) 27775 0.39 3.52E-1 5.84E-1 in-house 60∗ 59∗
Fn3-90 R78Q (R74Q) 27839 0.17 4.21E-04 3.99E-04 in-house 60∗ 47∗
Fn3-119 T19A 31726 0.16 4.08E-06 model 50∗
Fn3-119 V38M 31745 0.09 3.26E-05 model 50∗
Fn3-119 R41H 31748 0.10 1.22E-05 model 50∗
Fn3-119 R41C 31748 0.10 1.22E-05 1.01E-3 model 50∗
Fn3-119 R41S 31748 0.10 4.07E-06 model 50∗
Fn3-119 S59F 31766 0.33 3.39E-3 5.99E-3 model 50∗ 49∗
Fn3-119 R74L 31781 0.12 8.15E-06 model 50∗
Fn3-119 R74Q 31781 0.12 1.63E-05 model 50∗
Fn3-119 V78I 31785 0.14 4.07E-06 model 50∗
Fn3-119 V87L 31799 0.14 3.23E-05 model 50∗
Fn3-119 I92V 31799 0.16 6.12E-05 model 50∗
Ig-169 E18K (E14K) 35910 0.33 1.23E-05 1.20E-4 2y9r 58
Ig-169 A25V (A21V) 35917 0.16 4.06E-06 2y9r 58
Ig-169 I55T (I51T) 35947 0.14 4.08E-06 2y9r 58
Ig-169 T63N (T59N) 35955 0.21 4.08E-06 2y9r 58
Ig-169 I94T (I90T) 35986 0.12 3.39E-3 2y9r 58
Table 4.2 Population variants analysed in this study. SAVs are numbered by their position in the
domain structure. TITINdb domain position numbering (Laddach et al., 2017) is included in brackets
where this does not match the numbering of the structure used here. In-house differential scanning
fluorimetry (DSF) data 2 is denoted by *. All other Tm measurments are from circular dichromism
(CD) data reported in (Rudloff et al., 2015).
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4.2.2 Modelling of domains
Homology models of Fn3-119 and Fn-7, were obtained from TITINdb (Laddach et al., 2017). Mutants
were created using the Modeller protocol available at http://salilab.org/modeller/wiki/Mutate%
20model (Webb and Sali, 2014).
4.2.3 Molecular dynamics
Molecular dynamics is an established method which enables the simulation of the dynamical
properties of a system over time, using Newton’s equations of motion (Hospital et al., 2015).





The velocity v of particle i after time τ under constant force, given an initial velocity vi(0), is
described by the equation:






And the position r of the particle is given by the equation:




However, once a particle moves, the forces acting on it change. Therefore, in the context of
simulations, velocities, forces and positions are updated at finite time steps of chosen length ∆t.
Several algorithms can be used to calculate forces and velocities at subsequent times, according
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to discretisation choices. The molecular dynamics engine GROMACS, used for both atomistic and
Martini simulations, employs the leapfrog algorithm:






r(t+∆t) = r(t) + ∆tv(t+ 12∆t) (4.5)
This is used for both the atomistic molecular dynamics simulations and the coarse-grained
Martini simulations. For CafeMol simulations the velocity Verlet algorithm is instead used to update
velocities, forces and positions:
r(t+∆t) = r(t) + ∆tv + ∆t
2
2m F (t) (4.6)
v(t+∆t) = v(t) + ∆t2m [F (t) + F (t+∆t)] (4.7)
This algorithm is similar to the leapfrog algorithm, although velocities and positions are both
calculated at the same time. Because of this, velocities must be explicitly calculated, however the
algorithm has the advantage that it is self-starting, i.e. it is possible to calculate velocities and
positions at time t + ∆t from those at time t. In comparison, the leapfrog algorithm requires
information from the previous time step.
The calculation of force acting on each particle of the system is accomplished using molecular
mechanics force fields. Forces are calculated from the ensemble of all particle positions, denoted as
r, within the system.
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For all atom simulations we use the Gromos 54a8 forcefield (Reif et al., 2013). This consists of
the following terms, which use the ensemble of all positions to account for bonded interactions
(bond stretching, bond-angle bending, improper and proper dihedrals) (van Gunsteren et al., 2006):






n − b20n ]2 (4.8)










2Kξn [ξn − ξ0n ]
2 (4.10)
V proper(r;Kφ, δ,m) =
Nφ∑
n=1
Kφn [1 + cos(δn) cos(mnφn)] (4.11)
HereKb, b0 and bn represent the bond force constant, the optimum bond length and the observed
bond length. Kθ , θ0 and θn represent the angle force constant, optimum bond angle and observed
bond angle. Kξ , ξ0 and ξn represent the improper dihedral force constant, optimum improper
dihedral and observed improper dihedral. It is important to note that improper dihedrals play an
important role in maintaining chirality. Finally,Kφ, δ,m and φn represent the proper dihedral force
constant, the phase shift, the multiplicity and the observed proper dihedral angle.
Additionally two terms are used to account for non-bonded interactions (van der Waals, and
electrostatic interactions) (see equations 4.12 and 4.13). For all atomistic and Martini simulations
performed here, the Lennard-Jones potential was used to model van der Waals interactions.
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Here C12 and C6 are parameters of the 12/6 Lennard Jones interaction. The parameters qi and
qj denote the partial charges on atoms. Long-range electrostatics must also be accounted for. In this
work we use the Particle-mesh Ewald method (Essmann et al., 1995) for atomistic simulations and
the reaction field method (Tironi et al., 1995) for Martini coarse-grained simulations.
The Martini coarse-grained forcefield groups together, on average 4 heavy atoms, to form virtual
beads. Four different bead types are possible; polar, nonpolar, apolar and charged (Monticelli et al.,
2008). Each bead type is further split into subtypes based on polarity and hydrogen bonding capacity.
Forcefield terms are identical to those used by the Gromos forcefield. Here it is important to note
that, in the coarse-grained representation, proper dihedrals are used to enforce secondary structure,
thereby preventing secondary structure transitions.
The CafeMol software represents protein Cα atoms as beads, however uses residue specific
potentials and all atom information to define local contacts (Takada et al., 2015). The CafeMol
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Here each term is calculated given properties of the native structure (denoted by subscript zero),
with the native structure frequently defined by the initial coordinates. For example bn0 denotes the
bond length in the native structure. Distances between residue i and i+2 are used in a pseudo bond
angle term, and this potential is modelled as a Gaussian distribution. The dihedral angle term V trig
is also modelled as a Gaussian. For both these terms the strength of the interaction is given by the
constantsKpseudo−angle andKφ, and the widths of the Gaussians are controlled by the constants
Wpseudo−angle andWφ. Additionally a flexible local potential, V flploc is used to account for chirality.
To construct this potential, statistical probability distributions for bond angles and dihedral angles
were extracted from PDB structures. This gives the following potential energy functions:
V statba = −kBT ln
P (θ)
sin(θ) (4.17)
V statdih = −kBT lnP (φ) (4.18)
Here kB denotes the Boltzmann constant. The temperature T is 300 K. To create continuous
potential energy functions, cubic spline interpolation is used for bond angle distributions and
dihedral distributions are fitted to the truncated Fourier series.
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Native contacts are non-local pairs which are close to one another in the reference structure.
Non-native pairs are non-local pairs which are not close to one another in the reference structure.
The parameters di and dj denote residue-type specific radii.
A term to account for hydrophobic interactions takes the form:




Where the parameter cHP controls the strength of hydrophobic interactions, A(i) is the particle
type (i.e. the amino acid type) and the function SHP calculates the "buriedness" of particle i from
the local density ρi:
SHP (ρ) =

1, if ρ ≥ 1
clinearρ+ 0.5(1− clinear)
[
1 + cos π(1−ρ)1−ρmin
]
, if ρmin < ρ < 1
clinearρ, if ρ ≤ ρmin
(4.22)
Here clinear is a constant for the calculation of particle buriedness and ρmin is the minimum
local density of a particle. The parameter ρi is calculated using the following formula:
ρi =
∑
j∈HP,j ̸=i nA(j)uHP (ri,j , rmin,A(i),A(j), rmax,A(i),A(j))
nmax,A(i)
(4.23)
Where the degree of contact between the particles i and j is represented by the function uHP :
uHP (r, rmin, rmax) =

1, if r ≤ rmin
0.5
(
1 + cos π(r−rmin)rmax−rmin
)
, if rmin < r < rmax
0, if r ≥ rmax
(4.24)
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Here nA is the number of atom types that particle A represents, nmax,A is the maximum
coordination number for the particle type A, ri,j is the distance between hydrophobic particles i
and j, rmin,A,B defines the cut-off for the minimal distance between particle types A and B and
rmax,A,B defines the cut-off for the maximal distance between particle types A and B.
Debye-Hückel type electrostatic interactions are also implemented, to implicitly represent the
screening action of the solvent:














Where λD is the Debye-Hückel length, NA is the Avogadro number and I is the ionic strength.
4.2.4 Atomistic simulation parameters
Atomistic molecular dynamics simulations were performed using the GROMACS 2016.3 package
(Van Der Spoel et al., 2005) and the GROMOS 54a8 forcefield (Reif et al., 2013). Each titin domain
structure was centred in a triclinical simulation box filled with SPC-E water molecules (Leontyev
and Stuchebrukhov, 2010), with the minimal distance between the protein and box boundaries set at
15 Å. An appropriate number of solvent molecules were replaced with sodium or chloride ions to
neutralise the system. All bonds were constrained using the LINCS method (Hess, 2008). The system
was energy minimised using the steepest descent minimisation algorithm over 2000 steps with
positional restraints and 10000 steps without such restraints, both with the time step set at 0.001 ps.
Equilibration was carried out first in an NVT ensemble at 50 K, 100 K, 200 K and 300 K respectively,
with positional restraints at force constants of 2000, 1000, 500 and 250 kJ/mol nm2 for 50000 steps
each. Subsequently, an NPT ensemble was used at 100 K, 200 K and 300 K for 50000 steps each, with
an isotropic coupling at 1 bar pressure and 4.5E-5 bar−1 compressibility. A random velocity drawn
from the Maxwell-Boltzmann distribution was used at the start of equilibration. Temperature and
pressure coupling was achieved using the Berendsen thermostat and barostat (Berendsen et al., 1984).
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Every system was simulated for a 100 ns production run, in an NPT ensemble at 1 bar pressure.
Here the Parrinello-Rahman algorithm was used for pressure and temperature coupling (Parrinello
and Rahman, 1981). For minimisation, equilibration and production runs, the particle mesh Ewald
method (Essmann et al., 1995) was used to calculate the long-range electrostatic contribution to the
non-bonded interactions with a cut-off of 14 Å, a Fourier spacing of 1.2 Å and cubic interpolation.
Similarly a cut-off of 14 Å was used for van der Waals interactions, with a plain cut-off scheme for
the long-range treatment of these. The time step for equilibration and production runs was set to
0.002 ps.
4.2.5 Martini simulation parameters
Martini simulations were performed in GROMACS 2018.02 using the Martini-2.2 ElNeDyn (Periole
et al., 2009) and GO (Poma et al., 2017) coarse-grained force fields for biomolecules. These approaches
were chosen, as preliminary investigations showed that Martini simulations without additional
restraints resulted in a loss of a reasonable structural representation even for WT domains (see Fig.
4.3). The ElNeDynmethod maintains the structure of a protein using harmonic spring potentials as in
elastic network models, whereas the GO approach uses Lennard-Jones potentials based on contacts
in the starting structure. The GO approach has the advantage over the ElNeDyn model that it does
not rely on harmonic bonds which cannot be broken. Therefore, although still biased by the starting
structure, it is likely that more conformational space can be explored if the system is perturbed.
Each structure was converted into its coarse-grained representation using themartinize.py script (de
Jong et al., 2013), and was then solvated with standard Martini water in a cubic box with a minimum
distance of 30Å between the protein beads and the edge of the box. All bonds were constrained using
the LINCS method (Hess, 2008). Minimisation in a vacuum was carried out for 10 steps, followed by
5000 steps of minimization with solvent. The steepest descent algorithm was used. Equilibration
with restraints, at force constants of 2000, was carried out for 500000 steps (10 ns) in an NPT
ensemble, starting with a random velocity drawn from the Maxwell-Boltzmann distribution. Each
equilibrated system was simulated for a 100 ns production run. The Parrinello-Rahman algorithm
(Parrinello and Rahman, 1981) was used for pressure and temperature coupling. The reaction field
method was used for the calculation of long-range electrostatic interactions (Tironi et al., 1995), and
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Fig. 4.3 PDB structure 2y9r (domain Ig-169) depicted in blue aligned to its backmapped structure
(Wassenaar et al., 2014) after 100 ns simulation using the Martini forcefield (pink). It can be seen
that a reasonable representation of protein structure is lost during the simulation. Structures were
visualised using the UCSF Chimera software (Pettersen et al., 2004).
a plain cut-off scheme was used for van der Waals interactions. A cut-off of 11 Å was used for both
Coulomb and van der Waals interactions. The time step for all runs was set to 0.02 ps, however,
caution must be taken in interpreting this time step. As the coarse-graining approach results in a
smoother energy landscape, 1 ps in Martini time is roughly equivalent to 4 ps in real time.
4.2.6 CafeMol simulation parameters
Simulations were performed at 300 K, starting with a random velocity drawn from the Maxwell-
Boltzmann distribution. The Berendsen thermostat was used for temperature-pressure coupling.
Simulations were performed for 2.4082E7 steps, with a time step of 0.1 cafe-time. 1 cafe time ≈ 49 fs,
however, it is noted that caution must be taken in interpreting this timescale as intrinsic dynamics
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are accelerated by the coarse-graining approach. The Debye length was set to 20 Å (this controls
ionic screening), the ionic strength to 0.05 mol L−1 and the dielectric constant to 78.
4.2.7 Elastic network models
Anisotropic and Gaussian elastic network models were calculated using the ProDy software (Bakan
et al., 2011), using default parameters. In both Gaussian and Anisotropic network models, protein
Cαs are modelled as nodes. If nodes are within a particular distance cutoff Rc they are connected by
springs (Lezon et al., 2010). Rc is set to 10 Å for GNMs and 15 Å for ANMs (ProDy software default
parameters).
















−1, if i ̸= j & rij ≤ rc
0, if i ̸= j & rij > rc
−∑Nj,j ̸=i Γij , if i = j
(4.28)
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The probability distribution for fluctuations is modelled as a Gaussian isotropic distribution.
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is the normalisation constant and kBTγ Γ−1 is the co-variance
matrix. Mean square fluctuations (the expected values of residue fluctuations) and cross correlations
between nodes, and thus, in the present case, between residues, are given by the diagonal and





< ∆ri ·∆rj >= 3kBT
γ
(Γ−1)ij (4.32)
Normal modes are obtained through diagonalisation of the Kirchoff matrix. Mode frequencies and
mode shapes are given by eigenvalues and eigenvectors respectively.
The anisotropic network model differs from the Gaussian elastic network model in that it




2 (|ri − rj | − |r
0
i − r0j |)2 (4.33)







The potential for small Cα displacements can be calculated using a Taylor expansion about r0:
V (r) = V (r0) + (r − r0)TD + 12(r − r
0)TH(r − r0) (4.35)
First and second order derivatives of the potential V are denoted by D and H respectively. As the
reference structure is assumed to represent an energy minimum, V (r0) and D evaluate to 0, and
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the equation reduces to:
V (r) = 12(r − r
0)TH(r − r0) (4.36)
Each element Hi,j of the hessian matrixH , is a 3 by 3 matrix which holds anisotropic information
on the orientation of the modes.
Hij =

− γij|ri−r0|2 (r0i − r0j )(r0i − r0j )T , if i ̸= j & rij ≤ rc
0, if i ̸= j & rij > rc∑N
j,j ̸=iHij , if i = j
(4.37)
Similar to the Kirchoff matrix of the GNM model, the Hessian matrix can be diagonalised to
reveal the eigenvectors or normal modes of the ANM. In comparison to GNMs, here each mode
is described by a 3 component vector, which gives information on the directionality of the mode
(Lezon et al., 2010).
4.2.8 Analyses
Features derived from elastic network models (ENMs) were calculated using the ProDy software, and
are identical to those calculated by Ponzoni and Bahar (2018). It must be noted that we consider the
Q(SASA) an ENM feature for the purposes of our work, to maintain consistency with the grouping
of features used by the Bahar laboratory (Ponzoni and Bahar, 2018). The ENM-based features are as
follows:
• Mean square fluctuations (MSF): square displacements at each position calculated from all
modes of a Gaussian network model.
• Mechanical bridging score (MBS): this is a measure of the importance of each residue in
maintaining a graph representation of the structure.
• Effectiveness(EFF)/sensitivity(SNS): parameters calculated from a perturbation response scan-
ning matrix. The column average indicates the effectiveness of a residue in transmitting
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allosteric signals to the rest of the protein. The row average indicates the sensitivity of a
residue to deformations at other sites.
• Mechanical stiffness (STF): resistance of each residue pair to uniaxial tension. Averaged over
all pairs involving a given residue.
• Quotient solvent accessible surface area [Q(SASA)]: the quotient of the solvent accessible
surface area and surface area of the isolated residue. Calculated for the mutated WT position
using the POPS software (Cavallo et al., 2003).
Similarly, a number of features were calculated from atomistic molecular dynamics trajectories
using the software MDAnalysis (Michaud-Agrawal et al., 2011). 101 snapshots from each trajectory
have been used for more computationally intensive analyses, whereas 5001 snapshots have been
used where this is not an issue. Appendix A9 shows that 101 snapshots are sufficient to capture
trends in those properties which are more computationally intensive to calculate. The analyses are
as follows:
• Root mean square deviation (RMSD): root mean square deviation of Cα atoms from their
position in the static wild-type (WT) structure, calculated for 5001 snapshots of the trajectory.
• Root mean square fluctuations (RMSF): root mean square fluctuations of Cα atoms, in com-
parison to their mean positions, calculated over 5001 snapshots of the trajectory.
• Number of hydrogen bonds (HB): the total number of hydrogen bonds calculated for 101
snapshots of the trajectory.
• Number of hydrogen bonds at the mutated position (HBpos): the number of hydrogen bonds
involving the amino acid at the position of the mutant, calculated for 101 snapshots of the
trajectory.
• Number of contacts at the mutated position (CT): number of Cβs within 8 Å of the residue at
the mutated position (Cαs are used to represent glycines).
Two matrix properties of the trajectories were also calculated using the software Bio3D (Grant
et al., 2006) and GSATools respectively (Pandini et al., 2013):
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• Contact map (CM): contact map with each value giving the frequency a particular contact is
observed throughout the trajectory. Contacts are defined based on Cβs and a cut-off value of
8 Å. Calculated for 5001 snapshots of the trajectory.
• Mutual information (MI): For each trajectory snapshot, 4 residue fragments are transformed
into a structural alphabet letter, based on the relative orientations of their alpha carbons. This
is calculated for n− 3 overlapping fragments, where n is the number of residues the protein
consists of. Thus each snapshot is represented as a string, and these strings form an alignment
from which the normalised mutual information is calculated.
Additionally, dynamic graph-based features of the trajectories were calculated using the package
MD-TASK (Brown et al., 2017). Here each snapshot of the trajectory is transformed into graph
representation, in which the Cβs are represented by nodes, and those within 8 Å of one another are
connected by edges. The following features are then calculated from these graphs (specifically, both
the mean and standard deviation of these features are calculated per residue):
• Betweenness centrality (BC): the protein structure is transformed into a graph, where each
residue is represented by a node positioned at its Cβ atom (Cα for glycines), and the between-
ness centrality of each residue is calculated for 101 snapshots from the trajectory.
• Change in betweenness centrality (delta_BC): as for betweenness centrality but calculated as
the difference in betweenness centrality between the initial trajectory frame in comparison to
each of the 100 non-initial trajectory snapshots.
• Average shortest path (L): as for betweenness centrality, however here the average shortest
path from one residue to all other residues is calculated.
• Change in the average shortest path (delta_L): as for the average shortest path, however here
the difference between the initial trajectory frame in comparison to each of the 100 non-initial
trajectory snapshots is calculated.
All dynamics properties calculated per residue (e.g. RMSF), or per frame (e.g RMSD) were
transformed into numeric features, based on minimal differences between the mutant and two
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wild-type replicas. First di, which quantifies this difference at frame/position i is extracted for each
residue/frame (see Fig. 4.4):
di =

WT1i −muti, if |WT1i −muti| < |WT2i −muti| &muti ̸= median(WT1i ,WT2i ,muti)
WT2i −muti, if |WT2i −muti| < |WT1i −muti| &muti ̸= median(WT1i ,WT2i ,muti)
0, ifmuti = median(WT1i ,WT2i ,muti)
(4.38)
WhereWT1i andWT2i are values calculated from each wild-type replica for frame/residue i,
andmuti is the analogous value calculated from the mutant trajectory.









Where, depending on the property, n is either the number of frames or the number of residues.
For matrix-based properties (MI and CM) the Spearman correlations between WT and mutant
trajectories were used as features. Here the most positive pairwise correlation between a mutant
and WT replicas is selected.
Two structural features were also calculated. These are:
• Betweenness centrality: as for dynamic features but calculated only for the mutated position
of the WT at the initial time point after equilibration. As two replicas are available the average
of both replicas is used.
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Fig. 4.4 Extraction of dynamics-based features. Properties are calculated over multiple time frames or
residues, and the minimum differences (d) between wild-type and mutant trajectories are extracted.
• Average shortest path: as for betweenness centrality, however here the average shortest path
from the WT mutated residue to all other residues is calculated.
As well as structure-based features, sequence-based features are also calculated as follows:
• Position Specific Independent Counts score (PSIC): This indicates the likelihood of observing
an amino acid at a specific position and compares it to the background probability of observing
it at any position (Sunyaev et al., 1999).
• Kidera factors (KF): 10 orthogonal properties which describe the physicochemical attributes
of amino acids (Kidera et al., 1985).
Here both the WT properties, and differences between the WT and mutant properties, were calcu-
lated.
In addition to the calculation of features, principal component analysis was also performed
using 101 snapshots of each trajectory, reduced to a Cα representation, using the ProDy software
(Ponzoni and Bahar, 2018).
4.2.9 Random forest classifier
A random forest-based model, implemented in Scikit learn (Pedregosa et al., 2011), was trained to
classify SAVs as deleterious or neutral. Random forests were chosen due to their relative robustness
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and ability to deal with high dimensional data (small numbers of samples and large numbers of
features) (Breiman, 2001). Due to the small size of the dataset Leave One Out (LOO) cross-validation
was used to evaluate the performance of the classifier. Where > 6 features were available to build a
model, a model was first created using all features and trained on the training fold. The top six most
important features from this model were used to create a new model, again trained on the training
fold. The performance of this model was then evaluated based on its predictive performance on
the testing fold. Additionally, models were created which used the top six sequence-based features
and the top six dynamics-based features (selected based on two separate models trained on the
training fold). Again these models were trained on the training fold and evaluated based on their
performance on the testing fold. The random forests were created using an ensemble of 1000 trees,
and the maximum number of features to consider when splitting a node of a tree was set to 2.
The "balanced" option of the SciKit learn implementation was chosen, which assigns class weights
inversely proportional to their size in the training set. In this case, the option will have had minimal
impact on the algorithm, as the benchmark dataset we use is close to being balanced.
4.2.10 Data visualisation
Data were visualised using the Python package matplotlib (Hunter, 2007). Structures were visualised
using the VMD (Humphrey et al., 1996) and UCSF Chimera (Pettersen et al., 2004) software packages.
4.3 Results
4.3.1 Comparison between coarse-grained and atomistic simulations
The root mean square fluctuations of wild-type (WT) elastic network models, coarse-grained simula-
tions and atomistic simulations positively correlate with one another, with values of Spearman’s ρ≥
0.4 (see Fig. 4.5). Moreover, atomistic molecular dynamics simulations show Spearman correlations
between 0.7 and 0.93. The lowest correlation (0.7) between replicas is demonstrated by the domain
Fn3-119. In-house experiments 2 show that this domain has a comparatively lowmelting temperature
(50oC). Furthermore, the fact that it has not been possible to crystallise this domain suggests that
it is highly flexible. This flexibility is further supported by the RMSF values of our atomistic MD
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simulations (see Fig. 4.14). Because of this greater flexibility, it is likely that a smaller portion of the
conformational landscape accessible to this domain can be sampled during our 100 ns simulations.
Due to this, it appears that each replica explores a different basin of the energy landscape, leading
to smaller correlations between replicas.
Although properties of wild-type dynamics are captured through coarse-grained simulations, it
is clear these techniques are not able to capture differences between mutations. This is likely due to
the fact that the coarse-grained techniques used here model all forces in the "native" structure as
attractive (via the harmonic restraints of ENMs and Martini ElNeDyn models and GO potentials
of the CafeMol and Martini GO models). For computationally modelled mutant structures the
assumption that the input structure represents an energy minimum is likely to break down. In
comparison, clear differences can be seen between WT and mutant atomistic MD trajectories for a
large proportion of mutants, as evidenced by RMSF values (see Figs 4.6, 4.7, 4.8, 4.14).
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Fig. 4.5 Spearman correlations between RMSF values for elastic network, CafeMol, Martini ElNeDyn,
Martini GO and atomistic molecular dynamics (MD) models. The heatmaps are both coloured and
labelled by Spearman’s ρ and show results for the wild-type (WT) titin domains Ig-169, Fn3-119,
Fn3-7, Fn3-49 and Fn3-90. Two replicas are shown for atomistic molecular dynamics simulations
(MD1 and MD2). Structures are coloured by MD1 RMSF values and visualised using the UCSF
Chimera software (Pettersen et al., 2004). Positive correlations can be seen for all models, showing
that coarse-grained models are, to varying degrees, able to reflect WT dynamics. However, the
largest correlations are always seen between atomistic MD replicas.
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4.3.2 Variant analysis - atomistic simulations
For the domains Ig-169, Fn3-90, and Fn3-49, disease-associated mutant trajectories show higher
RMSF values than population mutant trajectories. The single exception to this is the buried Ig-
169 population variant (I55T), which appears to have a drastic impact on the domain’s dynamics,
leading to increased flexibility (see Fig. 4.6) and, what appears to be, the initialisation of unfolding.
Interestingly this mutant is in the same position as the I55N TMD associated "Belgian" mutant. It
is also extremely rare (gnomAD MAF 4.08E-06). Therefore we hypothesise this mutant may also
lead to a disease-associated phenotype in a homozygous or compound heterozygous configuration.
Interestingly whether the "Belgian" mutant is causative of the disease TMD is a matter of debate.
Although cosegregation with the disease phenotype is observed, biophysical studies uncovered only
small differences between the wild-type and mutant (Rudloff et al., 2015). However, our results
suggest that the protein dynamics are perturbed in a similar manner to other TMD-associated
mutants. Replicas for the I55T mutant and the W38R disease-associated mutant support clear
disturbance of the domain’s dynamics.
The RMSF values for the dynamics simulations for the domain Fn3-90 mutants reflect in-house
experimental data 2. Here it can be seen that the disease-associated G88E mutant displays an altered
RMSF profile, whereas the I14V population mutant shows dynamics similar to the wild-type. The
G88E population mutant displays characteristics between these two extremes. Differential scanning
fluorimetry (DSF) data 2 shows that the I14V mutant has a melting temperature of 59oC, similar
to the WT (60oC). In contrast, the R78Q mutant has a lower melting temperature of 47oC and the
G88V mutant is unfolded.
Although the RMSF profiles for the WT and mutant domain Fn3-49 do not, at first glance, appear
markedly different, a clear distinction can be seen at the C-terminal end, between residues 90 and
100 (see Fig. 4.8). Here the disease-associated mutant shows increased flexibility in comparison to
both WT replicas and the population mutant.
Principal component analyses also show clear distinctions between population and disease-
associated mutant trajectories for these three domains (Ig-169, Fn3-90, and Fn3-49) (see Figs 4.9-4.11).
HereWT and population mutant trajectories appear confined to distinct regions of the plots, whereas
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Fig. 4.6 Root mean square fluctuations (RMSF) for the wild-type and mutant domain Ig-169. Both
population (green) and disease-associated (magenta) mutants are depicted. Plots show RMSF values
for elastic network, CafeMol, Martini ElNeDyn, Martini GO and atomistic molecular dynamics
models. The position 55, to which both a population-associated and a disease-associated mutation
localise, is coloured blue on the amino acid sequence; however, these mutants are coloured according
to their class (population/disease) on the RMSF plots. Note that the units for RMSF values from the
Gaussian elastic network model (ENM) are relative/arbitrary (Bakan et al., 2011). It can be seen that
only atomistic molecular dynamics simulations allow for a clear separation between population
mutant and disease-associated mutant RMSF values, with the exception of the I55T population
mutant, which has been labelled on the plot. Like the disease mutants, this mutant demonstrates
higher RMSF values in comparison to the wild-type and other population mutants.
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Fig. 4.7 Root mean square fluctuations (RMSF) for the wild-type and mutant domain Fn3-90. Both
population (green) and disease-associated (magenta) mutants are depicted. Plots show RMSF values
for elastic network, CafeMol, Martini ElNeDyn, Martini GO and atomistic molecular dynamics
models. Note that the units for RMSF values from the Gaussian elastic network model (ENM)
are relative/arbitrary (Bakan et al., 2011). It can be seen that only atomistic molecular dynamics
simulations allow for a clear separation between disease-associated and population mutant RMSF
values. The G88V disease-associated mutant (labelled) shows the greatest difference in RMSF values
from the wild-type. Interestingly the R78Q population mutant (labelled), which has been shown to
be destabilised in comparison to the wild-type (WT) in vitro also exhibits greater RMSF values than
the wild-type.
4.3 Results 148
Fig. 4.8 Root mean square fluctuations (RMSF) for the wild-type and mutant domain Fn3-49. Both
population (green) and disease-associated (magenta) mutants are depicted. Plots show RMSF values
for elastic network, CafeMol, Martini ElNeDyn, Martini GO and atomistic molecular dynamics
models. Note that the units for RMSF values from the Gaussian elastic network model (ENM) are
relative/arbitrary (Bakan et al., 2011). It can be seen that atomistic molecular dynamics simulations
allow for separation of the disease-associated and population mutant trajectories, as the disease-
associated mutant shows increased RMSF values between residues 90 and 100. The other models
fail to achieve this separation.
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the disease-associated mutants explore greater conformational space. Again the exception to this is
the Ig-169 population I55T variant, for which both replicas follow a pattern closer to that of the
disease-associated variants.
In contrast, the wild-type and mutant trajectories for the Fn3-7 domain show similar dynamic
properties to one another (see Fig. 4.12). Moreover, principal component analysis shows a clear
overlap between all mutant and WT trajectories projected onto the first two principal components
(see Fig. 4.13). Interestingly this domain has a WT melting temperature 75oC , which is much higher
than the other studied domains (see Table 4.1); thus it is possible that a longer simulation time, or
simulation at increased temperatures, would be necessary to observe perturbation of this domain by
the disease-associated variant.
For the domain Fn3-119, variation in the RMSF profiles is seen between all simulations (see
Fig. 4.14), however no segregation between population and disease-associated mutants is evident.
Indeed, as has been discussed, even the WT replicas show higher variability than those of other
domains. One plausible explanation is that the lack of segregation may be due to under-sampling of
the conformational space available to this more flexible domain.
Principal component analysis for the domain Fn3-119 (see Fig. 4.15) shows an overlap in the
trajectories of population variants and disease-associated variants when projected onto the first
two principal components. Both WT trajectories appear confined to the top right-hand side of
the plot. The only mutant with a similar localisation is the S59F mutant. Interestingly this is the
variant with the highest MAF of those analysed here, and was found to have a thermal stability
similar to the wild-type by the Gautel laboratory 2 (a melting temperature of 49oC in comparison to
50oC). The disease-associated C5R and P25L mutant trajectories localise to areas of the plot which
diverge from the wild-type trajectories, and have been shown to have decreased thermal stability
(32oC and 33oC respectively). These observations give rise to the hypothesis that a number of rare
population-variants may have an impact on the protein dynamics and, therefore, function. Rather
than the binary outcome suggested by the results for Ig-169, a spectrum of impacts may exist.
Another explanation for the lack of clear segregation between disease-associated and population
mutant trajectories for the domains Fn3-7 and Fn3-119 could be attributed to the use of homology
models rather than crystal structures. It is possible that any inaccuracies in these could impact on
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Fig. 4.9 PCA of atomistic MD trajectories for the wild-type and mutant Ig-169 domain. 101 snapshots
of Cα coordinates from each trajectory have been taken for analysis. PC1 and PC2 explain 31 % and
9 % of the variance respectively. The top left plot shows the two wild-type replicas; the top right
plot shows wild-type, disease-associated mutant and population mutant trajectories; the bottom
left plot shows only population mutants, including two replicas for the I55T mutant; the bottom
right plot shows only disease-associated mutants. The PCA analysis shows that wild-type and
population mutant trajectories appear to be confined to a distinct region of the plot, whereas the
disease-associated mutants appear to explore greater conformational space. The exception to this is
the I55T mutant (outlined and labelled), for which both replicas follow a pattern more similar to
disease-associated variants.
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Fig. 4.10 PCA of atomisticMD trajectories for thewild-type andmutant Fn3-90 domain. 101 snapshots
of Cα coordinates from each trajectory have been taken for analysis. PC1 and PC2 explain 24 % and
13 % of the variance respectively. Projections for two wild-type replicas, a disease-associated mutant
(G88V) and two population mutants (I14V and R78Q) are shown. The I14V mutant appears confined
to the region of the plot occupied by the two wild-type replicas, whereas the R78Q population
mutant and G88V disease-associated mutant mainly occupy different areas of the plot. Interestingly
the R78Q population mutant (outlined and labelled) has been shown to be destabilised in comparison
to the wild-type (WT) in vitro.
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Fig. 4.11 PCA of atomistic MD trajectories for the wild-type and mutant Fn3-49 domain. Plots
show RMSF values for elastic network, CafeMol, Martini ElNeDyn, Martini GO and atomistic
molecular dynamics models. 101 snapshots of Cα coordinates from each trajectory have been
taken for analysis. PC1 and PC2 explain 20 % and 15 % of the variance respectively. Projections
for two wild-type replicas, a disease-associated mutant (V81E) and a population mutant (V42I) are
shown. The population mutant and wild-type replicas overlap and occupy a similar region of the
plot whereas the disease-associated mutant shows little overlap with these.
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Fig. 4.12 Root mean square fluctuations (RMSF) for the wild-type and mutant domain Fn3-7. Both
population (green) and disease-associated (magenta) mutants are depicted. Plots show RMSF values
for elastic network, CafeMol, Martini ElNeDyn, Martini GO and atomistic molecular dynamics
models. Note that the units for RMSF values from the Gaussian elastic network model (ENM) are
relative/arbitrary (Bakan et al., 2011). No clear differences between RMSF values for the population
mutant and disease-associated mutant can be seen.
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Fig. 4.13 PCA of atomistic MD trajectories for the wild-type and mutant Fn3-7 domain. 101 snapshots
of Cα coordinates from each trajectory have been taken for analysis. PC1 and PC2 explain 13 % and
9 % of the variance respectively. Projections for two wild-type replicas, a disease-associated mutant
(W22C) and a population mutant (A17T) are shown. The population mutant, disease-associated
mutant and wild-type replicas overlap and occupy a similar region of the plot.
the simulation of dynamics. However, atomistic simulations using homology models for the WT
and mutant Fn3-90 domain show good agreement with those simulations which use the in-house
crystal structure as a starting point (see Fig. 4.16). It is important to note that information from this
crystal structure was not used in the creation of the homology model.
4.3 Results 155
Fig. 4.14 Root mean square fluctuations (RMSF) for the wild-type and mutant domain Fn3-119. Both
population (green) and disease-associated (magenta) mutants are depicted. Plots show RMSF values
for elastic network, CafeMol, Martini ElNeDyn, Martini GO and atomistic molecular dynamics
models. Note that the units for RMSF values from the Gaussian elastic network model (ENM) are
relative/arbitrary (Bakan et al., 2011). Differences between the RMSF values for mutants are shown
by both the Martini GO and atomistic molecular dynamics simulations, however no systematic
distinction between disease-associated and population mutants is evident.
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Fig. 4.15 PCA of atomistic MD trajectories for the wild-type and mutant Fn3-119 domain. 101
snapshots of Cα coordinates from each trajectory have been taken for analysis. PC1 and PC2 explain
15 % and 10 % of the variance respectively. The top left plot shows the two wild-type replicas; the
top right plot shows wild-type, disease-associated mutant and population mutant trajectories; the
bottom left plot shows only population mutants; the bottom right plot shows only disease-associated
mutants. The PCA analysis shows that population mutant and disease-associated mutant trajectories
overlap and diverge from the wild-type replicas, which appear confined to the top right-hand side
of the plot.
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Fig. 4.16 Spearman correlations between RMSF values for mutant and wild-type (WT) atomistic
molecular dynamics trajectories for the domain Fn3-90. The simulations have been performed using
both a crystal structure and a homology model (_model) as a starting structure. The heatmap is both
coloured and labelled by Spearman’s ρ. Results are shown for both population mutants (I14V and
R78Q) and a disease-associated mutant (G88V). Clear correlations are seen between WT replicas
and between matched simulations (of the same mutant or WT) starting with coordinates from a
model or a crystal structure. It can be seen that the I14V population mutant trajectories are highly
correlated with all WT trajectories, whereas the G88V disease-associated mutant trajectories are
the least correlated with these. The R78Q population mutant trajectories show correlations which
are between those of the I14V population mutant trajectories and the G88V disease-associated
mutant trajectories. Interestingly the R78Q population mutant has been shown to be destabilised in
comparison to the wild-type in vitro.
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4.3.3 Variant analysis - elastic network models
On comparison of features derived from elastic network models for the mutant subsets, it is clear
there is a large overlap between the distributions for both the hotspot domains Ig-169 and Fn3-119
(see Fig. 4.17 and Fig. 4.18). Moreover, even if small differences can be detected between these
distributions, it is clear that no robust segregation can be achieved using any of these calculated
features alone. It is important to stress again here that these features only contain information about
the dynamics of the WT position and not information pertaining to the physicochemical nature of
the change.
Fig. 4.17 Violin plots of ENM-based features calculated for population variants (green) and disease-
associated variants (magenta) which localise to the domain Ig-169. Mean square fluctuations (MSF),
effectiveness (EFF), sensitivity (SNS), mechanical bridging score (MBS) and mechanical stiffness
(STF) are shown. All features are measured in arbitrary/relative units (Bakan et al., 2011). It can be
clearly seen that the distributions of these features for population variants and disease-associated
variants are largely overlapping.
Fig. 4.18 Violin plots of ENM-based features calculated for population variants (green) and disease-
associated variants (magenta) which localise to the domain Fn3-119. Mean square fluctuations (MSF),
effectiveness (EFF), sensitivity (SNS), mechanical bridging score (MBS) and mechanical stiffness
(STF) are shown. All features are measured in arbitrary/relative units (Bakan et al., 2011). It can be
clearly seen that the distributions of these features for population variants and disease-associated
variants are largely overlapping.
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4.3.4 The predictive power of dynamics-based features
Here we compare the predictive power of features extracted from atomistic molecular dynamics
simulations and ENMs in comparison to sequence-based features. To do this we create predictive
random forest-based models, and assess their performance using Leave One Out (LOO) cross-
validation. As described in the methods, the ENM-based features are identical to those calculated
by Ponzoni and Bahar (2018). As 5 ENM-based features are calculated in their work, in addition to
solvent accessible surface area, we similarly select the top 6 features according to their importance
calculated using the training data, to create our atomistic dynamics- and sequence-based models
(denoted RF_MD and RF_seq). We also create models allowing selection of the top 6 features from
all calculated features (RF_all6), including the two structure-based static network features, as well
as models which use the top 6 sequence-based features and the top 6 dynamics-based features
(RF_all12). In addition to using the whole dataset to benchmark the models, we create models using
the subset of the data for which crystal structures are available. This is to account for the possibility
that simulations which use homology models as starting structures may be less accurate at reflecting
true protein dynamics.
Based on the whole dataset, the atomistic dynamics- and sequence-based predictors are better
able to segregate variants than the ENM-based predictors, according to all calculated metrics (see
Table 4.3). Actually, the sequence-based predictor (F1 score 0.89) performs better than the dynamics-
based predictor (F1 score 0.78), however both predictors show identical recall (0.84). From this
analysis, it becomes clear that the perceived difference in performance is due to a greater number of
false positives predicted by the dynamics-based model.
Using the subset of the data with crystal structures, both the sequence-based and atomistic
dynamics-based models achieve even better segregation, whereas the ENM-based model performs
badly (see Table 4.4 for performance metrics). The sequence-based model achieves perfect prediction;
in comparison, the dynamics-based predictor performs almost as well and only misclassifies 2
population variants. Interestingly one of these variants is the Ig-169 I55T variant, which, as discussed
earlier, we suspect could lead to a disease phenotype, due to both its rarity and localisation to the same
position as the known "Belgian" disease-associated mutation. The other misclassified population
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variant is the Fn3-90 R78Q mutant, which as discussed earlier has reduced thermal stability in
comparison to the wild-type 2. Although we cannot conclude that either variant is disease causing,
the evidence suggests that these may not be functionally neutral. Therefore it is possible that the
dynamics-based predictor could actually be describing a more accurate decision boundary with
regards to whether variants have a functional impact.
In comparison to existing predictors, including PolyPhen2 (Adzhubei et al., 2010), Condel
(González-Pérez and López-Bigas, 2011) and FATHMM (Shihab et al., 2013), both our sequence- and
dynamics-based predictors show good performance, with the sequence-based predictor achieving the
best performance across the majority of metrics (see Tables 4.3 and 4.4). The predictor REVEL also
shows good performance on this dataset (Ioannidis et al., 2016). As this predictor has been specifically
trained to separate rare neutral from disease-associated variants, it is perhaps unsurprising that it
outperforms the majority of other predictors on this dataset. For a number of predictors a better
ROC-AUC score is achieved than scores for other metrics. This indicates that the features calculated
by these predictors have discriminative power, however the chosen cut-off for distinguishing disease-
associated from neutral variants is not optimised for distinguishing rare neutral from pathogenic
variants. It must be considered that the performance of these predictors may be inflated, as it
is possible that they contain a subset of variants from our dataset in their training data. This is
particularly likely in the case of REVEL, which was trained using rare variants. Moreover, as REVEL
and Condel are meta-predictors, these could be subject to inflated performance due to the problem
of type 1 circularity (see Section 1.4.1). However, we must be cautious when drawing conclusions
about the relative performance of predictors; due to the small size of our benchmark dataset and the
high variance of the LOO cross-validation procedure used to assess our predictor. If another set of
39 variants was used to benchmark the predictors, it is likely that their relative performance would
change. Moreover, as our predictors have been trained using only titin variants in 5 titin domains,
it is likely that our predictors are overfitting the data, i.e. they may not be able to generalise to
variants in other proteins/domains.
Feature importances from predictive models that have been trained on the entire data, in addition
to the number of times features are chosen during the LOO cross-validation procedure, are depicted
in Fig. 4.19. This shows that, based on all structures, the ∆ PSIC score has the most predictive
4.3 Results 161
power, closely followed by dynamics-based features and the Kidera factors 1, 3 and ∆ 4. The most
important dynamics-based features appear to be associated with contacts (both those of the mutated
position and global contact maps) and network-based metrics related to shortest paths. For the
model based on the crystal structure data set, the ∆ PSIC displays the highest importance, closely
followed by dynamics-based features, with those associated with shortest path lengths playing
the most prominent role. This suggests that the disruption of dynamic communication between
residues, as measured by changes in shortest path lengths between WT and mutant trajectories, is a
key determinant of variant pathogenicity.




RF_seq 0.9 0.94 0.84 0.89 0.8 0.93 0.93
RF_all12 0.85 0.84 0.84 0.84 0.69 0.91 0.91
REVEL (Ioannidis et al., 2016) 0.79 0.71 0.94 0.81 0.63 0.96 0.95
RF_all6 0.79 0.82 0.74 0.78 0.59 0.81 0.83
RF_MD 0.77 0.73 0.84 0.78 0.55 0.81 0.71
MutationAssessor (Betts et al., 2015) 0.72 0.63 0.94 0.76 0.51 0.91 0.93
FATHMM_U (Shihab et al., 2013) 0.74 0.67 0.89 0.76 0.52 0.85 0.88
Condel (González-Pérez and López-
Bigas, 2011)
0.77 0.74 0.78 0.76 0.54 0.92 0.93
Provean (Choi et al., 2012) 0.64 0.56 1 0.72 0.43 0.93 0.92
PPH2 (Adzhubei et al., 2010) 0.54 0.5 0.94 0.65 0.2 0.7 0.6
MutationTaster (Schwarz et al., 2010) 0.49 0.47 1 0.64 0.15 0.68 0.61
RF_ENM 0.59 0.58 0.58 0.58 0.18 0.65 0.73
FATHMM_W (Shihab et al., 2013) 0.64 1 0.22 0.36 0.37 0.74 0.79
Table 4.3 Performance of predictors on titin missense variants which localise to crystal structures
and homology models (n=39). RF_seq, RF_all, RF_MD and RF_ENM are the predictors we have
trained using sequence-based, mixed, atomistic dynamics and ENM-based features. The predictors
Condel and REVEL are both meta-predictors.
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Fig. 4.19 The importance of different features for predicting the impact of SAVs using random
forest-based models. The number of times a feature is selected during the cross-validation procedure
is indicated on the left-hand side of each plot and feature importances are depicted for a model
trained using all calculated features in the right-hand side of the plot. Shown for models trained on
39 variants (localised to crystal structures and homology models) and a subset of 15 variants (only
crystal structures). Features have been described in Section 4.2.8
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RF_seq 1 1 1 1 1 1 1
REVEL (Ioannidis et al., 2016) 0.93 1 0.86 0.92 0.87 1 1
RF_all6 0.87 0.78 1 0.88 0.76 0.93 0.92
RF_all12 0.87 0.78 1 0.88 0.76 0.86 0.8
RF_MD 0.87 0.78 1 0.88 0.76 0.8 0.69
FATHMM_U (Shihab et al., 2013) 0.8 0.7 1 0.82 0.66 0.95 0.94
Provean (Choi et al., 2012) 0.73 0.64 1 0.78 0.56 1 1
Condel (González-Pérez and López-
Bigas, 2011)
0.8 0.83 0.71 0.77 0.6 0.95 0.95
MutationAssessor (Betts et al., 2015) 0.73 0.67 0.86 0.75 0.49 0.93 0.94
PPH2 (Adzhubei et al., 2010) 0.6 0.54 1 0.7 0.37 0.88 0.88
MutationTaster(Schwarz et al., 2010) 0.53 0.5 1 0.67 0.25 0.65 0.61
FATHMM_W (Shihab et al., 2013) 0.6 1 0.14 0.25 0.29 0.77 0.81
RF_ENM 0.27 0.17 0.14 0.15 -0.49 0.16 0.35
Table 4.4 Performance of predictors on titin missense variants which localise to crystal structures
only (n=15). RF_seq, RF_all, RF_MD and RF_ENM are the predictors we have trained using sequence-
based, mixed, atomistic dynamics and ENM-based features. The predictors Condel and REVEL are
both meta-predictors.
4.4 Discussion
Through this work, we have shown that features frommolecular dynamics trajectories show promise
for distinguishing between disease and population variants, and offer a clear performance advantage
over elastic network derived models. Although our dynamics-based predictive models do not
reach the performance of our sequence-based model, this is due to the misclassification of several
population variants as disease-associated variants. Some evidence suggests that these "misclassified"
variantsmay not be functionally neutral. This leads us to the hypothesis that dynamics-based features
may be better at detecting functional impact in cases where sequence-based features fail. Moreover,
we must consider that our disease-associated dataset may be biased towards variants which localise
to conserved positions, as such variants are normally considered the most likely causative variants.
Conversely, disease associations for variants which localise to less conserved positions may be more
difficult to detect, and thus under-represented in our disease subset. Future experiments will be
designed to probe whether this the case, and additionally whether our conclusions remain robust if
these techniques are applied to larger datasets and different protein domain-types.
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Coarse-grained techniques were able to produce reasonable representations of wild-type protein
dynamics, but were unable to show differences between mutant trajectories. As already discussed,
this is likely due to the restraints (elastic network and GO) which are required to maintain protein
structure in the coarse-grained representation (WT Martini simulations without restraints resulted
in a loss protein topology). It is possible that restraints could be relaxed or removed to a degree which
would allow differences between wild-type and mutant domains to be seen, whilst still maintaining
topology (unless a mutation is severely disruptive). If atomistic information is required, as our
results suggest, the use of enhanced sampling techniques (such as Monte Carlo, replica exchange
and simulated annealing (Hospital et al., 2015; van Gunsteren et al., 2018)) and/or implicit solvent
(Kleinjung and Fraternali, 2014) could be investigated. These techniques could lower computational
costs.
The degree to which rare variants have an impact on protein structure, and therefore function, is
a matter of debate. Therefore, one of the aims of this work has been to gain a better understanding of
this. We find the majority of rare variants show dynamical features which are highly similar to the
wild-type protein, with only a minority showing properties which are clearly distinct. These variants
we consider likely to have a functional impact, although whether such an impact is associated with
disease cannot be discerned from the information available. Only for the domain Fn3-119 was
large variety seen in the dynamic properties of rare variants, however clear differences were also
seen between WT replicas. As we have already discussed, our results and in-house experimental
data from the Gautel laboratory 2 suggest this domain is intrinsically more flexible. Therefore it
may be necessary to conduct longer simulations to sufficiently sample conformational space. More
generally, if molecular dynamics techniques are to be used on a large-scale for the assessment
of variant impact, necessary simulation times must be benchmarked for different domain types.
Here enhanced sampling techniques may play a role in sufficiently sampling conformational space
(Hospital et al., 2015; van Gunsteren et al., 2018).
Simulations for the domain Fn3-90 using a crystal structure and a homology model show good
agreement with one another. This suggests that simulations of high-quality homology models
may accurately represent protein dynamics. However, the dynamics of the two domains for which
only homology models are available (Fn3-7, Fn3-119) did not show clear segregation between
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population and disease-associated variants. This could be due to inaccuracies in the homology
models, under-sampling of conformational space, or an actual overlap in the impact of rare and
disease-associated variants. An NMR structure for the domain Fn3-119 is currently being solved by
the Gautel laboratory 2, and promises to shed light on this issue.
A number of disease-associated variants are known to impact on protein interactions. It would
be interesting to take a sample of these and see how many can be correctly classified by studying
the dynamics of a single domain/protein in isolation. It is likely that a fraction of variants prevent
interactions, due to conformational changes, observable in the monomer, which impact on the
binding site. Alternatively, some variants may have no impact on the conformation of the monomer,
instead only exerting an impact on the binding site. The results from such an investigation could
shed light on how broadly applicable the approach presented here is.
In conclusion, it is clear that protein dynamics can play an important role in understanding
the impact of missense variants. The incorporation of the physicochemical nature of a mutation in
dynamics simulations, and extraction of features associated with the differences between wild-type
and mutant trajectories, appears to allow for a better distinction between pathogenic and non-
pathogenic variants than WT dynamics features from Cα elastic network model representations.
However, more work is needed to discern whether dynamics features may have an advantage over
sequence-based features for classifying "problem case" variants. Finally, our results present scope
for future development, benchmarking and application. We have shown dynamics features hold
predictive power, now it is necessary to discern the best way to harness this.
Chapter 5
Discussion and perspectives
Despite technological progress, which enables the sequencing of human genomes at an unprece-
dented rate, we are still far from a full understanding of the genetic code. However, potential
applications of such an understanding are manifold, and include drug development, precision
medicine, diagnostics and prognostics. The limits of our current comprehension are highlighted by
the problem of missing heritability, discussed throughout this work, where the genetic component
of a phenotype remains unidentified. Variant impact predictors can play an important role in
elucidating which variants lead to a given phenotype. Here, another limitation is encountered; a
large proportion of current predictors rely on sequence-based evolutionary features, which give
little insight into potential disease mechanisms. Therefore the overarching aim of this work was to
gain a better understanding of which protein structural and functional properties could be of use in
both the prediction and interpretation of the impact of genetic missense variants.
A specific purpose, here, was to contribute to improving the computational impact prediction of
titin variants. These are of particular interest as they provide a prime example of variants which are
difficult to classify using statistical methods, and thus necessitate the use of alternative means of
assessment, such as computational impact predictors. We have facilitated the improved assessment
of titin variants directly through the creation of TITINdb, a resource presented in Chapter 2, which
allows users to access titin homology models, structures and missense variants. Additionally,
this goal has been addressed in Chapter 4, through the creation of computational sequence- and
dynamics-based predictors, for the assessment of titin missense variants. Furthermore, as these titin
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missense variants localise to Fn3 and Ig domains, which are ubiquitous throughout the proteome,
we believe this also addresses our overarching aim to uncover which properties can be used to
predict the impact of missense variants. The large-scale analysis of missense variants in health
and disease, presented in Chapter 3, further contributes to this goal. Although this analysis is not
directly associated with titin variants, we believe the trends uncovered have implications for the
assessment of all missense variants, including those which localise to the titin protein.
Active debate in the field is associated with the relative properties of rare and common variants.
It has been both argued that common variants have more functional impact than rare variants, and
that rare variants are more similar to disease-associated variants (Alhuzimi et al., 2018; Mahlich
et al., 2017). Understanding this is of utmost importance to discerning which titin variants are
likely to be disease-associated. Our research suggests that rare variants, overall, display properties
between those of common and disease-associated variants, but are most similar to common variants.
Zooming into the molecular scale, in particular on protein dynamics, our work suggests that the
majority of rare titin variants have little functional impact, whereas a minority perturb dynamics to
a similar degree as disease-associated variants. This supports the hypothesis that a small proportion
of rare variants may act as phenotypic modifiers in particular constellations or possess undiagnosed
disease associations.
The work we have presented in Chapter 3 highlights that greater understanding of the impact
of SAVs can be gained by taking an integrative approach. Furthermore, recent developments in
proteomics technologies can be harnessed to gain insight into the potential impact of variants in their
cellular environment. Even since the completion of this work, new data has become available which
probes changes in protein thermal stability throughout the cell cycle (Becher et al., 2018). From
our analysis, it is clear that a complex interplay exists between the variant enrichment of proteins
and their constituent structural regions, transcript expression, protein abundance, protein thermal
stability and protein turnover. Future challenges will be associated with the further untangling of
this data, to understand which correlations represent causal relationships. Although high throughput
proteomics technologies are now able to take measurements for several thousand proteins, they
have not yet obtained full coverage of the proteome. Attaining greater coverage would facilitate the
use of such proteomics features in variant impact predictors.
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Prediction and its assessment rely on accurate benchmark datasets. We show that predictors
which have been trained on common variants do not choose an appropriate decision boundary
for distinguishing rare neutral variants from rare pathogenic ones. Moreover, our incomplete
understanding of which rare variants are functionally neutral, and biases in the detection of disease-
associated variants, may impact on the accurate training and assessment of variant impact predictors.
Emerging data in the field from saturation mutagenesis studies hold promise to aid in the clarification
of these issues (Baugh et al., 2016; Findlay et al., 2018; Gray et al., 2018). This data will offer a gold
standard with which to benchmark variant impact predictors in the future. However, it is important
to note that saturation mutagenesis studies do not necessarily measure the impact of variants on all
functions of a protein.
We demonstrate that atomistic protein dynamics show promise in the prediction of variant
impact, and on our dataset of titin variants show clear performance advantages over dynamics-based
features derived from elastic network models. Whether dynamics-based features offer advantages
over sequence-based features remains to be seen. Although an initial assessment suggests that our
sequence-based predictor outperforms that based on dynamics features, some evidence suggests
that the misclassified false positives from our dynamics-based predictor may actually have a func-
tional impact. As titin is, in essence, a polymer consisting of linked Fn3 and Ig domains, it is also
possible that both predictions and insights into molecular disease mechanisms could be improved
by simulating multidomain constructs. Moreover, the impact of variants on titin protein-protein
interaction complexes should be considered. Unfortunately as described in Chapters 1 and 2, atomic
details exist for only a few of titin’s protein-protein interactions. However, elucidating these is
an area of active research, so it is possible that more atomic-resolution data for such interactions
will be available soon. As a starting point, the impact of Ig-169 variants on titin’s interactions
with obscurin and obscurin-like protein could be simulated. Despite titin’s highly similar mode
of interaction with both partners, subtle distinctions have been noted (Pernigo et al., 2015). Any
differences observed between the impact of variants on interactions with each of these partners
could shed light on disease mechanisms. As discussed in Chapter 4, this domain (Ig-169) is a hotspot
for variants associated with the diseases TMD and LGMD-2J. Because we have simulated the impact
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of the variants on the monomeric domain, it would be interesting to compare the results with
simulations of variant impact on both complexes.
Our work suggests that sequence-based predictors performwell if trained on appropriate datasets.
This raises the question, why should one invest in dynamics-based methods which have a much
higher computational cost? There are several reasons for this. Firstly, we hypothesise that dynamic
information may offer predictive power where sequence-based methods fail. Our results hint that
this may be the case, for example the R78Q Fn3-90 titin variant (R27839Q based on IC isoform
numbering) is predicted to be pathogenic by our dynamics-based predictor, but neutral by our
sequence-based predictor. Although we cannot conclude this variant has any disease associations,
experimental data show that this variant destabilises the Fn3-90 domain. We believe the next
steps towards investigating this hypothesis should be to benchmark dynamic and sequence-based
predictors on saturation mutagenesis datasets. In particular, it will be interesting to compare the
performance of these predictors on rheostat positions, i.e. those protein positions for which a
range of impacts exist (Miller et al., 2017). As discussed in the introduction, it has been shown that
existing, primarily sequence-based, predictors perform poorly on variants which localise to these
positions. Therefore these variants offer ideal test cases for dynamic methods. Secondly, we have to
consider that this is a first attempt to use atomistic molecular dynamics-based features in a machine
learning-based framework for the prediction of variant deleteriousness, whereas sequence-based
methods are at a comparatively mature stage of development. Moreover, sequence-based methods
incorporate alignments which utilise data from a much larger number of proteins. It is not clear
how much dynamics-based methods could be improved given a larger training dataset and further
development. Furthermore, it is also possible that dynamics-based information from homologs could
further enhance performance. Thirdly, dynamic-based methods promise to give greater insight into
molecular disease mechanisms than sequence-based methods. Additionally, simulation trajectories
can be repurposed for use in drug screens and searches for potential ligand binding sites (Durrant
and McCammon, 2011).
How is the use of atomistic molecular dynamics feasible for the assessment of variant impact
on a large scale? Even with increased computational power and algorithmic improvements, which
exploit parallel computing via the use of graphical processing units (GPUs) and potentially field-
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programmable gate arrays (FPGAs) (Kutzner et al., 2015; Schaffner and Benini, 2018), proteome-wide
assessment of SAVs using dynamics techniques is not feasible by any single research group. Rather,
trajectories from multiple research groups could be pooled. We envisage the creation of an online
database, akin to the protein data bank (PDB) to store and enable access to wild-type and mutant
trajectories deposited by research groups across the world. Associated with this database, a machine
learning-based variant impact predictor could iteratively learn from deposited data; this would
enable the predictor to improve in parallel with the growth of the database. Therefore a group
wishing to decipher the impact of a particular variant could simply run trajectories for the mutant
protein and potentially a wild-type and neutral variant (in order to keep the database balanced)
and submit these to the database to obtain the predictive results. Challenges here would lie in
data curation, annotation and storage; however, these are not insurmountable given sufficient
resources. Moreover, annotation of deposited trajectories with forcefield usage and simulation
parameters would allow for additional benchmarking of the impact of these parameters on the
predictive capacity of dynamics-based features.
Another consideration is that the proteome-wide assessment of dynamics is unlikely to be
necessary. Those variants which cannot be classified based on functional, structural and proteomics
features (as highlighted in Chapter 3) should be prioritised for dynamics investigation. This will
increase the computational feasibility of the approach. Moreover, as discussed in Chapter 4 the use
of enhanced sampling techniques (Hospital et al., 2015; van Gunsteren et al., 2018) and potentially
implicit solvent (Kleinjung and Fraternali, 2014) may increase the efficiency of computational
assessment. Additionally, a large database of mutant and wild-type trajectories might facilitate the
design of coarse-grained methods which are able to capture the impact of mutations on protein
dynamics.
To make full use of such a database, accurate metadata, both regarding patient phenotypes and
available biophysical data describing WT and mutant proteins, would be necessary. The degree
by which protein structure has to be disrupted to impact on function is not fully understood.
Furthermore, the degree by which protein function must be perturbed to give rise to a disease
phenotype is yet to be fully elucidated. However, to decipher how genetic variants lead to disease,
we must understand both these links. The first steps towards such an understanding are initialised
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by cataloguing available data. Unfortunately, despite the large amount of genetic data which can be
accessed, the amount of individualised per-patient data, with associated phenotype information
is much smaller. The safeguarding of patients, and associated controls regarding data sharing,
whilst a necessity from an ethical perspective, can prove a hindrance to scientific advance (Raza
and Hall, 2017). As an example as to how these problems can be overcome, the Danish healthcare
system provides a paradigm for the notation, storage and access to patient data. Their detailed
electronic records (notably opt-out rather than opt-in) have allowed researchers to create disease
trajectories, which describe the temporal progression of diseases (Jensen et al., 2014). We believe
that the association of such trajectories, with the impact of a patient’s genetic variants at the
molecular level, will be essential to gain a complete understanding of the link between phenotype
and genotype. Furthermore, personalised phased genomic data is necessary if the problem of
epistasis, the combinatorial impact of variants, is to be approached. Although databases such as
gnomAD (Lek et al., 2016) represent a huge advance, these give us no information about which
combinations of variants occur in an individual, and whether these occur in cis (on the same allele)
or trans (on different alleles). This is of huge importance to understanding diseases with compound
heterozygous inheritance.
In conclusion, through this work, we have shed light on a small part of the puzzle associated
with deciphering the impact of genetic variants and, in the grand scheme of things, taken tiny but
significant steps towards improving their assessment. Of greater importance are the questions this
work leads us to ask and the future steps we believe need to be taken. Central to this is the sharing
of data associated with the computational simulation of protein dynamics. It was exactly this open
collaborative approach which enabled the advances of the genomic revolution and the reading of
the genetic code (Contreras and Knoppers, 2018; Hood and Rowen, 2013). Now this approach is
necessary in order for us to understand the genetic code, and ultimately devise our own instruction
manual.
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Appendix A
Supplementary data
Supplementary data can be downloaded at https://github.com/AnnaLaddach/Thesis_Anna_Laddach_
2019_Appendix-A.git
This consists of:
1. The impact of using different cut-offs for the minimum number of protein core residues.
2. Details of the number of SAVs which localise to different protein regions in the gnomAD
common and rare, COSMIC and Clinvar datasets.
3. A list of pathways annotated by functional cluster ("proliferative", "nucleotide processing"
and "response").
4. Proteins enriched in COSMIC non-driver variants at protein-protein interaction sites.
5. Statistics for comparisons of structural network features between datasets.
6. Numbers of proteins and SAVs which underlie correlations between proteomic/transcriptomic
features and variant enrichment.
7. Pairwise Spearman correlations between all studied proteomics and transcriptomics features.
8. Enrichment of functional pathways by proteomics/transcriptomic features.
9. Properties of trajectories can be represented by 101 snapshots.
